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ABSTRACT 
 
David Irvin: Astrocytes and Their Response to Pathology 
(Under the direction of C. Ryan Miller) 
 
 
Glioblastoma (GBM), the most common primary malignant brain tumor, remains fatal and 
lacks effective treatment options. The influence of initiating mutations and cellular origin on GBM 
pathogenesis remains elusive. Previous studies utilizing genetically engineered mouse models 
(GEMM) have outlined some mutational and cellular requirements for GBM in different 
developmental contexts. However, the influence of particular mutations in differing cell types 
remains incompletely characterized. Groups such as The Cancer Genome Atlas (TCGA) have 
utilized high-throughput molecular analysis of human GBM and identified three frequently mutated 
core signaling pathways: the receptor tyrosine kinase (RTK), retinoblastoma (RB), and the P53 
pathways. Leveraging this knowledge, we have designed conditional, inducible GEMMs to target 
commonly mutated signaling pathways in different cellular contexts in the adult mouse brain. In 
this model system, we outlined the genetic requirements of GBM initiation in glial fibrillary acidic 
protein (GFAP)+ astrocytes. We defined the resulting molecular heterogeneity, stochastic growth 
rates, and genotype-dependent survival effects. Also, we found tumor transcriptomes from our 
GEMM separate based on brain region, implicating the influence of regional heterogeneity on 
tumor subtype. Finally, we noted that tumor transcriptomes are reminiscent of purified neural cell 
types, suggesting that the initially mutated cell influences resulting tumor heterogeneity. 
GEMMs have been used to target different mutations to distinct cell populations to 
generate GBM. However, it remains unclear whether heterogeneity within a targeted cell 
population influences resulting tumor composition. Therefore, we targeted the same mutations to 
two different astrocyte subpopulations in adult conditional, inducible GEMMs and used genetic
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lineage tracing, fate mapping, and immunofluorescence to monitor transformation as well as 
cellular composition of the tumor microenvironment over time. We found that tumor growth rate 
and composition of the microenvironment varied depending on the initially transformed astrocyte 
population. 
Using GEMM, we and others have shown that terminally differentiated astrocytes can 
serve as a cell of origin, however the molecular mechanisms which allow for their de-
differentiation to a more primitive cell type remain unclear. Using immunofluorescence, we found 
expression of the primitive transcription factor Sox2 in the adult murine astrocytes. To test whether 
Sox2 was important for astrocyte de-differentiation, we wounded the brains of adult mice with 
Sox2 deleted in astrocytes and observed an inappropriate wounding response by glial cell 
populations. Next, we engineered in a conditional Sox2 knockout into our GEMM tumor model 
and found tumorigenesis was unaffected. The results suggest that Sox2 could play a role in 
astrocyte reentry into the cell cycle under diverse pathological conditions, including traumatic 
injury and tumorigenesis. 
Overall this research explores the requirements for tumorigenesis in murine astrocytes 
and examines the molecular mechanisms that enables their response to pathological stimuli. The 
models we developed will be useful for future studies elucidating the roles of the transformed cell 
of origin on GBM pathogenesis, subtype specific preclinical modeling of GBM, and the role of 
tumor microenvironment in GBM. 
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Chapter I: Introduction 
 
Diffuse gliomas are the most common primary brain tumor. They account for 27% of 
primary brain tumors in the United States and over 80% of these are considered malignant (1). 
Gliomas are diagnosed based on histology into two groups, the more aggressive astrocytoma 
which resemble astrocytes and oligodendroglioma which resemble oligodendrocytes. However, it 
currently remains unknown whether these tumors actually arise from these cells of origin. Diffuse 
glioma (WHO grade II) are diagnosed based on cellular atypia and hold a 10-15 year median 
survival (2). In contrast, anaplastic glioma (WHO grade III) are diagnosed based on the presence 
of frequent mitotic figures and have a median survival of 3-5 years (2). Glioblastoma (GBM, 
astrocytoma grade IV) is the most common and biologically aggressive primary brain tumor (2). 
It is diagnosed based on the presence of microvascular proliferation and necrosis, features that 
portend a dismal median survival of 12-15 months. The clinical outcomes of patients with diffuse 
gliomas have not improved significantly over the past 40 years (2). 
While lower-grade gliomas lack a standard of care, the current standard for GBM includes 
surgical resection followed by concurrent fractionated radiation and the DNA alkylating agent 
temozolomide (3, 4). However, these treatments provide only transient survival benefits and they 
fail to address the underlying molecular drivers of tumor growth. Comprehensive genomic profiling 
of GBM has identified four different transcriptome subtypes: neural, proneural, mesenchymal and 
classical (5). Methylation profiling has revealed that a GBM CpG island methylator phenotype (G-
CIMP) comprises around 30% of the proneural GBM (6). Each subtype possesses unique cellular 
composition, therapeutic responses, and clinical outcomes (5-8). Furthermore, primary GBM, 
which arise without clinical evidence of a previously-existing lower-grade glioma, and secondary 
GBM, which develop via progression of a lower-grade precursor glioma, are molecularly distinct
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(9). Also, four transcriptome subtypes of lower-grade (II and III) gliomas with distinct mutations 
and clinical outcomes have been identified (10). The fact that these tumors display high degrees 
of morphological, molecular, and biological heterogeneity has driven efforts to modify glioma 
classification beyond histopathology alone to include both morphological and genotypic features 
(9). Further defining the underlying sources of this extensive heterogeneity would facilitate tumor 
classification and development of targeted, mechanism-based strategies to manage these fatal 
diseases. 
Two main models have been put forward to account for cancer heterogeneity (11). In the 
mutation model, distinct tumor subtypes are thought to arise from transformation of a single cell 
type by different oncogenic mutations. Large scale sequencing studies of surgically resected 
human tumors have shown frequent gene mutations in three “core GBM signaling pathways”: the 
G1/S cell cycle checkpoint, receptor tyrosine kinase (RTK)/mitogen activated protein kinase 
(MAPK)/phosphoinositide 3-kinase (PI3K), and TP53 pathways (12, 13). These same studies 
have also shown that GBM transcriptome subtypes show enrichment of specific mutations. For 
instance, IDH1 mutations were enriched in the proneural subtype, EGFR mutations in the 
classical subtype, PDGFR mutations in the neural subtype, and NF1 mutations in the 
mesenchymal subtype (5). However, these studies are unable to differentiate mutations driving 
glioma growth and passenger mutations acquired during tumor progression. 
Genetically engineered mouse models (GEMM) have become an indispensable 
experimental tool for defining mutations that drive glioma growth. Various groups have shown that 
mutations in many genes, including loss-of-function mutations in Cdkn2a, Nf1, Pten, or Trp53 
tumor suppressor genes and activating mutations in Egfr, Kras, or Akt1 oncogenes, have been 
shown to produce gliomas either alone or when combined to transform a single cell type: cells 
expressing the glial fibrillary acidic protein (GFAP) (14-21). Likewise, mutations in Cdkn2a, Nf1, 
Pten, or Trp53 tumor suppressor genes and activating mutations in Kras or Akt1 oncogenes have 
 3  
been shown to induce glioma in oligodendrocyte progenitor cells (OPC) (22-24) and neural stem 
cells (NSC) (21, 25, 26). 
In contrast to the mutation model of heterogeneity, the cellular origin model proposes that 
the transformation of different cell types leads to distinct tumor subtypes. The brain is composed 
of multiple cell lineages with overlapping hierarchies. Moreover, their gene expression profiles 
vary based on brain location and developmental stage (27, 28). The cell of origin for GBM is 
currently unknown but NSC, progenitor cell types such as an OPC, or differentiated cell types 
such as an oligodendrocytes and astrocytes are potential candidates. The histological 
resemblance of gliomas to either astrocytes or oligodendrocytes provided initial evidence for their 
cell of origin. Through comparative transcriptome profiling, The Cancer Genome Atlas (TCGA) 
showed that human GBM subtypes harbor transcriptomes similar to purified neural cell types 
including: mouse astrocytes, neurons, OPC, and NSC (5), suggesting that these cell types could 
be GBM cells of origin. Clinical studies have also shown that the majority of GBM make contact 
with the walls of the lateral ventricle, an area in the adult brain populated with NSC. These studies 
thus implicate NSC as a GBM cell of origin (29). 
GEMM have become an important tool for defining potential cells of origin for glioma. 
Specifically, genetic lineage tracing in GEMM is critical for appreciating how the initially 
transformed cell of origin relates to resulting cancer subtypes. Lineage tracing has provided 
critical insights into the cellular pathogenesis of medulloblastoma, a common primitive 
neuroectodermal tumor in children. Like GBM, medulloblastoma is a heterogeneous disease 
composed of multiple molecular subtypes. Lineage tracing in the developing brainstem and 
cerebellum has revealed that distinct cell types are transformed by specific mutations: mutations 
activating SHH signaling transform cerebellar granule neuron precursors, WNT activating 
mutations transform dorsal brainstem and lower rhombic lip progenitors, while activated MYC 
transforms cerebellar stem cells (30). 
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Various GEMM have confirmed the ability of different mutations to transform each of these 
neural cell types to induce glioma. For example, mutations that inactivate RB family pocket 
proteins (18, 31, 32), Cdkn2a (20, 21, 25), Nf1 (33, 34), Pten (15, 18, 32, 34), or Trp53 (15, 18, 
25, 33-35) and activate Hras (19, 35), Kras (16, 21, 36) or Akt1 (25, 36, 37) have been shown to 
transform GFAP+ NSC and astrocytes. The combination of Trp53 deletion and Hras activation 
has been shown to transform neurons expressing Synapsin 1 (Syn1) (35). Deletion of Cdkn2a 
(24), Nf1 (22, 38), or Trp53 (22, 38), overexpression of Pdgfb (23), and activation of Kras (23, 24) 
or Akt1 (23, 24) has been shown to transform OPC expressing neural/glial antigen 2 (NG2, a 
proteoglycan encoded by Cspg4) or 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase 
encoded by Cnp). Deletion of Nf1, Trp53, and Pten has been shown to transform ASCL1+ neural 
progenitor cells (39). Finally, deletion of Cdkn2a (20, 21, 25), Nf1 (26), Pten (25, 26), or Trp53 
(20, 26) and activation of Kras (21, 36), Idh1R132H (40), or Akt1 (21, 36) has been shown to 
transform NSC that express the intermediate filament protein nestin (encoded by Nes). These 
GEMM indicate that mutations in core GBM signaling pathways can transform a variety of neural 
cell types. Recently, identical initiating mutations in two different cell types (NSC and neural 
progenitors) have been shown to produce two phenotypically and molecularly distinct GBM 
subtypes (39). In combination, these GEMM data suggest that both initiating mutations and the 
initially transformed neural cell type may interact to contribute to the extensive molecular 
heterogeneity seen in GBM. 
Developmental origin of the initially transformed cell is an additional variable which could 
influence resulting tumor heterogeneity. The developmental origin of astrocytes has been 
extensively studied (41). In mice, astrocytes are generated from embryonic day 12 to post-natal 
days 14-21 (42, 43). Throughout this time, astrocytes arise from distinct precursor populations 
located in different regions of the brain. During embryogenesis, astrocytes are produced via 
asymmetrical division of stem-like radial glia located in ventricular (VZ) and subventricular zones 
(SVZ). Maximal astrocyte production occurs perinatally, when a 6-8 fold expansion in astrocyte 
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cell numbers (44) is achieved via both asymmetric division of intermediate progenitors in the 
VZ/SVZ (45, 46) and symmetric division of local GFAP astrocytes (43). Production from VZ/SVZ 
progenitors gradually ceases in early post-natal development (45, 46). In contrast, local 
production from GFAP astrocytes in other regions continues at low levels (<0.5%) three to four 
weeks after birth (43). 
Regional astrocyte diversity is generated perinatally through production from specific 
progenitor cell populations. For example, dorsal (Emx1+), medial (Dbx-1+), and intermediate 
(Nkx2.1+) progenitors produce astrocytes in the cortex, diencephalon, and hypothalamus, 
respectively (47). Specific progenitor populations also influence regional astrocyte heterogeneity 
in the developing spinal cord (48). These distinct cellular ontogenies could account for different 
regional transcriptomes seen in the adult mouse brain (49-51), as well as regional expression of 
astrocyte markers, such as GFAP, GLAST, GLT1, and ALDH1L1 (42). Specificity of these 
markers has been utilized to develop GEM models that target specific astrocyte subpopulations 
(48). While astrocytes expressing GFAP or ALDH1L1 are abundant throughout the brain (52), 
GLAST or GLT-1 expressing astrocytes are restricted regionally (53-56). Oncogenic mutations 
have been exclusively targeted to astrocytes using the GFAP promoter in mouse models of glioma 
(14). Thus, it remains unclear whether subpopulations of astrocyte are uniformly susceptible to 
oncogenic mutations. One recent report showed regional growth differences of cultured NF1-null 
astrocytes harvested from the cortex, cerebellum, brain stem, and olfactory bulb of the neonatal 
mouse brain (51). However, whether astrocyte heterogeneity impacts gliomagenesis in the intact, 
adult mammalian brain remains unexplored. 
 Cells and growth factors present in the local microenvironment are also able to interact 
with the initially transformed cell to influence resulting tumor heterogeneity. Glial cells in the 
surrounding microenvironment show regional transcriptome variability, which may reflect their 
distinct ontogenies and could impact tumor pathogenesis (57). Moreover, gliomas consist of a 
mixture of transformed cells and recruited glia. In fact, recruited astrocytes may constitute a 
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majority of cells within a given tumor (58) and have been shown to promote tumor invasion (37). 
Furthermore, tumor-associated OPC have been shown to promote neovascularization and disrupt 
the blood brain barrier (59). Microglia may also make up a sizable fraction of cells within a tumor 
(60) and these cells have been shown to create a symbiotic microenvironment that promotes 
tumor growth (61-63). However, the role of the cellular microenvironment upon resulting tumor 
heterogeneity remains unclear. 
 Based on these finding, and the results of our work, we propose that initiating mutations, 
cell of origin, and regional/microenvironmental heterogeneity interact to influence glioma 
heterogeneity. However, the specific molecular mechanisms that allow terminally differentiated 
cell types such as astrocytes to undergo dedifferentiation and proliferation is still incompletely 
understood. Recent gene expression studies have indicated that Sox2, an HMG box transcription 
factor previously thought to be restricted to NSC, is expressed in cortical astrocytes early in 
development and throughout adulthood in mice (52, 64, 65). Sox2 expression is critical during 
embryogenesis, characteristic of multipotent, actively dividing NSC, and necessary to induce 
dedifferentiation of fibroblasts into pluripotent stem cells (66-69). Sox2 could also be critical for 
maintenance of plasticity of adult astrocytes, thus making them a strong candidate cell of origin 
for glioma. In the normal adult brain, terminally differentiated astrocytes are quiescent; NSC and 
OPC are thought to be the only proliferating cells. However, in response to CNS damage, 
differentiated adult astrocytes are able to transiently reenter the cell cycle, express primitive cell 
markers, and undergo hypertrophy to aide in the wound response process termed reactive gliosis 
(70). Alternatively, proliferation of terminally differentiated astrocytes is able to occur in response 
to mutations. 
The presence of transcription factors associated with stemness in astrocytes suggests 
that these cells may be primed for dedifferentiation and cell cycle reentry in response to two 
distinct pathological responses: traumatic injury and oncogenic mutations. Stem cell transcription 
factors have previously been shown to dedifferentiate several terminally differentiated cell types. 
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For example, a transcription factor cocktail consisting of Sox2, Oct4, c-Myc, and Klf-4 has been 
shown to induce fibroblasts dedifferentiation and to reprogram them into induced pluripotent stem 
cells (iPS) (71). Sox2 is likely the most important transcription factor within this cocktail, since 
removal of Sox2 resulted in reduced efficiency of iPS induction. In contrast, removal of c-Myc 
failed to fully ablate iPS induction, suggesting Sox2 is more critical (72). Additional evidence of 
the critical role of Sox2 to reprograming is that generation of iPS from fibroblasts is achievable 
with the use of Oct4, Sox2, Nanog, and Lin28. These results suggest that c-Myc and Klf4 are 
supporting factors, whereas Sox2 and Oct4 are central for iPS generation (73). Moreover, Sox2 
is specifically involved in the induction of NSC from fibroblasts (74). This evidence indicates that 
Sox2 is critical for the induction of stemness, especially in the brain. 
Conditional, inducible GEMM are ideally suited for experimentally addressing how these 
separate variables influences tumor heterogeneity as well as the molecular mechanisms 
underlying astrocyte entry into the cell cycle. We have developed GEMM using mutations in the 
G1/S and RTK core GBM pathways in adult GFAP+ brain cells (14, 32). To disrupt the G1/S 
checkpoint, we inactivated all three members of the Rb family of pocket proteins using a single 
GFAP-driven transgene encoding the N-terminal 121 amino acids of SV40 large T antigen (T121, 
T) (31). A conditional knock-in encoding constitutively active Kras (KrasG12D, R) and a conditional 
Pten knockout (PtenDel, P) were used to separately activate MAPK and PI3K signaling (12, 75-
77). 
Despite the existence of various glioma GEMM (14), most studies have only examined the 
genomic profiles of high-grade glioma from terminally aged mice.  Genomic evolution during 
malignant progression has yet to be examined. Here, we use our conditional, inducible GEM 
glioma models to examine the genetic requirements for tumorigenesis and the genomics of tumor 
evolution during malignant progression. We showed that functional ablation of all three Rb family 
proteins was required for low-grade glioma initiation and tumor growth rates varied by brain 
region. Mutation and region specific transcriptome profiles were evident in these tumors, 
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suggesting that driver mutations and the initially transformed cell contribute to genomic 
heterogeneity. Low-grade glioma stochastically progressed to glioblastoma, in part through 
acquisition of location-specific copy number alterations. Although high-grade tumors were 
initiated by identical mutations in GFAP+ astrocytes, their transcriptomes were heterogeneous 
and consisted of three subtypes that resembled human mesenchymal, proneural, and neural 
glioblastomas. These subtypes were confirmed in a test set of high-grade mouse glioma driven 
by different oncogenic mutations in different cells of origin. High-grade tumor transcriptome 
subtypes correlated with brain region and resembled the transcriptomes of purified neural cells. 
In combination, these results suggest that oncogenic drivers influence low-grade glioma genomic 
profiles and that regional astrocyte identity and progression-acquired mutations contribute 
strongly to the genomic heterogeneity of glioblastomas. 
Also, we leveraged our GEMM to determine whether subpopulations of adult astrocytes 
respond similarly to identical oncogenic mutations. We targeted TRP mutations to different 
subpopulations of adult astrocytes using GFAP-CreER and GLAST-CreER and used genetic 
lineage tracing to monitor tumor growth and fate map transformed cells over time. Here, we 
demonstrate that TRP mutations transform GFAP astrocytes into rapidly growing tumors that are 
broadly distributed in multiple brain regions. In contrast, targeting these same mutations to the 
GLAST subpopulation produce slower growing tumors with regional differences in growth, 
significant microenvironmental responses from local, proliferating glia, and delayed malignant 
progression. 
Finally, we used our GEMM to explore the molecular mechanism which allow astrocytes 
to reenter the cell cycle. We used Sox2-GFP mice to establish that Sox2 was expressed in 
astrocytes outside of neurogenic niches in the adult brain. We used hGFAP-CreER;Sox2f;Sox2-
GFP mice to show that Sox2 deletion in astrocytes altered the process of wound healing, 
increasing the number of proliferative cells near the wound and lengthening the process of wound 
healing. We found that stable knockdown of Sox2 does influence the proliferation of tumorigenic 
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astrocytes immortalized with TRP mutations in vitro in a genotype dependent manner, however 
genetic ablation of Sox2 in our glioma GEMM does not influence tumor initiation in vivo. These 
results indicate that Sox2 is important for astrocyte proliferation in response to extrinsic 
pathological stimuli during wounding, however Sox2 expression is not essential for tumor initiation 
and growth. 
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Chapter II: Genomic profiles of low-grade murine gliomas evolve during progression to 
glioblastoma. 
 
Introduction 
 
Diffuse gliomas are the most common primary brain cancers and are characterized by 
extensive morphological, molecular, genomic, and biological heterogeneity. Diagnostic 
classification has traditionally been based on tumor cell morphology and prognosis: astrocytomas 
resemble astrocytes and are biologically aggressive, while oligodendrogliomas resemble 
oligodendrocytes and are more indolent. Histology grade has been used to further predict 
prognosis and guide care (9, 78). Low-grade gliomas (LGG, grade II) have a 10-15-year survival 
and lack the proliferation, angiogenesis, and necrosis present in high-grade gliomas (HGG). HGG 
include anaplastic gliomas (grade III) and glioblastoma (GBM, grade IV) and have prognoses of 
3-5 years and 12-15 months, respectively (9, 78). Recent genomics discoveries have provided an 
impetus to modify classification to include both morphological and genotypic features (9). Despite 
advances in classification, the failure of adjuvant therapies, inevitability of tumor recurrence, and 
dismal patient outcomes have continued to fuel research to define the sources of glioma 
heterogeneity. 
Two main sources have been proposed: initiating mutations and cellular origin (11). In the 
mutation model, different oncogenic mutations transform a single cell type to produce different 
tumor subtypes. Support for this model has come from The Cancer Genome Atlas (TCGA), which 
examined the genomic heterogeneity of primary GBM, LGG, and anaplastic gliomas (5, 10, 12, 
13, 79). TCGA and other groups have defined four transcriptome subtypes of primary GBM by 
comprehensive molecular profiling and found that select mutations correlated with transcriptome 
subtype (5, 7, 13). The most frequently mutated genes functioned in 3 “core GBM pathways” -
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G1/S cell cycle, receptor tyrosine kinase (RTK), and TP53 (5, 12, 13). TCGA and other groups 
have also defined 3-4 transcriptome subtypes of “lower grade gliomas” (including grade II and 
grade III, anaplastic gliomas) that were enriched for particular mutation profiles (10, 80, 81). 
In contrast, the cellular origin model proposes that tumor subtypes arise from 
transformation of different cell types by identical driver mutations. The mammalian brain is 
composed of multiple cell lineages with overlapping hierarchies. Cell distribution, as well as gene 
expression profiles, vary according to developmental stage and brain region (28). Preliminary 
support that the cellular origin model influences glioma pathogenesis comes from the finding that 
GBM subtypes mimic particular neural cell transcriptomes (5, 13). Genetically-engineered mouse 
(GEM) models have also been used to show that different neural cell types can be transformed 
to induce gliomas in vivo (14). We and others have used GEM to show that oncogenic mutations 
can transform astrocytes, the most common neural cell type (14, 18, 35, 82). Astrocyte location 
is programmed during development and remains static in adult life (43, 47). Importantly, 
astrocytes are biologically heterogeneous due to both region-specific and intra-regional 
microenvironmental influences (49, 83). We have found that transformation of different 
populations of astrocytes with identical driver mutations produces tumors with distinct natural 
histories, suggesting that intrinsic astrocyte heterogeneity contributes to glioma pathogenesis 
(82). 
GEM models are uniquely suited to address the genetic and cellular mechanisms of 
glioma pathogenesis because they allow temporal control of driver mutations at defined 
developmental time points and control of cellular origin. Despite the existence of numerous glioma 
GEM models, most studies have only examined the genomic profiles of tumors from terminally 
aged mice (14). The evolution of genomic profiles during the course of malignant progression has 
yet to be examined. In this report, we expanded on our previous work with a series of conditional, 
inducible GEM models in which the mitogen-activated protein kinase (MAPK) and/or 
phosphatidylinositol-3-kinase (PI3K) effector arms of RTK signaling are mutationally activated in 
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G1/S checkpoint-defective adult mouse astrocytes (32, 82). We use this model system here to 
examine the genetic requirements for tumorigenesis within G1/S and MAPK pathways and the 
genomics of tumor evolution during progression from low- to high-grade disease. 
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MATERIALS AND METHODS 
Genetically-engineered mice. Heterozygous TgGZT121 (T), KrasG12D (R), GFAP-CreER, PLP-
CreER, NG2-CreER, and Rosa26-tdTomato mice and homozygous Pten (P), p53, Rb1, and Nf1 
mice were maintained on C57/Bl6 background (>94%). PCR genotyping was performed as 
previously described (75, 82, 84). Recombination was induced with 1 mg of intraperitoneal 4-
hydroxytamoxifen for five consecutive days. Animal studies were approved by the UNC 
Institutional Animal Care and Use Committee. 
 
Histopathology. Diagnosis and grading was conducted using WHO criteria.(9) Tumor burden 
was quantified 2 months after induction using hematoxylin and eosin stained sections and digital 
image analysis (85). 
 
Genetic lineage tracing. Genetic lineage tracing and immunofluorescence staining was 
performed on mice sacrificed ~2-months after induction, as previously described (82). 
 
Microarray analyses. RNA from brains harvested 2 months after induction were hybridized to 
Agilent Whole Mouse Genome 4×44K microarrays (G4122F), while brains from terminally aged 
mice were hybridized to 4x44Kv2 (G4846A). Stratagene Universal Mouse Reference RNA 
(Agilent, #740100) was co-hybridized to each array. DNA was hybridized to Agilent Mouse 244A 
microarrays (G4415A) using a pooled DNA reference made from wild-type C57/Bl6 and 
phenotypically wild-type syngeneic littermates. All original raw microarray data are deposited in 
UNC Microarray Database (http://genome.unc.edu) and NCBI GEO (GSE49269). 
 
Bioinformatics. Microarray data was normalized using Lowess. Further analyses, including 
CombatR removal of batch effects, consensus clustering with ConsensusClusterPlus, and 
principal components analysis (PCA), significance analysis of microarrays (SAM), SigClust, 
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silhouette width, classification to nearest centroids (ClaNC), and single-sample gene set 
enrichement (ssGSEA) analyses were performed in R. SWITCHdna analyses were conducted in 
R using the current (GSE49269) and published datasets (GSE22927) (18). Neural lineage-
specific gene signatures were examined using GSE9566 (52). Mouse genes were converted to 
human orthologs using the Jax MGI database. Human lower-grade astrocytoma signatures were 
examined using GSE35158 (81). TCGA subtypes were predicted using murine orthologs of TCGA 
GBM ClaNC 840 classifier genes.12,25 High-grade TR(P) tumor subtypes were validated using 3 
similar datasets (GSE22927, GSE35917, and GSE29458) (18, 35, 86). Data from 236 human 
GBM (TCGA) with aCGH, sequencing, and mRNA and protein expression data were analyzed 
using the cBio Cancer Genomics Portal (87). ConsensusClusterPlus and gene set variation 
analysis (GSVA) analyses were conducted on the current dataset (GSE49269), orthotopic patient 
derived xenograft (PDX) models (GSE38814), and human glioblastomas (Level 3) from the TCGA 
data portal (https://tcga-data.nci.nih.gov/tcga/). 
 
Met expression in cultured T astrocytes. Cultured T astrocytes were infected with recombinant 
MSCV retroviral particles encoding Met (Addgene #17493). Receptor expression and proliferation 
were analyzed by immunoblot and CellTiter AQ (Promega) proliferation assays as previously 
described (75, 84). 
 
Magnetic Resonance Imaging. Pre- and post-gadolinium enhanced T1 and T2-weighted images 
of TRP+/- mouse brains were acquired at weekly intervals beginning 2-months after induction. 
Tumor volumes on T2 scans were calculated using MIPAV software. 
 
Supplement. Supplemental methods, figures, and tables can be found online. 
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RESULTS 
Core GBM pathway mutations induce regional variability in adult murine astrocyte-derived 
tumorigenesis 
We have shown that an N-terminal, 121 amino acid mutant SV40 large T antigen (T121, T) 
transgene expressed from the glial fibrillary acidic protein (GFAP) promoter ablates the G1/S 
checkpoint and immortalizes cultured murine astrocytes (75, 88). Cooperativity among activating 
mutations in the MAPK (KrasG12D, R) and PI3K (Pten deletion, P) pathways was required to induce 
GBM in a non-germline GEM (nGEM) orthotopic allograft model system (75, 84). To determine 
the effects of these mutations on adult astrocytes in situ, we developed germline GEM models 
with floxed T, R, and/or P oncogenic alleles. Mutation were induced in astrocytes via tamoxifen-
induced, GFAP-CreER-mediated recombination. We also showed that T, but not R, P, or RP, was 
sufficient to induce tumorigenesis and that R and/or P mutations potentiated progression of T-
driven high-grade gliomas (32). Lineage tracing showed that recombination occurred specifically 
in astrocytes and was extremely rare in microglia, oligodendrocyte precursor cells (OPC), and 
neurons (82). We used T(RP) GEM models here to examine the influence of driver mutations and 
cellular origin on gliomagenesis and how tumor genomic profiles evolve during progression (Fig 
S2.1). 
Histopathological evaluation of T(RP) tumors at 2 months suggested that mutations in 
multiple pathways influenced low-grade tumor burden (Fig S2.2, Table S2.1) (32). Low-grade 
tumors were evident in all T(RP) mice and small, high-grade tumors with elevated mitotic activity 
developed in a subset of TRP-/- mice (Fig 2.1A). To further explore whether progression had 
occurred in TRP+/- mice that exclusively developed low-grade tumors, we used tdTomato lineage 
tracing and Ki-67 immunostaining to detect cycling tumor cells (82). TRP+/- mutations increased 
tdTomato cell density at 2 months (Fig 2.1B) and produced classic glioma features, including 
perineuronal satellitosis (Fig 2.1C). Ki-67 staining revealed hypercellular foci with increased 
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proliferation relative to surrounding diffuse tumor (Fig 2.1D), suggesting that TRP+/- induces focal 
high-grade disease even at this early time point in their malignant evolution. 
Histopathology also demonstrated that T(RP) mutations induced regional differences in 
tumorigenesis (Fig S2.2). We next examined whether initiating genotype influenced regional 
growth patterns using a newly-developed histological and digital image analysis method to 
quantify regional cellularity (85). Compared to lineage tracing, use of hematoxylin and eosin 
(H&E)-stained sections was more straightforward and avoided complex breeding and confocal 
imaging. We validated this method by quantifying cellularity of histologically normal brains and 
controlling for variability along the sagittal sectioning axis (Fig S2.3A). We found that the 
cellularity of P, R, and RP brains was not significantly different than wild-type C57Bl/6 mice, a 
quantitative result consistent with their lack of tumor (Fig S2.3BC). Both initiating genotype (Fig 
2.1E) and brain region (Fig 2.1F) significantly affected tumor burden. These results suggest that 
the anatomic location of the cell of origin, as well as MAPK and/or PI3K pathway genotype, 
influences tumor development in G1/S-defective adult astrocytes. 
 
Lower-grade T(RP) glioma transcriptomes have signatures reflective of oncogenic drivers 
and astrocyte location 
We next examined the transcriptomes of gliomas harvested 2 months after induction from 
2 regions with the highest tumor burden across genotypes, olfactory bulb and forebrain. 
Unsupervised PCA showed separation of normal olfactory bulbs and forebrains, as well as low-
grade tumors in both regions (Fig 2.2A). Moreover, low-grade tumors with and without KrasG12D 
grouped separately in both locations; olfactory bulbs without tumor did not show a KrasG12D effect 
(Fig 2.2B). Consensus clustering confirmed the effects of KrasG12D status and brain region on 
tumor transcriptomes (Fig 2.S4). These findings demonstrate that T(RP) low-grade tumors have 
KrasG12D oncogenic driver- and astrocyte location-specific transcriptome signatures. 
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SAM was conducted to identify genes differentially expressed between low-grade tumors 
and normal brain, as well as low-grade tumors with and without KrasG12D (Table S2.2AB) (89). 
Gene ontology (GO) analyses of genes upregulated in tumor versus normal brains showed 
enrichment of proliferation, cell cycle, and mitosis-related processes (Table S2.3A). In contrast, 
genes upregulated in tumors with KrasG12D versus those without showed enrichment of immune 
and cell stress responses (Table S2.3B). To determine whether KrasG12D signature genes 
identified in mouse LGG (Table S2.3C) were differentially expressed among human gliomas, we 
assessed their enrichment in lower-grade (non-GBM) astrocytomas (81). The KrasG12D signature 
was manifest in the “pre-glioblastoma” (PG) subtype (Fig 2.2C). These patients had the shortest 
survival and their tumors consisted of more anaplastic (grade III) than diffuse (grade II) 
astrocytomas. Moreover, PG gliomas had genomic landscapes similar to GBM, including frequent 
EGFR amplification and CDKN2A and PTEN deletions (10, 81). Taken together, these data 
suggest that the molecular phenotype of rapidly-progressing, KrasG12D-driven murine LGG is 
similar to aggressive lower-grade human astrocytomas (32). 
GO analysis showed that low-grade T(RP) tumors harbored dysregulated G1/S and G2/M 
cell cycle checkpoint genes (Fig 2.2D, Table S2.3A). We therefore tested for aberrant G1/S 
signaling by p16 immunofluorescence. Unlike adult, age-matched wild-type mice that lack p16 
expression in astrocytes (Fig 2.2EF), TRP mutations induced p16 expression in transformed 
astrocytes (Fig 2.2G) (90). These findings are consistent with compensatory upregulation of G1/S 
checkpoint genes in TRP-induced low-grade tumors. 
 
Ablation of all Rb family members is required for astrocyte tumorigenesis 
We compared Rb1 loss to T121 and KrasG12D to Nf1 loss to determine if mutations within 
the same pathway could substitute for one another at tumor initiation. T(RP) mice were examined 
in all genotypic combinations and floxed Rb1 and Nf1 were substituted for T and R, respectively. 
Rb1 deletion failed to initiate tumorigenesis anywhere in the brain, in both the presence and 
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absence of Pten deletion (Fig 2.3A, Table S2.4B), a finding consistent with previous literature 
(18). Rb1;Pten co-deletion combined with either KrasG12D or Nf1 loss likewise showed no evidence 
of tumorigenesis. In contrast, all mice harboring T(RP) developed astrocytomas (32). T mice with 
either Nf1 or Nf1;Pten deletion(s) developed tumors (Fig 2.3A). Collectively, these results 
demonstrate that Rb1 loss is insufficient for tumorigenesis in adult astrocytes, even when 
combined with activating MAPK (KrasG12D or Nf1 deletion) and PI3K (Pten deletion) mutations. 
Rather, they suggest functional compensation among Rb family members occurs in these cells 
and that inhibition of all 3 Rb family proteins is required for astrocyte tumorigenesis. 
Further support for this hypothesis was evident in human GBM, where G1/S cell cycle 
checkpoint (RB pathway) mutations occur in 83% (Fig S2.5A). Importantly, while inactivating 
mutations and copy number losses were restricted to RB1, RB1 alterations trended towards co-
occurrence with reduced mRNA or protein expression in its pocket protein family members 
encoded by RBL1 or RBL2. This suggests functional compensation amongst RB proteins also 
occurs in human GBM and that downregulated expression of multiple RB family members is 
required to disrupt the G1/S checkpoint, particularly in the ~40% of GBM that lack the most 
common RB pathway mutation, CDKN2A/CDKN2B deletions. 
 
KrasG12D potentiates tumorigenesis 
We next compared KrasG12D with Nf1 deletion to determine whether different MAPK 
mutations contributed similarly to tumorigenesis. Kras is mutated in 2% and Nf1 is mutated in 
11% of human GBM (Fig S2.5B) (13). Each has previously been used in glioma GEM to model 
the downstream RAS-MAPK pathway activation elicited by more common alterations in upstream 
RTK genes (26, 32, 91). Moreover, we have recently shown that KrasG12D potentiates MAPK 
signaling, growth, migration, and invasion of G1/S-defective murine astrocytes in vitro and 
facilitates development of GBM when allografted into syngeneic mouse brains (75). We have also 
shown that KrasG12D induces progression to high-grade gliomas when targeted to G1/S-defective 
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murine astrocytes, but it remained unclear whether Nf1 deletion can functionally recapitulate its 
oncogenic effects in situ (32). 
As we previously described, KrasG12D alone or in combination with Pten deletion was 
insufficient for tumor initiation in adult astrocytes (32). We confirmed that these mice had normal 
brain architecture using histology and quantitative image analysis. Indeed, no increased cellularity 
was found in any brain region in R, P, and RP mice (Fig S2.3BC, Table S2.4B). We extended 
these findings and found that RP mutations were also insufficient for oligodendrocyte 
tumorigenesis in PLP-CreER mice (data not shown). This suggests that MAPK and/or PI3K 
mutations are insufficient to initiate tumorigenesis in multiple glial cell lineages in the adult brain, 
in the absence of concomitant Rb pathway disruption. 
Nf1 with or without Pten deletion was also unable to initiate tumorigenesis (Fig 2.3A, Table 
S2.4A). However, only KrasG12D, but not Nf1 deletion, increased progression to high-grade 
tumors. Previous work showed that Kras, but not other Ras isoforms, was activated upon Nf1 
deletion and that KrasG12D phenocopied Nf1 deletion in neonatal murine astrocytes in vitro and in 
vivo (92). Our work here shows that KrasG12D and Nf1 deletion fail to initiate tumorigenesis on their 
own, but only KrasG12D potentiates tumorigenesis in G1/S-defective adult astrocytes. 
 
KrasG12D tumors stochastically progress and acquire CNA 
We used a separate cohort of T(RP) mice to show that KrasG12D was critical for progression 
to anaplastic gliomas, while Pten deletion facilitated progression to GBM (32). To explore the 
genomics of malignant progression, we developed a new cohort of T(RP) mice here with similar 
tumor grades, survival, and histopathological features across all possible genotypes (Figs 2.3B, 
S2.6, Table S2.4B). The vast majority of T(P) mice developed low grade tumors (WHO grade II) 
but remained asymptomatic 9-18 months after induction. In contrast, TR(P) mice developed 
tumors that frequently progressed to lethal high grade disease. Survival of TR(P) mice was 
variable (Fig S2.6), suggesting that malignant progression occurred stochastically. We therefore 
 20  
monitored progression in TRP+/- mice using serial contrast-enhanced magnetic resonance 
imaging (MRI). High-grade tumors were evident on T1 and T2 imaging and enhanced with 
gadolinium, facilitating use of contrast enhancement (Fig 2.3C) as a surrogate for histological 
progression. At 3-5 months after induction, all mice developed focal, enhancing high-grade tumors 
(Fig 2.3DEF) in addition to low-grade tumors undetected by MRI (Fig 2.3DEGH). High-grade 
tumor onset was variable; growth was relentless and ultimately proved uniformly fatal (Fig 2.3IJ). 
These findings suggest that low-grade TRP tumors stochastically progress into rapidly 
proliferating, lethal high-grade tumors. 
Copy number alterations (CNA) are a hallmark of human glioma (12, 13). We 
hypothesized that similar alterations could drive malignant progression in TR(P) mice. Therefore, 
we performed array comparative genomic hybridization (aCGH) on T(RP) tumors harvested 
before and after onset of malignant progression. The former was systematically harvested at 2 
months from T(RP) mice. The latter was harvested from neurologically asymptomatic T(P) mice 
after 9-18 months and TR(P) mice at neurological morbidity. 
Lower-grade tumors harvested at 2 months from both T(P) and TR(P) mice possessed 
minimal and infrequent CNA (Fig 2.4A). Furthermore, lower-grade tumors from T(P) mice 
contained few CNA even after 18 months (Fig 2.4B), suggesting that copy number abnormalities 
may be a consequence of KrasG12D-induced malignant progression. This hypothesis was 
supported by the fact that high-grade tumors from morbid TR(P) mice developed widespread 
CNA, including frequent gains of chromosomes 1 and 6 (Fig 2.4CDE). Similar CNA were evident 
in all 3 high-grade TR(P) tumor genotypes, but CNA were most frequent in TR and least frequent 
in TRP-/- tumors. Only 3 high-grade tumors (7%) had no CNA and all were from TRP-/- mice with 
short survival (1.9-2.1 months). These results suggest that most high-grade TR(P) tumors acquire 
CNA during malignant progression. 
Among the core GBM pathways, Ccnd2, Stat1, Met, Braf, Kras, Raf1, and Mdm4 genes 
were gained in >20% (Fig 2.4F). Clear associations with brain region were also evident for each 
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gene (Fig 2.S7E). Specifically, diencephalon and brain stem tumors consistently showed more 
CNA than cortex or olfactory bulb tumors, suggesting variable vulnerability to genomic instability 
based on location of the astrocyte cell of origin (Fig S2.7). Other notable, but less frequent CNA 
were gains of Egfr, Erbb2, Pdgfrb, and Pik3ca oncogenes and loss of Pten, Cdkn2a, and Trp53 
tumor suppressors (Table S2.5). Chromosomal gains are frequently associated with oncogene 
overexpression in gliomas, including CMET (93). We therefore tested whether c-Met 
overexpression would potentiate T astrocyte proliferation in vitro. Increased receptor expression 
and phosphorylation was noted (Fig 2.4G) and increased proliferation was evident (Fig 2.4H). 
These results suggest that astrocytes in different brain regions have different susceptibilities to 
CNA, the acquisition of which manifests as a growth advantage. 
 
Gene expression profiling identifies 3 high-grade tumor subtypes that correlate with 
astrocyte location 
Because TR(P) mice had variable survival and their high-grade tumors harbored diverse 
CNA, we hypothesized that these tumors would also harbor significant inter-tumor heterogeneity. 
We therefore compared the expression profiles of 43 terminal TR(P) high-grade tumors using 
microarrays (Table S2.6). Three subtypes were identified using unsupervised consensus 
clustering (Fig S2.8ABC). SigClust confirmed clusters were unique (data not shown) and 
silhouette width analysis identified 42 core high-grade tumor samples with expression profiles 
most representative of each subtype (Fig S2.8D). Subtype did not correlate with initiating 
oncogenic mutations (Table S2.6), a finding consistent with the lack of a Pten deletion-related 
effect in low-grade tumors transcriptomes (Fig 2.2AB). These results suggest that Pten deletion 
does not significantly contribute to transcriptome heterogeneity, either before or after malignant 
progression in this model system. Although initiating TR(P) genotype correlated with survival (Fig 
S2.6A), subtype did not (Fig S2.9A). Subtype also significantly correlated with brain region (Fig 
S2.9B). Subtype 1 (S1) tumors were primarily located in the brainstem (72%) and some grew as 
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exophytic masses in the fourth ventricle. S2 tumors were primarily located in the olfactory bulb 
(50%). S3 tumors were located in all brain regions. These results suggest that regional astrocyte 
heterogeneity gives rise to high-grade tumors with distinct transcriptomes. 
High-grade tumor transcriptomes were also distinct from their genotype-matched low-
grade tumor counterparts (Fig 2.5A). This finding confirms that, despite consistent tumor initiation 
from identical TR(P) mutations, progression is associated with significant transcriptome evolution. 
These results are consistent with the transcriptome differences between non-genotype-matched 
human low- and high-grade tumors and suggest that secondary mutations acquired during 
malignant progression significantly influence glioma transcriptomes (94-96). This notion contrasts 
with a recent description of a proneural GEM that maintained similar expression at early and 
terminal time points (97). 
 
Transcriptome subtypes of high-grade murine tumors phenocopy human GBM 
We created a 600-gene classifier that correctly predicted subtype with 0% cross validation 
and error rates (Fig 2.5B, Table S2.7). In order to further characterize these subtypes, we 
examined differentially expressed genes using SAM (Table S2.8) and defined their biological 
functions using GO analyses (Table S2.9) (89). Immune and cytokine response, NF-ĸB pathway, 
and extracellular matrix genes were significantly expressed in S1 tumors, suggesting that this 
subtype was similar to human mesenchymal GBM (5, 7). We therefore classified the human GBM 
subtype of individual murine high-grade tumors using the 840-gene TCGA classifier. Nearly all 
high-grade S1 tumors (94%) were classified as, and clustered with, mesenchymal GBM (Fig 
S2.9CE, Table S2.6). S1 tumors were also enriched in mesenchymal GBM (Fig S2.9D) and 
cultured murine astrocyte signatures (Fig 2.5C), similar to human mesenchymal GBM (5, 52). 
Cell cycle, proliferation, and metabolism genes were significantly expressed in S2 tumors. 
The majority (75%) were classified as, and clustered with, proneural GBM (Fig S2.9CE, Table 
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S2.6). S2 tumors also expressed proneural GBM (Fig S2.9D) and proliferation and murine 
oligodendrocyte precursor signatures (Fig 2.5C), similar to human proneural GBM (5, 52, 98). 
Genes highly expressed in S3 tumors were enriched in synaptic transmission and other 
neuronal processes. TCGA classifier predicted 65, 29, and 6% of S3 tumors as human neural, 
proneural, and mesenchymal GBM, respectively, and all were enriched in a murine neuronal 
signature (Figs 2.5C, S2.9CE, Table S2.6) (52). ssGSEA showed enrichment of primarily 
proneural and neural GBM signatures (Fig S2.9D). These results imply that the transcriptomes of 
S3 tumors are heterogeneous, but are most similar to human neural GBM. 
Seven TR(P) mice developed 2 distinct high-grade tumors in different brain regions; four 
had different S1-S3 subtypes (Table S2.6). Six pairs were analyzed by aCGH and none contained 
identical genomic copy number landscapes (Table S2.10). Together, these data suggest that 
CNA acquired stochastically during progression significantly contribute to high-grade tumor 
transcriptome heterogeneity. 
 
S1-S3 subtypes are present in other adult GEM models of high-grade gliomas 
S1-S3 subtypes were validated in an independent test set of transcriptome data compiled 
from 3 adult high-grade GEM tumor models with different initiating mutations and cellular origins 
(Table S2.11) (18, 35, 86). The 600-gene classifier showed similar expression in both the 
discovery (Fig 2.5B) and validation sets (Fig 2.5D). Furthermore, validation samples clustered by 
both predicted human GBM and mouse S1-S3 subtypes. Similar to the results with TR(P) tumors, 
S1, S2, and S3 tumors in the validation dataset were primarily predicted as human mesenchymal, 
proneural, and neural, respectively (Fig S2.9F, Table S2.11). One dataset contained normal brain 
samples and these clustered with S3 neural tumors. This finding recapitulates the clustering of 
human non-neoplastic brain with neural GBM (5). 
Consensus hierarchical clustering of high grade TR(P) tumors with human patient-derived 
xenografts (PDX) and human GBM (TCGA dataset) using 8916 overlapping genes confirmed the 
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heterogeneity of GEM tumors and identified closely matching human PDX and GBM counterparts 
in all four TCGA subtypes (Fig 2.6, Tables S2.12-13). This validation suggests that 1) high-grade 
tumor expression profiles are conserved across adult GEM models despite different oncogenic 
drivers, cellular origins, and methods of tumor initiation; and that 2) expression profiles are 
conserved in murine and human high-grade gliomas. 
 
Deletion of p53 affects the CNA landscapes of murine high-grade tumors upon malignant 
progression 
Because high-grade tumors from both TR(P) and Rb1/Pten/p53 triple KO models 
reproduce multiple human GBM subtypes, we compared their CNA landscapes (18). While 
Rb1/Pten/p53 KO tumors harbored CNA in all autosomes (Fig S2.10B), the chromosomal pattern 
was more restricted in TR(P) tumors (Fig S2.10A). The role of p53 in maintenance of genomic 
integrity is well established (99). We therefore hypothesized that p53 deletion contributed to the 
difference between genomic landscapes in these models. To test this hypothesis, we bred a 
floxed Trp53 allele into T(RP) mice. At 2-6 months after induction, all T(RP);p53+/- mice harbored 
low-grade tumors and 4/14 had progressed to high-grade disease (Table S2.14). Similar to T(RP) 
mice without p53 deletion (Fig 2.4A), low-grade T(RP);p53+/- tumors harvested 2 months after 
induction were largely devoid of CNA (Fig S2.10C). In contrast to T mice without KrasG12D, where 
low-grade tumors failed to progress (Fig S2.6A) and lacked CNA even after 18 months (Fig 2.4B), 
a T;p53+/- mouse developed GBM with widespread CNA by 11 months after induction, similar to 
Rb1/Pten/p53 triple KO tumors (Fig S2.10D). These data support the conclusion that 
heterozygous p53 deletion in adult astrocytes results in widespread genomic instability. 
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DISCUSSION 
Driver mutations and cellular origin have been proposed as the major sources of cancer 
genomic heterogeneity (11). We previously developed a series of germline GEM models where 
adult murine astrocytes were targeted with driver mutations that dysregulated the Rb (T), MAPK 
(R), and/or PI3K (P) pathways to induce gliomagenesis (32, 75, 82, 84, 88). This model system 
provided a unique opportunity to investigate both sources of tumor heterogeneity during the 
evolutionary process of malignant progression. 
The role of initiating mutations on glioma heterogeneity 
We previously showed that ablation of the Rb family of pocket proteins encoded by Rb1 
(pRb), Rbl1 (p107), and Rbl2 (p130) was sufficient for low-grade tumor initiation in adult 
astrocytes, but KrasG12D, Pten, or their combination was not. Rather, KrasG12D and Pten deletion 
cooperated in Rb-deficient astrocytes to potentiate progression to GBM (32). We extended these 
findings here and found that deletions of Rb1, Nf1, or Pten, as well as double and triple 
combinations of these mutations, were insufficient for tumorigenesis (Fig 2.3). We also found that 
Nf1 deletion was less potent than KrasG12D for tumor initiation and progression (Fig 2.3) and that 
Pten deletion drove progression of T-driven tumors when combined with KrasG12D. 
We found that initiating mutations influence LGG burden as well as progression to lethal 
anaplastic gliomas, including GBM (Fig S2.6). Indeed, simultaneous activation of MAPK and PI3K 
through KrasG12D and Pten deletion in T astrocytes produced increasingly dense LGG and these 
tumors progressed more quickly (Figs 2.1, S2.2). High-grade tumors showed contrast 
enhancement on MRI and their growth was extremely rapid and lethal (Fig 2.3). We have 
previously shown that TR(P) tumors spontaneously acquire Pten loss-of-heterozygosity and 
Trp53 missense mutations (32). We extend these findings here and show that they also acquire 
CNA during progression, the frequency of which correlated with initiating genotype (Fig 2.4). 
Finally, we find that the transcriptomes of TR(P)-induced tumors evolve during the course of 
progression from low- to high-grade disease (Fig 2.5). 
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G1/S checkpoint function is critical for cell growth regulation; thus, virtually all human GBM 
acquire RB pathway mutations (12, 13). The RB pathway is controlled by p16INK4A and p15INK4B 
(encoded by CDKN2A and CDKN2B) as well as the RB family of G1/S checkpoint proteins: RB1, 
p107, and p130 (encoded by RB1, RBL1, and RBL2). CDKN2A/CDKN2B deletions are the most 
frequent RB pathway mutations in human GBM (~50-60%). RB1 mutations are less frequent 
(~10%) (5, 12, 13). RBL1 and RBL2 are infrequently mutated in human gliomas, but we found 
that their decreased expression tends to co-occur with inactivating RB1 mutations in GBM that 
lack CDKN2A/CDKN2B deletions (Fig S2.5). Human GBM data were supported here through our 
direct comparison of the tumor initiating potential of different Rb pathway mutations. Specifically, 
Rb1 deletion alone could not substitute for T121 or combine with KrasG12D to initiate tumorigenesis 
(Fig 2.3). These results suggest that p107 and/or p130 functionally compensate for Rb1 loss in 
adult murine astrocytes and possibly in human GBM. Similar results have been found in other cell 
types, as Rb1-deleted mouse embryonic fibroblasts and stem cells require p107 and p130 to 
avoid senescence, proliferate, and maintain pluripotency (100). 
In addition to affecting tumorigenesis, initiating mutations – KrasG12D but not Pten deletion 
– were also reflected in LGG expression profiles (Fig 2.2). Distinct transcriptome profiles (Fig 2.5) 
were evident in low-grade, Kras mutant tumors that were destined to progress to GBM [TR(P)] 
versus tumors that did not progress [T(P)] (Fig 2.3). The former tumors also had transcriptome 
signatures similar to the IDH wild-type, PG subtype of lower-grade human gliomas that feature 
activating RTK mutations (e.g. EGFR) and poor prognosis (10, 79-81). These findings are 
consistent with recent genetic studies of human gliomas suggesting that activating RTK and 
MAPK mutations drive malignant progression, while PI3K pathway mutations are a consequence 
of this process (101). One notable difference between TR(P) and human LGG is the extent of 
genomic instability (81). Whereas the former have relatively quiescent genomes, regardless of 
initiating genotype or tumor latency, human IDH wild-type lower-grade gliomas have more 
widespread copy number alterations, similar to GBM (10, 80, 81). This difference may be 
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attributable to species differences or the relative paucity of anaplastic, grade III gliomas present 
in our GEM tumors harvested 2 months after induction. 
 
Influence of cellular origin on glioma heterogeneity 
We also explored the impact of cellular origin on tumorigenesis, focusing on the inherent 
regional heterogeneity of astrocytes. We previously used lineage tracing to show that TRP 
mutations induce rapid proliferation of adult GFAP+ astrocytes throughout the brain and low-grade 
tumor growth over time (82). We expanded these findings here using a routine H&E-stained 
sections and digital morphometry to measure relative tumor burden at a single time point (85). 
We found that both initiating genotype and brain region influence low-grade tumor burden (Fig 
2.1). Genomic analyses showed that low-grade tumors retained transcriptome signatures (Fig 
2.2), and high-grade tumors acquired CNA (Fig S2.7), associated with their regional origin. 
Marked genomic heterogeneity was evident in high-grade TR(P) tumors (Fig S2.9). Three 
subtypes discovered in these mice were also present in an independent cohort of high-grade 
GEM tumors driven by diverse driver mutations and cellular origins (Fig 2.5). Finally, high-grade 
tumor subtype correlated with regional origin, suggesting that transcriptome heterogeneity may 
arise in part from regional differences in astrocyte biology (Fig S2.9). 
Human gliomas have been subtyped based on their transcriptomes in order to realize the 
potential of personalized medicine (5, 7, 10, 13, 79, 102, 103). GEM have been essential in 
defining the role of cellular origin in subtype specificity of other cancer types, but their use for 
glioma subtypes has been complicated by variability in model systems and driver mutations (14). 
Previous human studies have provided evidence that specific mutations are subtype defining in 
GBM: PDGFRA and EGFR amplifications are characteristic of proneural and classical GBM, while 
NF1 loss is characteristic of mesenchymal GBM (5). Data from GEM models support these 
correlations: PDGF drives proneural tumorigenesis when targeted to OPC, while Nf1 deletion 
induces mesenchymal differentiation (86, 104). However, the link between Nf1 deletion and 
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mesenchymal GBM has been inconsistent: Nf1 and Trp53 deletion induced proneural GBM in 
embryonic mouse NSC, as well as adult OPC (22, 38). The Egfr mutation, classical GBM 
relationship remains to be explored experimentally. 
In contrast, we and others have shown that GEM models targeting adult astrocytes with 
defined sets of mutations, including TR(P) and Trp53/Pten±Rb1, produce tumors from all 4 human 
GBM subtypes (18, 32). We used our large transcriptome dataset to define 3 subtypes of high-
grade TR(P) tumors that were evident in a validation dataset composed of adult glioma models 
with diverse oncogenic mutations and cellular origins (Fig 2.5). Further, we previously used GEM 
to show that regional astrocyte heterogeneity influences glioma tumorigenesis (82). This suggests 
that spatial astrocyte allocation and regional heterogeneity may account for tumor transcriptomes 
that are independent of driver mutations (47, 83). We have extended these findings here to show 
regional differences in tumor CNA (Fig S2.7). Taken together, these data suggest that factors 
other than initiating mutations, such as cellular origin and spontaneous, progression-associated 
mutations can promote tumor transcriptome diversity. 
Proneural GBM arises from mutations directly targeting OPC in GEM and our validation 
set includes data from one such model.58,65 Proneural GBM have also been produced by virally 
infecting NSC to overexpress PDGF, indirectly targeting PDGFRα+ OPC, and by targeting 
Trp53;Nf1 deletions to embryonic NSC (38). A subset of our TR(P) HGG had proneural GBM 
transcriptomes (S2), frequently occurred in the olfactory bulb, were enriched in an OPC 
transcriptome signature, and express OPC markers such as PDGFRα (data not shown). 
The GFAP promoter present in our adult GEM is not active in the oligodendroglial lineage, 
as tdTomato lineage tracing shows no co-localization with NG2, PDGFRα, O4, or CNPase (data 
not shown) (82). Rather, it targets ~60% of astrocytes throughout the brain, as well as 
subventricular NSC. Thus, OFB tumors could arise from either OFB astrocytes or NSC progeny 
that migrate from SVZ. We previously showed that stereotactic injection of an astrocyte-specific, 
Ad-GFAPCre into the OFB of TRP;tdTomato mice induces only OFB tumors; viral injection into 
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the SVZ induces tumors only in the SVZ and adjacent diencephalon (82). Taken together, these 
data suggest that OFB TRP tumors harbor an S2, proneural-like transcriptome due to induction 
of an OPC-like transcriptional program specifically in local astrocytes. Additional site specific 
induction experiments followed by transcriptomal analysis will shed light on this issue. 
A transcriptome shift between proneural and mesenchymal subtypes has been 
demonstrated in response to Nf1 loss or radiation therapy (7, 84, 104). We found that S1, 
mesenchymal-like, TR(P) tumors often arose in the brainstem and expressed signatures of 
cultured astrocytes (Fig 2.5). Like TR(P), mesenchymal tumors primarily developed in the 
brainstem of GEM in which Trp53;Pten deletions were targeted to adult astrocytes (Fig S2.9) (18). 
Mesenchymal gliomas have also been induced in astrocytes with Trp53 plus Hras or Nf1 
mutations (35, 105). Taken together, these data suggest that regional astrocyte heterogeneity 
may be an important determinant in the development of high-grade mesenchymal gliomas as 
well. 
Lastly, we described S3, neural-like high-grade tumors that occurred throughout the brain. 
These tumors had heterogeneous transcriptomes enriched for neuron signatures. These tumors 
maintained expression of astrocytic markers, but individual S3 high-grade tumors also highly 
expressed OPC, astrocyte, and oligodendrocyte signatures, suggesting that these tumors 
acquired divergent differentiation programs upon transformation (Fig 2.5). Similar transcriptome 
heterogeneity was evident in neural-like gliomas induced by Trp53 plus Hras mutations in 
hippocampal NSC (35). 
Determining how cellular origin, driver mutations, acquired genomic changes, and regional 
brain microenvironments contribute to high-grade glioma transcriptome heterogeneity has proven 
difficult, given the wide variety of model systems used. Our current study builds on previous GEM 
genomic analyses to suggest that there can be multiple cellular origins for GBM (Fig 2.5). S1-S3 
GFAP-Cre TR(P) high-grade tumors cover the transcriptome diversity present in previous high-
grade tumor GEM (Fig 2.5) and suggest that while initiating oncogenic drivers and/or acquired 
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CNA contribute to genome-wide transcriptome profiles (Fig 2.4), the cell of origin, brain region, 
as well as factors such as the regional microenvironment can play a prominent role in resulting 
tumor heterogeneity.  
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Figure 1.1. Initiating mutations and brain region influence tumorigenesis at 2-months. All 
T(RP) mice harbored low grade gliomas (blue). A subset (25%) of TRP-/- mice had progressed to 
high grade (red) (A).   Lineage tracing in TRP+/- mice (B) showed tdTomato (red) tumor cells in 
the cortex (CTX), diencephalon (DI), brainstem (BS), and olfactory bulb (OFB). tdTomato+ tumor 
cells developed perineuronal satellitoses around NeuN+ (green) neurons (C). Hypercellular, 
hyper-proliferative [Ki-67+ (green)] tumor foci were present in each region (D). Morphometric 
analyses showed that both initiating mutations and brain region affected tumor burden (two-way 
ANOVA P<0.002). Regional differences were evident between T-TP-/- mice (one-way ANOVA 
P=0.002), but not TP-TR or TR-TRP (P>0.11) (EF).   Scale bars 50 (B), 10 (C), and 100 µm (D). 
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Figure 1.2. Low-grade murine glioma transcriptomes show driver- and brain region-
associated signatures enriched in aggressive lower-grade human gliomas. Principal 
component analysis (PCA) showed that normal (black) and tumor (red, blue) olfactory bulbs 
(OFB) and forebrains (FB) have distinct transcriptomes (A). Transcriptomes of OFB and CTX 
tumors with (red) and without (blue) KrasG12D were also distinct. Although OFB transcriptomes 
from histologically normal mice with (black with red outlines) and without (black) KrasG12D were 
indistinguishable, the transcriptomes of low-grade OFB tumors with KrasG12D (red) were distinct 
from those without (blue) (B). A KrasG12D-related gene signature derived from OFB tumors was 
enriched in pre-glioblastoma (PG), but not neuroblastic (NB) or early progenitor-like (EPL) 
subtypes of human lower grade astrocytomas (C). mRNA expression (Log2 median-centered) of 
G1/S and G2/M cell cycle checkpoint genes was dysregulated in OFB tumors compared to 
histologically normal OFB (D). p16 was expressed in neuron-specific enolase (NSE)-positive 
cortical neurons, but not Gfap- or tdTomato-positive cortical astrocytes in adult wild-type, C57Bl/6 
(E) and GFAP-CreER;Rosa26-tdTomato (F) mice, respectively. In contrast, p16 was expressed 
in TRP-transformed Gfap/tdTomato-positive cortical astrocytes from age-matched TRP;GFAP-
CreER;Rosa26-tdTomato mice (G). Scale bar 10 µm. 
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Figure 1.3. KrasG12D and Nf1 loss potentiate tumorigenesis and low grade gliomas 
stochastically progress to rapidly proliferative, lethal high grade glioma. Among Rb pathway 
mutations, Rb1 loss (RbDEL) alone failed to initiate low-grade tumors in adult GFAP+ astrocytes at 
2 months post-induction, even in the presence of activating MAPK or PI3K mutations. Rather, 
ablation of all three Rb family members, pRb, p107, p130, using a single GFAP-driven T121 
transgene [T] was required. The activating MAPK pathway mutations KrasG12D [R] and Nf1DEL 
alone failed to initiate tumors. Both cooperated with T, but not Rb1DEL, to drive tumorigenesis. The 
activating PI3K pathway mutation PtenDEL [P] alone also failed to initiate tumorigenesis, but drove 
progression when combined with T and R, but not Nf1DEL. Histopathological examination of brains 
from terminally-aged mice (B) showed that 0-7% of T, TP+/-, and TP-/- mice harbored high-grade 
tumors (all WHO grade III). In contrast, 71-76% of TR, TRP+/-, and TRP-/- mice harbored high-
grade tumors [Chi-squared P≤0.001, TR(P)b vs. T(P)].   GBM developed in 35, 54, and 62% of 
TR, TRP+/-, and TRP-/- mice (Chi-squared P=0.065, TRP-/- vs. TR). Gadolinium contrast enhancing 
(C), high-grade (D), T121-positive tumors (E) developed focally in the context of widespread low-
grade tumors (D, F, H). A representative GBM with microvascular proliferation (G) from a TRP+/- 
mouse is shown (C-H). Quantification of serial T2-weighted magnetic resonance images showed 
logarithmic increases in high-grade tumor volume in 9 TRP+/- mice with mean doubling of 3±1 
days (I). Median time to first appearance of high-grade tumors, median survival, and mean time 
to death after appearance of high-grade tumors was 119±7 (range 84-154), 122±2, and 14±3 
days, respectively (J). 
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Figure 1.4. Initiating mutations influence CNA acquisition during malignant progression of 
high-grade TR(P) gliomas. Frequency plot of aCGH data showed minimal acquisition of copy-
number abnormalities (CNA) in T(P) and TR(P) lower-grade tumors at 2 months after induction 
(A). However, terminal low-grade tumors (> 1 year survival) rarely acquired CNA (B). All TR high-
grade tumors (C) showed gains of chromosome 6, but only 64-72% TRP+/- high-grade tumors (D) 
show similar gains (Fisher P=0.15). Half of TR, but only 16-20% of TRP+/- high-grade tumors 
showed chromosome 1 gains (Fisher P=0.17). TRP-/- high-grade tumors (E) acquired the least 
CNA and had the lowest frequency (13-25%) of chromosome 6 gains (Fisher P≤0.04). Initiating 
mutations (F) significantly influenced the development of CNA in recurrently altered (>20% of 
samples, Table S3) Rb, RTK/MAPK/PI3K, and p53 pathway genes (Fisher’s P≤0.16). To test 
whether c-Met increased astrocyte proliferation, we transfected T astrocytes with lentiviral vectors 
encoding Met and found increased receptor expression and phosphorylation (p-Met) by 
immunoblot (G). Met significantly increased T astrocyte proliferation by MTS assay in vitro (H). 
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Figure 1.5. High-grade murine glioma transcriptomes are heterogeneous and reminiscent 
of distinct neural cell types. PCA shows that low- and high-grade tumor transcriptomes were 
distinct. Separation of low-grade tumors from OFB and forebrain (FB), low-grade tumors with and 
without KrasG12D (Fig. 1.1), and S1-S3 high-grade tumor subtypes (Figs. S1.7) were preserved 
when low- and high-grade glioma transcriptome datasets were combined (A). Hierarchical 
clustering of high-grade TR(P) gliomas showed transcriptomal heterogeneity, with 3 subtypes 
defined by a 600-gene classifier (200 per subtype, Table S1.5) (B). ssGSEA of TR(P) gliomas 
showed enrichment of distinct neural cell lineage signatures (C). Cultured astrocyte, 
oligodendrocyte precursor cell (OPC), and neuron signatures were enriched in high-grade S1, 
S2, and S3 tumors and mesenchymal, proneural, and neural human GBM subtypes, respectively. 
Hierarchical clustering of an independent test set composed of 3 adult high-grade glioma GEM 
models with different initiating mutations showed that the 600-gene classifier accurately clustered 
samples according to their predicted S1-S3 subtypes (D).  
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Figure 1.6. High-grade murine gliomas are genomically heterogeneous and mimic human 
PDX and GBM subtypes. Consensus hierarchical clustering of high grade TR(P) gliomas with 
human patient-derived xenografts (PDX) and GBM (TCGA dataset) using 8916 overlapping genes 
identified five clusters. Sample annotation tracks include ClusterID (top), tumor type - GEM, PDX, 
GBM (middle), and TCGA subtype for human GBM (bottom). Silhouette widths for each sample 
are shown below. 
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Figure S1.1. Experimental Outline. An experimental map shows the timepoints after tamoxifen 
induction, the genotype of mice used, the pathology of the tumor at these timepoints, and the 
figures referencing each experimental timepoint. 
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Figure S1.2. Initiating mutations influence low-grade tumor burden. Representative H&E (A-
E, K-O) and T121 immunohistochemistry (F-J, P-T) images of wild-type (WT), T, TP, TR, and TRP 
mice shows tumor throughout the brain at 2 months after induction. T and TP mice had similar 
low-grade tumor burden (see Fig. 1AB). In contrast, TR and TRP mice had higher burden of low-
grade disease and had developed hypercellular foci of higher grade tumor (Fig. 1ABEF) at this 
time. Scale bars 1 mm (A-J) and 20 µm (K-T). 
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Figure S1.3. Morphometric analysis of nuclear density in phenotypically wild-type mice. 
Distance from sagittal midline affected nuclear density only in the OFB (A, N=3 wild-type C57Bl/6 
mice). Thus, nuclear density in all 4 brain regions was only obtained on sections 200-300 µm from 
midline. Adult wild-type C57Bl/6, as well as floxed P, R, and RP mice (N=5 per genotype) 
sacrificed at 2 months after induction showed no evidence of tumorigenesis and were thus 
phenotypically wild-type (B). No differences in cortex (CTX), diencephalon (DI), brainstem (BS), 
or olfactory bulb (OFB) nuclear densities were evident across these genotypes (one-way ANOVA 
P≥0.34), but nuclear density in the OFB was significantly greater than the other 3 brain regions 
(C, two-way ANOVA P<0.0001). 
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Figure S1.4. Lower-grade glioma transcriptomes cluster according to initiating mutations 
and brain region.   Consensus hierarchical clustering of olfactory bulb (OFB) and forebrain (FB) 
lower-grade glioma transcriptomes (Fig. 1.3A, Table S1.1) with the 5000 most variable genes 
identified four clusters (A) composed largely of normal or tumor FB (cluster 1), low-grade OFB 
tumors with KrasG12D (cluster 2), OFB tumors without KrasG12D (cluster 3), and normal OFB (cluster 
4). Consensus hierarchical clustering of only FB tumor transcriptomes (Fig. 1.3A, Table S1.1) 
showed 3 clusters (B) consisting of tumors with KrasG12D (cluster 1), normal FB (cluster 2), and 
tumors without KrasG12D (cluster 3), confirming that the influence of KrasG12D on lower-grade tumor 
transcriptomes was independent of brain region. 
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Figure S1.5. RB, RTK, MAPK, and PI3K pathway genes are frequently altered in human 
GBM. mRNA expression, copy number, and sequencing data from 291 GBM analyzed by TCGA 
were obtained from the cBio Portal for Cancer Genomics (3). Eighty three percent (N=241) 
harbored one or more significant RB pathway gene alterations. RB1 alterations trended towards 
co-occurrence with alterations in its pocket protein family members, RBL1 or RBL2 (P=0.097 and 
P=0.074, respectively) (A). Sixty two percent (N=180) harbored one or more significant RTK 
pathway gene alterations (B). Thirteen percent (N=38) harbored one or more significant MAPK 
pathway gene alterations. Forty nine percent (N=144) harbored one or more significant PI3K 
pathway gene alterations. 
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Figure S1.6. KrasG12D facilitates malignant progression to high grade glioma.   TR, TRP+/-, 
and TRP-/- mice developed neurological morbidity and showed significantly decreased median 
survivals of 4.5, 4.0, and 2.8 months, respectively (Log-rank P < 0.009 for all pairwise 
comparisons). In contrast, T, TP+/-, and TP-/- mice were neurologically asymptomatic when 
sacrificed 7-15 months after induction, similar to previously reported data (A) (23). H&E (B-EF, I-
M) and T121 immunohistochemistry (F-I, N-Q) showed low-grade tumors throughout the brain in a 
neurologically asymptomatic T mouse sacrificed 13 months after induction (B, F, J, N).   In 
contrast, multiple high-grade tumor (WHO grade III) foci were evident throughout the brains of 
symptomatic TR (C, G, K, O) and TRP-/- (D, H, L, P) mice. A second symptomatic TRP-/- mouse 
(E, I, M, Q) developed a diencephalic GBM with central hemorrhage and necrosis (indicated by 
*). Scale bars 1 mm (B-I) and 20 µm (J-Q). 
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Figure S1.7. Astrocyte location influences CNA acquired upon malignant progression in 
TR(P) high-grade tumors. Frequency plots of aCGH data showed that high-grade tumors 
developed copy number mutations that correlated with brain region in terminally-aged TRP+/- mice 
(A-D). Astrocyte location significantly influenced the development of CNA in frequently altered 
G1/S, RTK/MAPK, and TP53 pathway genes (E). 
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Figure S1.8. High-grade TR(P) glioma transcriptomes are heterogeneous and consist of 
three subtypes. Consensus clustering was performed using either 2000 or 5000 genes with 
highest median absolute deviation for k=3-6 (A). The bimodal distribution at 0 and 1 in the 
consensus index indicated well-defined subtypes (B). Consensus clustering reached a local 
maximum at 6 clusters (C), but 3 contained ≤2 tumors (A, bottom right). Positive silhouette widths 
identified 42 of 43 tumors as core subtype members (D). One sample with negative silhouette 
width was excluded from subsequent analyses (Table S2.4). 
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Figure S1.9. High-grade TR(P) glioma transcriptome subtypes correlate with brain region 
and human GBM subtype, but do not influence survival. In contrast to initiating mutations 
(Fig. S5B), high-grade glioma subtype did not influence survival (A, Log-rank P=0.4). S1 and S2 
subtypes were predominantly located in the brainstem (BS) and olfactory bulb (OFB), respectively 
(B, Fisher P=0.004). S1-S3 subtype correlated with human TCGA GBM subtype (C, Fisher P=2.2 
x 10-12). Similar S1-S3 and TCGA GBM subtype associations were evident in the GEM high-grade 
tumor test set (D). S3 tumors were found in BS, OFB, cortex (CTX) and diencephalon (DI). High-
grade TR(P) tumors (black bars) and human GBM (colored subtypes) expressed TCGA GBM 
840-gene classifier similarly and high-grade mouse tumors grouped according to their predicted 
TCGA subtype by hierarchical clustering (E). ssGSEA showed enrichment of mesenchymal, 
proneural, and neural/ proneural TCGA subtype signatures in high-grade S1, S2, and S3 TR(P) 
tumors, respectively (F). 
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Figure S1.10. Copy number landscapes of GEM high-grade tumor models with and without 
p53 deletion are distinct. Frequency plots of aCGH data from 41 TR(P) high-grade tumors 
showed frequent CNA only on chromosomes 1 and 6 (A). In contrast, 21 Rb1/Pten/p53 triple KO 
high-grade tumors (GSE22927) showed frequent CNA across the genome (B) [5], suggesting that 
p53 deletion in Rb1;Pten-deleted murine astrocytes significantly affected the spectrum of CNA 
acquired during malignant progression. Frequency plot of aCGH data from 10 astrocytomas from 
7 T(RP) mice with heterozygous p53 deletion showed minimal CNA at ~2 months after induction 
(C). GBM harvested from a terminally-aged, neurologically symptomatic T;Trp53+/- mouse showed 
a pattern of gains and losses more similar to Rb1/Pten/p53 triple KO (A) than TR(P) high-grade 
tumors (B), suggesting that p53 deletion induces widespread genomic instability and variable 
CNA landscapes during malignant progression (D). 
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Table S2.1. TRP LGG cohort: Mice sacrificed at 2 months after induction 
Mouse ID Genotype 
GFAP- 
CreER 
4OHT 
induction 
Sex 
Age at 
induction 
(days) 
Survival 
(days) 
Diagnosis 
(Fig. 2.1A) 
LGA Burden 
(Figs. 2.1EF, 
S2.3) 
Transcriptome 
samples (Figs. 
2.2, 2.5A, S2.4) 
207979 TP-/- No Yes M 61 67 Normal     
207967 TRP-/- No Yes F 61 67 Normal   
221182 P+/- Yes No M 100 66 Normal   FB 
223979 R Yes No F 127 74 Normal  OFB 
217861 TP+/- Yes No F 119 65 Normal   OFB, FB 
220435 TRP-/- Yes No M 111 66 Normal  OFB 
221699 TRP-/- Yes No M 90 66 Normal   OFB, FB 
219892 P-/- Yes Yes F 98 64 Normal S3 OFB 
219921 P-/- Yes Yes M 101 64 Normal S3 OFB 
220057 P-/- Yes Yes F 95 64 Normal S3 OFB 
221927 P-/- Yes Yes M 116 63 Normal S3 OFB 
221928 P-/- Yes Yes M 116 63 Normal S3 OFB 
214254 P+/- Yes Yes F 63 70 Normal S3 OFB 
217463 P+/- Yes Yes F 99 66 Normal S3 OFB 
217871 P+/- Yes Yes M 92 66 Normal S3 OFB, FB 
219899 P+/- Yes Yes M 98 64 Normal S3  
220724 P+/- Yes Yes F 107 66 Normal S3 OFB 
217708 R Yes Yes M 94 66 Normal S3  
219670 R Yes Yes M 98 65 Normal S3 OFB 
220060 R Yes Yes M 95 64 Normal S3  
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225561 R Yes Yes F 87 74 Normal S3 OFB 
225567 R Yes Yes F 87 74 Normal S3  
215214 RP-/- Yes Yes F 101 59 Normal S3 OFB, FB 
219159 RP-/- Yes Yes F 104 65 Normal S3 OFB 
219898 RP-/- Yes Yes M 98 64 Normal S3 OFB 
219918 RP-/- Yes Yes M 101 64 Normal S3 OFB 
220062 RP-/- Yes Yes M 98 45 Normal S3 OFB 
207970 RP+/- Yes Yes F 61 67 Normal S3  
214987 RP+/- Yes Yes M 104 59 Normal S3 OFB 
215216 RP+/- Yes Yes M 101 59 Normal S3 OFB, FB 
220061 RP+/- Yes Yes M 95 64 Normal S3 OFB 
221181 RP+/- Yes Yes M 100 66 Normal S3 OFB 
217872 T Yes Yes M 92 66 A2 1EF   
219147 T Yes Yes F 104 65 A2 1EF OFB, FB 
220727 T Yes Yes F 107 66 A2 1EF OFB, FB 
221184 T Yes Yes M 100 66 A2 1EF OFB, FB 
221940 T Yes Yes M 114 63 A2 1EF OFB, FB 
217857 TP-/- Yes Yes F 91 66 A2 1EF OFB 
219594 TP-/- Yes Yes F 98 65 A2 1EF OFB 
219595 TP-/- Yes Yes M 98 65 A2 1EF OFB 
219699 TP-/- Yes Yes M 98 65 A2 1EF OFB 
221180 TP-/- Yes Yes M 100 66 A2 1EF OFB 
215217 TP+/- Yes Yes M 101 59 A2   OFB, FB 
216188 TP+/- Yes Yes F 85 59 A2  OFB, FB 
219438 TP+/- Yes Yes F 97 65 A2   OFB 
219591 TP+/- Yes Yes M 98 65 A2  OFB 
219973 TP+/- Yes Yes M 101 64 A2   OFB, FB 
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246036 TP+/- Yes Yes F 98 63 A2   
214252 TR Yes Yes F 63 70 A2 1EF OFB 
222912 TR Yes Yes M 147 74 A2 1EF FB 
225569 TR Yes Yes F 87 74 A2 1EF FB 
225800 TR Yes Yes M 82 74 A2 1EF  
245121 TR Yes Yes M 134 60 A2 1EF   
245308 TR Yes Yes F 129 60 A2   
245310 TR Yes Yes F 129 60 A2 1EF   
215534 TRP-/- Yes Yes M 96 59 A2 1EF OFB, FB 
215697 TRP-/- Yes Yes M 94 59 A2 1EF OFB, FB 
216103 TRP-/- Yes Yes M 89 59 A2  FB 
216498 TRP-/- Yes Yes F 84 44 A2   OFB 
243054 TRP-/- Yes Yes M 129 63 A2  OFB, FB 
246037 TRP-/- Yes Yes M 98 63 A2     
214253 TRP-/- Yes Yes F 63 70 A3 1EF OFB, FB 
245665 TRP-/- Yes Yes M 106 60 A3     
214828 TRP+/- Yes Yes F 133 66 A2  OFB, FB 
216175 TRP+/- Yes Yes F 114 66 A2   OFB, FB 
217494 TRP+/- Yes Yes M 99 66 A2  OFB, FB 
217703 TRP+/- Yes Yes F 87 73 A2     
217706 TRP+/- Yes Yes F 87 73 A2  OFB 
219439 TRP+/- Yes Yes F 97 65 A2   OFB, FB 
219596 TRP+/- Yes Yes F 70 66 A2  OFB, FB 
219695 TRP+/- Yes Yes F 98 65 A2   OFB, FB 
219913 TRP+/- Yes Yes F 101 64 A2   OFB 
 
Summary 
    
 
5
2 
GFAP-CreER 4OHT induction Genotype Diagnosis 
Transcriptome Total 
Mice OFB FB 
No Yes 
TP-/- 
Normal 
  1 
TRP-/-     1 
Yes 
No 
P+/- 
Normal 
 1 1 
R 1  1 
TP+/- 1 1 1 
TRP-/- 2 1 2 
Yes 
P+/- 
Normal 
4 1 5 
P-/- 5  5 
R 2  5 
RP+/- 4 1 5 
RP-/- 5 1 5 
T 
A2 
4 4 5 
TP+/- 5 3 6 
TP-/- 5  5 
TR 1 2 7 
TRP+/- 8 6 9 
TRP-/- 
A2 4 4 6 
A3 1 1 2 
Total 52 26 72 
       
  Mean SD Min Max 
 
Age at induction (days) 98.3 17.2 61 147  
Post-induction survival (days) 64.7 5.3 44 74  
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Table S2.2. One versus rest SAM analysis of TRP LGG transcriptomes at 2 months after induction 
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Table S2.2B. One versus rest SAM analysis of T(RP) LGG transcriptomes at 2 months after induction 
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Table S2.3A. Enriched GO terms from LGG SAM analyses (FDR cutoff 0.0001) 
Comparison GO Term Description 
P-
value 
FDR q-
value 
LGG versus normal 
brain 
GO:002240
2 cell cycle process 
1.52E-
54 1.40E-50 
LGG versus normal 
brain 
GO:190304
7 mitotic cell cycle process 
7.61E-
48 3.50E-44 
LGG versus normal 
brain 
GO:000704
9 cell cycle 
2.42E-
47 7.42E-44 
LGG versus normal 
brain 
GO:004828
5 organelle fission 
1.20E-
38 2.76E-35 
LGG versus normal 
brain 
GO:000028
0 nuclear division 
6.25E-
38 1.15E-34 
LGG versus normal 
brain 
GO:000706
7 mitotic nuclear division 
7.74E-
34 1.19E-30 
LGG versus normal 
brain 
GO:005130
1 cell division 
6.18E-
33 8.11E-30 
LGG versus normal 
brain 
GO:000625
9 DNA metabolic process 
6.01E-
22 6.90E-19 
LGG versus normal 
brain 
GO:005172
6 regulation of cell cycle 
1.15E-
20 1.18E-17 
LGG versus normal 
brain 
GO:000705
9 chromosome segregation 
1.01E-
18 9.29E-16 
LGG versus normal 
brain 
GO:190258
9 single-organism organelle organization 
1.84E-
18 1.54E-15 
LGG versus normal 
brain 
GO:000699
6 organelle organization 
5.33E-
17 4.08E-14 
LGG versus normal 
brain 
GO:001056
4 regulation of cell cycle process 
9.93E-
17 7.02E-14 
LGG versus normal 
brain 
GO:000626
0 DNA replication 
2.51E-
16 1.65E-13 
LGG versus normal 
brain 
GO:001604
3 cellular component organization 
3.88E-
16 2.38E-13 
LGG versus normal 
brain 
GO:007184
0 cellular component organization or biogenesis 
1.46E-
15 8.37E-13 
    
 
1
2
9 
LGG versus normal 
brain 
GO:005130
2 regulation of cell division 
1.32E-
14 7.11E-12 
LGG versus normal 
brain 
GO:004476
3 single-organism cellular process 
1.79E-
12 9.16E-10 
LGG versus normal 
brain 
GO:000701
7 microtubule-based process 
4.14E-
12 2.00E-09 
LGG versus normal 
brain 
GO:000697
4 cellular response to DNA damage stimulus 
4.19E-
12 1.93E-09 
LGG versus normal 
brain 
GO:000628
1 DNA repair 
6.61E-
12 2.89E-09 
LGG versus normal 
brain 
GO:000734
6 regulation of mitotic cell cycle 
8.78E-
12 3.67E-09 
LGG versus normal 
brain 
GO:005127
6 chromosome organization 
1.09E-
11 4.37E-09 
LGG versus normal 
brain 
GO:007050
7 regulation of microtubule cytoskeleton organization 
3.82E-
11 1.46E-08 
LGG versus normal 
brain 
GO:003288
6 regulation of microtubule-based process 
7.22E-
11 2.65E-08 
LGG versus normal 
brain 
GO:000627
0 DNA replication initiation 
9.91E-
11 3.50E-08 
LGG versus normal 
brain 
GO:004578
7 positive regulation of cell cycle 
9.94E-
11 3.38E-08 
LGG versus normal 
brain 
GO:009006
8 positive regulation of cell cycle process 
1.03E-
10 3.37E-08 
LGG versus normal 
brain 
GO:000022
6 microtubule cytoskeleton organization 
1.17E-
10 3.71E-08 
LGG versus normal 
brain 
GO:000998
7 cellular process 
3.93E-
10 1.20E-07 
LGG versus normal 
brain 
GO:005178
3 regulation of nuclear division 
4.33E-
10 1.28E-07 
LGG versus normal 
brain 
GO:000007
5 cell cycle checkpoint 
4.89E-
10 1.40E-07 
LGG versus normal 
brain 
GO:190304
6 meiotic cell cycle process 
5.61E-
10 1.56E-07 
LGG versus normal 
brain 
GO:004469
9 single-organism process 
1.37E-
09 3.70E-07 
    
 
1
3
0 
LGG versus normal 
brain 
GO:000708
8 regulation of mitotic nuclear division 
1.65E-
09 4.33E-07 
LGG versus normal 
brain 
GO:003246
5 regulation of cytokinesis 
3.98E-
09 1.02E-06 
LGG versus normal 
brain 
GO:004578
6 negative regulation of cell cycle 
6.65E-
09 1.65E-06 
LGG versus normal 
brain 
GO:000631
0 DNA recombination 
7.29E-
09 1.76E-06 
LGG versus normal 
brain 
GO:003102
3 microtubule organizing center organization 
7.93E-
09 1.87E-06 
LGG versus normal 
brain 
GO:005129
7 centrosome organization 
7.93E-
09 1.82E-06 
LGG versus normal 
brain 
GO:004477
0 cell cycle phase transition 
8.94E-
09 2.00E-06 
LGG versus normal 
brain 
GO:004470
2 single organism reproductive process 
1.08E-
08 2.36E-06 
LGG versus normal 
brain 
GO:190198
7 regulation of cell cycle phase transition 
1.09E-
08 2.32E-06 
LGG versus normal 
brain 
GO:000091
0 cytokinesis 
1.13E-
08 2.35E-06 
LGG versus normal 
brain 
GO:005198
3 regulation of chromosome segregation 
1.46E-
08 2.97E-06 
LGG versus normal 
brain 
GO:000705
1 spindle organization 
1.64E-
08 3.28E-06 
LGG versus normal 
brain 
GO:005178
1 positive regulation of cell division 
1.81E-
08 3.54E-06 
LGG versus normal 
brain 
GO:004477
2 mitotic cell cycle phase transition 
1.93E-
08 3.69E-06 
LGG versus normal 
brain 
GO:009030
4 nucleic acid metabolic process 
2.78E-
08 5.22E-06 
LGG versus normal 
brain 
GO:009881
3 nuclear chromosome segregation 
3.08E-
08 5.66E-06 
LGG versus normal 
brain 
GO:190199
0 regulation of mitotic cell cycle phase transition 
3.25E-
08 5.85E-06 
LGG versus normal 
brain 
GO:005000
0 chromosome localization 
4.02E-
08 7.10E-06 
    
 
1
3
1 
LGG versus normal 
brain 
GO:005130
3 establishment of chromosome localization 
4.02E-
08 6.97E-06 
LGG versus normal 
brain 
GO:004593
0 negative regulation of mitotic cell cycle 
5.70E-
08 9.71E-06 
LGG versus normal 
brain 
GO:003246
7 positive regulation of cytokinesis 
8.93E-
08 1.49E-05 
LGG versus normal 
brain 
GO:000028
1 mitotic cytokinesis 
1.30E-
07 2.13E-05 
LGG versus normal 
brain 
GO:000708
0 mitotic metaphase plate congression 
1.49E-
07 2.41E-05 
LGG versus normal 
brain 
GO:000630
2 double-strand break repair 
1.74E-
07 2.76E-05 
LGG versus normal 
brain 
GO:000072
4 double-strand break repair via homologous recombination 
2.29E-
07 3.56E-05 
LGG versus normal 
brain 
GO:000072
5 recombinational repair 
2.29E-
07 3.50E-05 
LGG versus normal 
brain 
GO:002241
4 reproductive process 
2.33E-
07 3.51E-05 
LGG versus normal 
brain 
GO:000712
6 meiotic nuclear division 
2.35E-
07 3.49E-05 
LGG versus normal 
brain 
GO:006164
0 cytoskeleton-dependent cytokinesis 
2.60E-
07 3.80E-05 
LGG versus normal 
brain 
GO:003157
7 spindle checkpoint 
3.29E-
07 4.72E-05 
LGG versus normal 
brain 
GO:004393
3 macromolecular complex subunit organization 
3.48E-
07 4.92E-05 
LGG versus normal 
brain 
GO:003355
4 cellular response to stress 
3.76E-
07 5.23E-05 
LGG versus normal 
brain 
GO:190198
8 negative regulation of cell cycle phase transition 
4.55E-
07 6.25E-05 
LGG versus normal 
brain 
GO:000626
8 DNA unwinding involved in DNA replication 
5.29E-
07 7.16E-05 
LGG versus normal 
brain 
GO:000701
0 cytoskeleton organization 
5.51E-
07 7.34E-05 
LGG versus normal 
brain 
GO:000613
9 nucleobase-containing compound metabolic process 
7.05E-
07 9.26E-05 
    
 
1
3
2 
LGG versus normal 
brain 
GO:004648
3 heterocycle metabolic process 
7.72E-
07 1.00E-04 
LGG versus normal 
brain 
GO:005131
0 metaphase plate congression 
7.89E-
07 1.01E-04 
LGG versus normal 
brain 
GO:005164
0 organelle localization 
1.04E-
06 1.31E-04 
LGG versus normal 
brain 
GO:190199
1 negative regulation of mitotic cell cycle phase transition 
1.22E-
06 1.51E-04 
LGG versus normal 
brain 
GO:000081
9 sister chromatid segregation 
1.35E-
06 1.65E-04 
LGG versus normal 
brain 
GO:001094
8 negative regulation of cell cycle process 
2.08E-
06 2.51E-04 
LGG versus normal 
brain 
GO:007110
3 DNA conformation change 
2.44E-
06 2.91E-04 
LGG versus normal 
brain 
GO:009022
4 regulation of spindle organization 
2.90E-
06 3.42E-04 
LGG versus normal 
brain 
GO:003304
5 regulation of sister chromatid segregation 
3.71E-
06 4.32E-04 
LGG versus normal 
brain 
GO:000709
3 mitotic cell cycle checkpoint 
3.82E-
06 4.39E-04 
LGG versus normal 
brain 
GO:000672
5 cellular aromatic compound metabolic process 
4.23E-
06 4.80E-04 
LGG versus normal 
brain 
GO:190197
6 regulation of cell cycle checkpoint 
4.45E-
06 4.99E-04 
LGG versus normal 
brain 
GO:190136
0 organic cyclic compound metabolic process 
4.97E-
06 5.50E-04 
LGG versus normal 
brain 
GO:005165
6 establishment of organelle localization 
5.19E-
06 5.68E-04 
LGG versus normal 
brain 
GO:000626
1 DNA-dependent DNA replication 
6.00E-
06 6.49E-04 
LGG versus normal 
brain 
GO:005178
2 negative regulation of cell division 
7.83E-
06 8.37E-04 
LGG versus normal 
brain 
GO:000007
0 mitotic sister chromatid segregation 
8.44E-
06 8.92E-04 
LGG versus normal 
brain 
GO:190209
9 regulation of metaphase/anaphase transition of cell cycle 
8.47E-
06 8.85E-04 
    
 
1
3
3 
LGG versus normal 
brain 
GO:003007
1 regulation of mitotic metaphase/anaphase transition 
8.47E-
06 8.75E-04 
LGG versus normal 
brain 
GO:003304
4 regulation of chromosome organization 
8.83E-
06 9.02E-04 
LGG versus normal 
brain 
GO:005122
5 spindle assembly 
1.00E-
05 1.01E-03 
LGG versus normal 
brain 
GO:007189
7 DNA biosynthetic process 
1.27E-
05 1.27E-03 
LGG versus normal 
brain 
GO:007121
4 cellular response to abiotic stimulus 
1.48E-
05 1.46E-03 
LGG versus normal 
brain 
GO:003026
1 chromosome condensation 
1.50E-
05 1.47E-03 
LGG versus normal 
brain 
GO:005198
8 regulation of attachment of spindle microtubules to kinetochore 
1.53E-
05 1.48E-03 
LGG versus normal 
brain 
GO:005125
6 mitotic spindle midzone assembly 
2.15E-
05 2.06E-03 
LGG versus normal 
brain 
GO:000828
3 cell proliferation 
2.35E-
05 2.22E-03 
LGG versus normal 
brain 
GO:004500
5 DNA-dependent DNA replication maintenance of fidelity 
2.37E-
05 2.23E-03 
LGG versus normal 
brain 
GO:007147
8 cellular response to radiation 
2.53E-
05 2.35E-03 
LGG versus normal 
brain 
GO:004483
9 cell cycle G2/M phase transition 
2.56E-
05 2.36E-03 
LGG versus normal 
brain 
GO:000008
6 G2/M transition of mitotic cell cycle 
2.56E-
05 2.33E-03 
LGG versus normal 
brain 
GO:001096
5 regulation of mitotic sister chromatid separation 
2.59E-
05 2.34E-03 
LGG versus normal 
brain 
GO:003304
7 regulation of mitotic sister chromatid segregation 
2.59E-
05 2.31E-03 
LGG versus normal 
brain 
GO:000632
5 chromatin organization 
2.80E-
05 2.48E-03 
LGG versus normal 
brain 
GO:004426
0 cellular macromolecule metabolic process 
3.08E-
05 2.70E-03 
LGG versus normal 
brain 
GO:000707
6 mitotic chromosome condensation 
3.69E-
05 3.20E-03 
    
 
1
3
4 
LGG versus normal 
brain 
GO:000701
8 microtubule-based movement 
3.81E-
05 3.28E-03 
LGG versus normal 
brain 
GO:004593
1 positive regulation of mitotic cell cycle 
4.04E-
05 3.44E-03 
LGG versus normal 
brain 
GO:007182
4 protein-DNA complex subunit organization 
5.51E-
05 4.65E-03 
LGG versus normal 
brain 
GO:006500
4 protein-DNA complex assembly 
5.84E-
05 4.88E-03 
LGG versus normal 
brain 
GO:003304
3 regulation of organelle organization 
6.63E-
05 5.49E-03 
LGG versus normal 
brain 
GO:003243
5 
negative regulation of proteasomal ubiquitin-dependent protein 
catabolic process 
7.56E-
05 6.21E-03 
LGG versus normal 
brain 
GO:005125
5 spindle midzone assembly 
7.64E-
05 6.22E-03 
LGG versus normal 
brain 
GO:001056
9 
regulation of double-strand break repair via homologous 
recombination 
8.57E-
05 6.91E-03 
LGG versus normal 
brain 
GO:009023
1 regulation of spindle checkpoint 
9.66E-
05 7.72E-03 
LGG versus normal 
brain 
GO:004314
6 spindle stabilization 
9.75E-
05 7.73E-03 
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Table S2.3B. Enriched GO terms from LGG SAM analyses (FDR cutoff 0.0001) 
Comparison GO Term Description 
P-
value 
FDR q-
value 
TR(P) versus T(P) 
LGG GO:0006952 defense response 
1.26E-
11 9.48E-08 
TR(P) versus T(P) 
LGG GO:0051707 response to other organism 
6.70E-
10 2.52E-06 
TR(P) versus T(P) 
LGG GO:0098542 defense response to other organism 
1.57E-
09 3.94E-06 
TR(P) versus T(P) 
LGG GO:0051704 multi-organism process 
3.14E-
09 5.90E-06 
TR(P) versus T(P) 
LGG GO:0043207 response to external biotic stimulus 
4.58E-
09 6.90E-06 
TR(P) versus T(P) 
LGG GO:0009607 response to biotic stimulus 
4.82E-
09 6.04E-06 
TR(P) versus T(P) 
LGG GO:0009605 response to external stimulus 
1.47E-
08 1.58E-05 
TR(P) versus T(P) 
LGG GO:0051607 defense response to virus 
2.04E-
08 1.92E-05 
TR(P) versus T(P) 
LGG GO:0002376 immune system process 
4.26E-
08 3.57E-05 
TR(P) versus T(P) 
LGG GO:0006955 immune response 
8.18E-
08 6.16E-05 
TR(P) versus T(P) 
LGG GO:0045087 innate immune response 
1.12E-
06 7.67E-04 
TR(P) versus T(P) 
LGG GO:0050896 response to stimulus 
1.43E-
06 8.97E-04 
TR(P) versus T(P) 
LGG GO:0002252 immune effector process 
1.68E-
06 9.75E-04 
TR(P) versus T(P) 
LGG GO:0009615 response to virus 
1.78E-
06 9.59E-04 
TR(P) versus T(P) 
LGG GO:0048519 negative regulation of biological process 
2.01E-
06 1.01E-03 
TR(P) versus T(P) 
LGG GO:0048523 negative regulation of cellular process 
5.95E-
06 2.80E-03 
    
 
1
3
6 
TR(P) versus T(P) 
LGG GO:0006950 response to stress 
6.25E-
06 2.77E-03 
TR(P) versus T(P) 
LGG GO:0050794 regulation of cellular process 
1.01E-
05 4.24E-03 
TR(P) versus T(P) 
LGG GO:0002684 positive regulation of immune system process 
1.70E-
05 6.73E-03 
TR(P) versus T(P) 
LGG GO:0050789 regulation of biological process 
1.78E-
05 6.71E-03 
TR(P) versus T(P) 
LGG GO:0002682 regulation of immune system process 
1.81E-
05 6.48E-03 
TR(P) versus T(P) 
LGG GO:0008045 motor neuron axon guidance 
3.60E-
05 1.23E-02 
TR(P) versus T(P) 
LGG GO:0023051 regulation of signaling 
4.13E-
05 1.35E-02 
TR(P) versus T(P) 
LGG GO:0071310 cellular response to organic substance 
4.55E-
05 1.43E-02 
TR(P) versus T(P) 
LGG GO:0043903 
regulation of symbiosis, encompassing mutualism through 
parasitism 
7.01E-
05 2.11E-02 
TR(P) versus T(P) 
LGG GO:0065007 biological regulation 
8.60E-
05 2.49E-02 
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Table S2.3C. KrasG12D LGG signature (300 genes) 
Orthologous human genes used in ssGSEA (Fig. 2.2C) 
ABTB2 
ACADL 
ACAP1 
ADAM12 
ADORA2B 
AKR1B10 
ALDH1L1 
ALG13 
ALPL 
ANGPT2 
APLF 
APOBEC1 
ARHGAP18 
ARHGAP24 
ARHGAP31 
ARL11 
ARL6IP6 
ATP13A4 
B2M 
BAX 
BCL2L13 
BCL6B 
BORA 
BST2 
BVES 
C11orf82 
C12orf48 
    
 
1
3
8 
C1orf106 
C1orf183 
C1orf38 
C1QTNF6 
C2 
C2orf69 
C5orf62 
C6orf145 
CA3 
CACNG4 
CALCRL 
CAV3 
CBFB 
CBR3 
CCDC14 
CCDC69 
CCL4 
CCRL2 
CD48 
CD86 
CDC42EP1 
CDC42SE1 
CDCA3 
CDKN2A 
CHST7 
CLEC7A 
CMTM3 
CREB5 
CSPG4 
    
 
1
3
9 
CST7 
CTSC 
CTSD 
CTSS 
CTSZ 
CXCL10 
CXCL11 
CXorf21 
CYBB 
DCK 
DCTD 
DDX58 
DDX60 
DENND2A 
DHRS13 
DHX58 
DLL3 
DPF3 
DUSP6 
E2F2 
ECI2 
EDA2R 
EFEMP2 
EIF2AK2 
EME1 
ENTPD1 
EPN2 
EPS8 
EPSTI1 
    
 
1
4
0 
EPX 
ERCC6L 
ERI1 
ETV4 
ETV6 
EXOC4 
F2R 
FABP5 
FADD 
FAM5C 
FAM83D 
FAM84B 
FAM89A 
FBP1 
FBXO5 
FCGR1A 
FEN1 
FGFR1OP2 
FGFRL1 
FRK 
FZD9 
GALNT3 
GALNT4 
GAS1 
GBP4 
GBP5 
GBP7 
GM2A 
GNA14 
    
 
1
4
1 
GNG12 
GOLPH3 
GPC4 
GPNMB 
GRAMD3 
GSC 
GSTCD 
HCAR2 
HERC6 
HES6 
HEXB 
HIP1 
HLA-A 
HLA-DQA1 
HLA-DQB1 
HOXA1 
HOXA2 
HOXA5 
HOXA7 
HTRA2 
HTRA3 
HUS1 
ICAM1 
IFI27 
IFI27L2 
IFI44 
IFIH1 
IFIT1 
IFIT2 
    
 
1
4
2 
IGFBP2 
IGFBP3 
IL1RN 
IMPA2 
IRF5 
IRF7 
IRF8 
IRF9 
IRGM 
ISG15 
ITGA4 
ITGAX 
ITPR2 
ITPRIPL2 
JAM2 
KCNIP3 
KIAA1274 
KIF15 
KLF3 
KLHL5 
KRAS 
LGALS3BP 
LGALS9 
LIMS1 
LIMS2 
LIX1L 
LPAR6 
LPCAT1 
LRRC25 
    
 
1
4
3 
LTBR 
LYN 
MAD2L1 
MASP1 
MASTL 
MB21D1 
MDFIC 
MEGF6 
METRNL 
MLKL 
MMP15 
MOSC2 
MPEG1 
MPZL1 
MRPL51 
MYO1F 
NASP 
NKX2-2 
NRM 
OAS2 
OIP5 
PALB2 
PAPSS1 
PARP12 
PARP9 
PDE4B 
PDGFRA 
PIK3CG 
PIWIL4 
    
 
1
4
4 
PLCB2 
PLEK 
PLEKHF2 
PLK4 
PMAIP1 
PPIC 
PPP1R14B 
PRKCQ 
PRKD3 
PRND 
PROKR1 
PROS1 
PRR11 
PTGR2 
PTPRC 
RAB31 
RAD18 
RASAL3 
RBPMS2 
REEP3 
RFC3 
RHOQ 
RNF122 
RNF213 
RRS1 
RSAD2 
RTP4 
SAMD9L 
SEPT9 
    
 
1
4
5 
SERPINB5 
SH3BP4 
SHMT1 
SKA3 
SKAP2 
SLC12A4 
SLC15A3 
SLC16A10 
SLC25A43 
SLC27A6 
SLC37A2 
SLFN12L 
SLFN13 
SMAD5 
SMPDL3B 
SP100 
SPECC1 
SPRY1 
SPRY4 
SRD5A1 
STAT1 
STK17B 
SUCLG2 
SULF2 
TAMM41 
TBCCD1 
TDP2 
TESK2 
TGIF2 
    
 
1
4
6 
TLCD1 
TLR2 
TLR6 
TM7SF3 
TMEM106A 
TMEM106B 
TMEM144 
TMEM173 
TMEM176A 
TMEM176B 
TMEM194A 
TMEM209 
TMEM229A 
TMEM238 
TMEM37 
TMEM71 
TNFAIP8 
TNFRSF1A 
TNFSF10 
TOR1AIP1 
TRAF4 
TREM2 
TRIB2 
TRIM21 
TRIM25 
TRIP13 
TSPAN12 
TTPA 
TUBE1 
    
 
1
4
7 
TXN 
ULBP1 
USP18 
VAV3 
VCAN 
VEGFC 
VRK1 
WIPF1 
XAF1 
ZBP1 
ZC3HAV1 
ZRANB3 
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Table S2.4A. GFAP-CreER mice with alternative genotypes: Rb1DEL vs T and KrasG12D vs Nf1DEL 
Mouse ID 
Genotype 
Group 
Genotype 
Age at induction 
(days) 
Survival 
(days) 
Diagnosis 
250631 Nf1 Nf1-/- 119 189 Normal 
250612 Nf1;Pten Nf1-/-;Pten+/- 118 191 Normal 
249594 Nf1;Pten Nf1+/-;Pten-/- 36 184 Normal 
247642 Nf1;Pten Nf1+/-;Pten+/- 95 175 Normal 
250564 Rb1;Nf1 Rb1+/-;Nf1+/- 118 191 Normal 
250017 Rb1;Nf1;Pten Rb1-/-;Nf1-/-;Pten-/- 252 162 Normal 
251054 Rb1;Nf1;Pten Rb1-/-;Nf1+/-;Pten-/- 114 185 Normal 
251276 Rb1;Nf1;Pten Rb1-/-;Nf1+/-;Pten-/- 95 185 Normal 
250356 Rb1;Nf1;Pten Rb1-/-;Nf1+/-;Pten+/- 179 185 Normal 
251062 Rb1;Nf1;Pten Rb1+/-;Nf1-/-;Pten-/- 110 185 Normal 
250016 Rb1;Nf1;Pten Rb1+/-;Nf1-/-;Pten+/- 252 183 Normal 
250358 Rb1;Nf1;Pten Rb1+/-;Nf1-/-;Pten+/- 102 63 Normal 
250013 Rb1;Nf1;Pten Rb1+/-;Nf1+/-;Pten-/- 105 78 Normal 
250773 Rb1;Nf1;Pten Rb1+/-;Nf1+/-;Pten-/- 104 191 Normal 
250012 Rb1;Nf1;Pten Rb1+/-;Nf1+/-;Pten+/- 105 78 Normal 
250630 Rb1;Nf1;Pten Rb1+/-;Nf1+/-;Pten+/- 119 189 Normal 
248559 Rb1;Pten Rb1+/-;Pten+/- 173 119 Normal 
248590 Rb1;Pten Rb1+/-;Pten+/- 172 60 Normal 
248916 Rb1;Pten Rb1+/-;Pten+/- 148 119 Normal 
250700 Rb1;Pten Rb1+/-;Pten+/- 113 191 Normal 
250561 Rb1 Rb1-/- 118 191 Normal 
248558 Rb1;Kras Rb1+/-;KrasG12D 173 119 Normal 
252660 Rb1;Kras;Pten Rb1-/-;KrasG12D;Pten-/- 98 37 Normal 
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249234 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten-/- 131 63 Normal 
251580 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten-/- 117 70 Normal 
252508 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten-/- 101 32 Normal 
252661 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten-/- 98 94 Normal 
252666 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten-/- 115 38 Normal 
248915 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten+/- 148 119 Normal 
248922 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten+/- 148 60 Normal 
249182 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten+/- 135 60 Normal 
250362 Rb1;Kras;Pten Rb1+/-;KrasG12D;Pten+/- 101 63 Normal 
250628 Rb1;Nf1 Rb1-/-;Nf1+/- 119 191 Normal 
249593 T;Nf1 T;Nf1-/- 36 184 A3 
245462 T;Nf1 T;Nf1+/- 355 184 A2 
246372 T;Nf1 T;Nf1+/- 211 175 A2 
247966 T;Nf1 T;Nf1+/- 73 175 A2 
249871 T;Nf1;Pten T;Nf1-/-;Pten-/- 117 72 A2 
249961 T;Nf1;Pten T;Nf1-/-;Pten-/- 117 72 A2 
250898 T;Nf1;Pten T;Nf1-/-;Pten-/- 130 169 A3 
247640 T;Nf1;Pten T;Nf1-/-;Pten+/- 95 175 A2 
249890 T;Nf1;Pten T;Nf1-/-;Pten+/- 116 72 A2 
249591 T;Nf1;Pten T;Nf1+/-;Pten-/- 155 63 A2 
249870 T;Nf1;Pten T;Nf1+/-;Pten-/- 117 72 A2 
250765 T;Nf1;Pten T;Nf1+/-;Pten-/- 144 232 A2 
251496 T;Nf1;Pten T;Nf1+/-;Pten-/- 122 184 A2 
245449 T;Nf1;Pten T;Nf1+/-;Pten+/- 355 99 GBM 
246071 T;Nf1;Pten T;Nf1+/-;Pten+/- 312 184 A3 
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246522 T;Nf1;Pten T;Nf1+/-;Pten+/- 272 184 A3 
247171 T;Nf1;Pten T;Nf1+/-;Pten+/- 147 175 A2 
247472 T;Nf1;Pten T;Nf1+/-;Pten+/- 242 64 A2 
247641 T;Nf1;Pten T;Nf1+/-;Pten+/- 95 175 A2 
247658 T;Nf1;Pten T;Nf1+/-;Pten+/- 166 184 A2 
247965 T;Nf1;Pten T;Nf1+/-;Pten+/- 73 175 A2 
247967 T;Nf1;Pten T;Nf1+/-;Pten+/- 73 175 A2 
248900 T;Nf1;Pten T;Nf1+/-;Pten+/- 81 184 A2 
249328 T;Nf1;Pten T;Nf1+/-;Pten+/- 56 184 A2 
249589 T;Nf1;Pten T;Nf1+/-;Pten+/- 155 63 A2 
250615 T;Nf1;Pten T;Nf1+/-;Pten+/- 118 189 A2 
 
Summary  
Genotype Group Diagnosis N Mean Survival  
Rb1 
Normal 
1 
191 
 
Rb1;Kras 1  
Rb1;Kras;Pten 10  
Rb1;Nf1 2  
Rb1;Nf1;Pten 11  
Rb1;Pten 4  
Nf1 1  
Nf1;Pten 3  
T;Nf1 
A2 3 
180 
 
A3 1  
T;Nf1;Pten A2 18 143  
    
 
1
5
1 
A3 3  
GBM 1  
Total   59 137  
   
  
Age at induction (days)  
  
Mean 138.3  
  
SD 67.1    
Min 36  
 
 
Max 355  
  
   
  
Abbreviations: A2 Diffuse Astrocytoma   
  A3 Anaplastic Astrocytoma 
  GBM Glioblastoma   
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Table S2.4B. TRP HGG cohort: Mice aged to neurological morbidity 
Mouse 
ID 
Genotyp
e 
GFAP-
CreER 
4OHT 
induction 
Se
x 
Age at 
induction (d) 
Surviva
l (d) 
Cause of 
death 
Diagnosi
s 
aCG
H 
Transcriptom
e 
11612
0 
P-/- Yes Yes F 31 408 Sac Normal     
12342
0 
P-/- Yes Yes F 31 336 Sac Normal   
12736
0 
P-/- Yes Yes F 31 298 Sac Normal     
13172
1 
P-/- Yes Yes F 118 444 Sac Normal   
23471
0 
P+/- No Yes M 100 281 Sac Normal     
93218 R Yes Yes F 86 335 Sac Normal   
93249 R Yes Yes F 90 110 Sac Normal     
97306 R Yes Yes M 120 260 Sac Normal   
10081
4 
R Yes No M 113 357 Sac Normal     
10083
5 
R Yes Yes M 113 350 Sac Normal   
12843
5 
R Yes Yes F 109 173 Sac Normal     
13113
7 
R Yes Yes M 100 172 Sac Normal   
11630
8 
RP-/- Yes Yes M 102 130 Sac Normal     
11872
2 
RP-/- Yes No F 183 228 Sac Normal   
11877
5 
RP-/- Yes Yes M 110 132 Sac Normal     
11938
9 
RP-/- Yes Yes M 107 43 Sac Normal   
13329
5 
RP-/- Yes Yes M 96 35 Sac Normal     
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13677
0 
RP-/- Yes Yes M 106 17 Sac Normal   
14497
7 
RP-/- Yes Yes M 98 211 Sac Normal     
14498
2 
RP-/- Yes Yes M 103 130 Sac Normal   
14527
0 
RP-/- Yes Yes F 97 106 Sac Normal     
14816
9 
RP-/- Yes Yes M 116 99 Sac Normal   
14820
7 
RP-/- Yes Yes M 118 165 Sac Normal     
10301
9 
RP+/- Yes Yes M 97 489 Sac Normal   
12060
0 
RP+/- Yes Yes M 119 433 Sac Normal     
12095
9 
RP+/- Yes Yes M 116 127 Sac Normal   
12598
4 
RP+/- Yes Yes M 115 275 Sac Normal     
12714
9 
RP+/- Yes Yes F 100 509 Sac Normal   
12932
2 
RP+/- Yes Yes F 105 173 Sac Normal     
12932
5 
RP+/- Yes Yes M 105 363 Sac Normal   
87610 T Yes Yes M 99 537 Sac A3     
90627 T Yes Yes F 94 333 Sac A2   
93248 T Yes Yes F 90 496 Sac A2     
96555 T Yes Yes M 101 451 Sac A2   
97165 T Yes Yes F 93 456 Sac A3     
98123 T Yes Yes F 119 421 Sac A2   
22343
0 
T Yes Yes F 138 408 Sac A3     
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4 
22357
3 
T Yes Yes M 138 408 Sac A2   
22424
3 
T Yes Yes F 122 280 Brain tumor A2     
22424
7 
T Yes Yes F 122 408 Sac A2   
22555
4 
T Yes Yes F 87 408 Sac A2     
23531
7 
T Yes Yes F 140 365 Sac A2   
23549
4 
T Yes Yes M 133 365 Sac A2     
24436
8 
T Yes Yes M 113 126 Sac A2   
11304
4 
TP-/- Yes Yes M 126 375 Sac A2     
12589
5 
TP-/- Yes Yes M 116 307 Sac A2   
12718
4 
TP-/- Yes Yes F 98 509 Sac A2     
13571
7 
TP-/- Yes Yes F 117 221 Sac A3   
13676
8 
TP-/- Yes Yes F 102 388 Sac A3     
14099
4 
TP-/- Yes Yes M 78 367 Sac A2   
14402
8 
TP-/- Yes Yes M 110 297 Sac A2     
14460
1 
TP-/- Yes Yes M 103 297 Sac A3   
14496
8 
TP-/- Yes Yes F 119 276 Sac A2     
14497
3 
TP-/- Yes Yes F 98 297 Sac A2   
14497
5 
TP-/- Yes Yes M 98 297 Sac A2     
    
 
1
5
5 
14621
5 
TP-/- Yes Yes M 103 276 Sac A2   
23813
9 
TP-/- Yes Yes F 128 282 Sac A2     
23878
8 
TP-/- Yes Yes M 108 318 Sac A2   
24094
3 
TP-/- Yes Yes F 103 179 Brain tumor A2     
24500
6 
TP-/- Yes Yes F 66 193 Sac A2   
24500
9 
TP-/- Yes Yes M 66 283 Sac A2     
24691
0 
TP-/- Yes Yes F 118 217 Sac A2   
11875
4 
TP+/- Yes Yes F 116 376 Sac A2     
11936
7 
TP+/- Yes Yes F 109 566 Sac A2   
12092
8 
TP+/- Yes Yes M 117 433 Sac A3     
12093
9 
TP+/- Yes Yes F 116 139 Sac A2   
12272
5 
TP+/- Yes Yes F 106 345 Sac A3     
12279
1 
TP+/- Yes Yes M 105 390 Sac A2   
12322
4 
TP+/- Yes Yes M 99 426 Sac A2     
12501
9 
TP+/- Yes Yes M 120 381 Sac A2   
12776
7 
TP+/- Yes Yes F 94 101 Sac A3     
23310
7 
TP+/- Yes Yes M 112 456 Sac A2   
23347
9 
TP+/- Yes Yes M 131 421 Sac A3     
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23578
4 
TP+/- Yes Yes F 125 365 Sac A2   
23583
7 
TP+/- Yes Yes M 133 365 Sac A2     
23604
9 
TP+/- Yes Yes M 125 345 Sac A2   
23693
8 
TP+/- Yes Yes M 154 365 Sac A2     
23693
9 
TP+/- Yes Yes M 154 365 Sac A2   
23748
1 
TP+/- Yes Yes F 146 233 Sac A2     
24004
9 
TP+/- Yes Yes M 142 364 Sac A2   
24094
2 
TP+/- Yes Yes F 103 308 Sac A2     
24235
4 
TP+/- Yes Yes F 106 367 Sac A2   
24241
8 
TP+/- Yes Yes F 96 367 Sac A2     
24460
0 
TP+/- Yes Yes M 96 371 Sac A2   
24724
4 
TP+/- Yes Yes F 95 217 Sac A2     
24724
6 
TP+/- Yes Yes F 95 217 Sac A2   
87606 TR Yes Yes F 99 150 Brain tumor A3     
93246 TR Yes Yes F 90 147 Brain tumor A3   
95392 TR Yes Yes F 109 112 Sac A2     
96556 TR Yes Yes M 97 168 Brain tumor A3   
96564 TR Yes Yes F 97 131 Sac A3     
97166 TR Yes Yes F 93 150 Brain tumor A3   
97169 TR Yes Yes F 92 139 Brain tumor A3     
97172 TR Yes Yes F 92 129 Sac A3   
97302 TR Yes Yes F 120 155 Brain tumor A3     
    
 
1
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11777
2 
TR Yes Yes M 122 160 Brain tumor GBM   
12240
6 
TR Yes Yes F 109 111 Sac A2     
12281
3 
TR Yes Yes M 108 136 Brain tumor A3   
12429
6 
TR Yes Yes M 95 146 Brain tumor A3     
12503
6 
TR Yes Yes F 120 158 Brain tumor GBM   
12504
0 
TR Yes Yes M 120 140 Brain tumor A3     
15964
0 
TR Yes Yes M 125 140 Brain tumor GBM   
16209
1 
TR Yes Yes F 97 130 Brain tumor A2     
23210
9 
TR Yes Yes F 134 108 Brain tumor A3   
23212
0 
TR Yes Yes F 133 161 Sac GBM     
23235
0 
TR Yes Yes F 127 107 Brain tumor A2   
23236
6 
TR Yes Yes F 127 107 Brain tumor GBM 1 1 
23247
3 
TR Yes Yes F 123 133 Sac A2   
23276
8 
TR Yes Yes M 118 123 Brain tumor A3     
23310
5 
TR Yes Yes F 112 148 Brain tumor A3   
23369
8 
TR No Yes M 122 281 Sac Normal     
23420
0 
TR Yes Yes F 110 125 Brain tumor A3   
23474
0 
TR No Yes F 94 421 Sac Normal     
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23475
0 
TR Yes Yes F 97 137 Brain tumor GBM  1 
23531
6 
TR Yes Yes F 140 150 Brain tumor GBM 1 1 
23534
4 
TR Yes Yes F 139 136 Brain tumor GBM 2 2 
23534
6 
TR Yes Yes M 139 91 Brain tumor A2     
23579
1 
TR Yes Yes F 129 130 Brain tumor A3 1 1 
23579
3 
TR Yes Yes M 129 109 Brain tumor A2     
24083
5 
TR Yes Yes F 106 114 Brain tumor A3   
24092
9 
TR Yes Yes F 99 108 Brain tumor A2     
24209
2 
TR Yes Yes F 109 127 Brain tumor A3 1 1 
24362
7 
TR Yes Yes F 100 93 Brain tumor A2     
24442
0 
TR Yes Yes M 52 116 Brain tumor A2   
24586
1 
TR Yes Yes M 117 120 Brain tumor A3 1 1 
24674
2 
TR Yes Yes F 133 147 Brain tumor GBM 1 1 
24701
8 
TR Yes Yes F 114 120 Brain tumor A3     
24702
9 
TR Yes Yes M 112 145 Brain tumor GBM   
24703
1 
TR Yes Yes M 112 107 Brain tumor GBM     
11518
9 
TRP-/- Yes Yes M 105 90 Sac A3   
11877
3 
TRP-/- Yes Yes M 110 62 Sac A3     
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12272
6 
TRP-/- Yes Yes F 106 40 Sac A2   
12597
6 
TRP-/- Yes Yes F 116 71 Brain tumor A3     
12597
8 
TRP-/- Yes Yes F 116 31 Sac A3   
12777
0 
TRP-/- Yes Yes F 94 71 Brain tumor GBM     
12932
6 
TRP-/- Yes Yes M 168 75 Brain tumor GBM   
13050
9 
TRP-/- Yes Yes F 148 36 Brain tumor GBM     
13746
8 
TRP-/- Yes Yes M 91 110 Brain tumor GBM   
14248
6 
TRP-/- Yes Yes M 90 101 Brain tumor GBM     
15880
8 
TRP-/- Yes Yes M 102 107 Brain tumor GBM   
16423
7 
TRP-/- Yes Yes F 115 59 Brain tumor GBM     
16590
4 
TRP-/- Yes Yes F 101 51 Sac A2   
23531
1 
TRP-/- No Yes F 84 421 Sac Normal     
23548
9 
TRP-/- Yes Yes F 135 55 Brain tumor GBM   
23607
0 
TRP-/- Yes Yes M 115 95 Brain tumor A3 1 1 
23607
2 
TRP-/- Yes Yes F 115 79 Sac A3   
23770
3 
TRP-/- Yes Yes M 137 25 Sac A2     
23903
2 
TRP-/- Yes Yes M 94 44 Brain tumor GBM   
24049
4 
TRP-/- No Yes F 122 311 Sac Normal     
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24108
6 
TRP-/- Yes Yes F 96 57 Sac A3   
24110
2 
TRP-/- Yes Yes F 94 99 Brain tumor GBM 1 1 
24248
6 
TRP-/- Yes Yes M 91 98 Brain tumor GBM 1 1 
24248
7 
TRP-/- Yes Yes M 91 53 Sac A2     
24389
2 
TRP-/- Yes Yes M 81 52 Sac A2   
24494
1 
TRP-/- Yes Yes M 75 66 Sac A2     
24523
7 
TRP-/- Yes Yes F 128 64 Brain tumor GBM 1 1 
24558
6 
TRP-/- Yes Yes F 109 71 Brain tumor A3 1 1 
24566
5 
TRP-/- Yes Yes M 106 60 Sac A3 1 1 
24627
0 
TRP-/- Yes Yes F 84 58 Brain tumor GBM 2 2 
24644
3 
TRP-/- Yes Yes M 65 63 Sac A2   
24675
1 
TRP-/- Yes Yes M 131 29 Brain tumor A2     
24733
0 
TRP-/- Yes Yes F 85 58 Sac A2   
24751
4 
TRP-/- Yes Yes M 65 100 Brain tumor A3     
24826
7 
TRP-/- Yes Yes F 154 77 Sac GBM   
24832
8 
TRP-/- Yes Yes F 149 58 Sac A3     
24833
8 
TRP-/- Yes Yes F 148 56 Brain tumor GBM   
24885
8 
TRP-/- Yes Yes M 110 85 Brain tumor GBM     
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11676
5 
TRP+/- Yes Yes M 93 147 Sac A3   
11676
6 
TRP+/- Yes Yes M 93 171 Brain tumor GBM     
11937
1 
TRP+/- Yes Yes F 109 167 Sac A2   
11937
3 
TRP+/- Yes Yes M 109 122 Brain tumor GBM     
12224
8 
TRP+/- Yes Yes M 111 127 Brain tumor A3   
12272
8 
TRP+/- Yes Yes M 106 73 Sac A3     
12777
7 
TRP+/- Yes Yes M 114 122 Brain tumor GBM   
12844
3 
TRP+/- Yes Yes M 110 130 Brain tumor A3     
15882
4 
TRP+/- Yes Yes M 100 109 Brain tumor A3   
16348
8 
TRP+/- Yes Yes M 122 143 Brain tumor GBM     
23229
4 
TRP+/- Yes Yes M 128 134 Brain tumor A2   
23247
4 
TRP+/- No Yes F 123 198 Sac Normal     
23258
8 
TRP+/- Yes Yes F 122 133 Sac A3   
23310
6 
TRP+/- Yes Yes F 112 143 Brain tumor GBM 1 1 
23311
7 
TRP+/- Yes Yes M 107 112 Brain tumor GBM 1 1 
23335
2 
TRP+/- Yes Yes F 98 129 Brain tumor GBM 1 1 
23429
0 
TRP+/- No Yes M 108 281 Sac Normal   
23445
1 
TRP+/- Yes Yes M 107 129 Brain tumor GBM 1 1 
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23445
8 
TRP+/- Yes Yes M 104 143 Brain tumor GBM 1 1 
23474
2 
TRP+/- Yes Yes F 94 134 Sac A2     
23531
2 
TRP+/- Yes Yes F 84 113 Brain tumor GBM   
23534
2 
TRP+/- Yes Yes F 139 114 Sac A2     
23548
3 
TRP+/- Yes Yes F 135 114 Brain tumor A2   
23578
3 
TRP+/- Yes Yes F 125 114 Sac A2     
23602
4 
TRP+/- Yes Yes M 120 120 Brain tumor GBM 2 2 
24049
6 
TRP+/- Yes Yes F 122 119 Sac A3     
24189
8 
TRP+/- Yes Yes F 121 140 Brain tumor GBM 1 1 
24384
5 
TRP+/- Yes Yes F 84 98 Brain tumor A3     
24385
2 
TRP+/- Yes Yes M 82 127 Brain tumor GBM 1 1 
24393
0 
TRP+/- Yes Yes M 79 98 Brain tumor A2     
24418
9 
TRP+/- Yes Yes M 60 119 Brain tumor A3 1 1 
24419
0 
TRP+/- Yes Yes F 64 93 Brain tumor A3 1 1 
24459
0 
TRP+/- Yes Yes M 101 122 Brain tumor A3   
24460
5 
TRP+/- Yes Yes F 100 126 Brain tumor GBM 1 1 
24470
6 
TRP+/- Yes Yes F 87 101 Brain tumor GBM 2 2 
24493
9 
TRP+/- Yes Yes M 75 120 Brain tumor A3 2 2 
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24497
4 
TRP+/- Yes Yes M 83 120 Brain tumor A2   
24501
6 
TRP+/- Yes Yes F 72 108 Brain tumor A3 1 1 
24511
6 
TRP+/- Yes Yes F 134 106 Brain tumor GBM 2 2 
24512
2 
TRP+/- Yes Yes M 134 123 Brain tumor A2     
24522
6 
TRP+/- Yes Yes F 130 106 Brain tumor A2   
24524
2 
TRP+/- Yes Yes M 128 99 Brain tumor A3     
24527
7 
TRP+/- Yes Yes F 125 87 Sac A2   
24529
6 
TRP+/- Yes Yes F 125 107 Sac A2     
24530
4 
TRP+/- Yes Yes F 123 130 Brain tumor A3 1 1 
24566
0 
TRP+/- Yes Yes F 106 116 Brain tumor GBM 1 2 
24566
2 
TRP+/- Yes Yes F 106 106 Brain tumor GBM 1 1 
24593
6 
TRP+/- Yes Yes F 107 107 Brain tumor GBM 1 1 
24594
0 
TRP+/- Yes Yes M 107 109 Brain tumor A3   
24595
6 
TRP+/- Yes Yes M 106 120 Brain tumor A3     
24603
5 
TRP+/- Yes Yes F 98 87 Brain tumor A2   
24630
0 
TRP+/- Yes Yes M 77 127 Brain tumor GBM 1 1 
24630
2 
TRP+/- Yes Yes M 77 102 Brain tumor GBM 1 1 
24642
8 
TRP+/- Yes Yes M 68 102 Brain tumor A3     
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24698
8 
TRP+/- Yes Yes F 116 79 Brain tumor A2   
24719
4 
TRP+/- Yes Yes F 95 107 Brain tumor A2     
24833
5 
TRP+/- Yes Yes F 148 102 Sac A2   
94846 WT Yes Yes F 39 533 Sac Normal     
95397 WT Yes Yes M 113 451 Sac Normal     
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Summary 
GFAP-CreER 
4OHT 
induction 
Genotype Diagnosis 
aCGH 
samples 
Transcriptome 
samples 
Total 
Mice 
Mean 
Survival 
No Yes 
P+/- Normal   1 281 
TR Normal     2 351 
TRP+/- Normal   2 240 
TRP-/- Normal     2 366 
Yes 
No 
R Normal   1 357 
RP-/- Normal     1 228 
Yes 
WT Normal   2 492 
P-/- Normal     4 372 
R Normal   6 233 
RP+/- Normal     7 338 
RP-/- Normal     10 107 
T 
A2     11 
390 
A3     3 
TP+/- 
A2     20 
345 
A3     4 
TP-/- 
A2     15 
299 
A3     3 
TR 
A2     10 
130 A3 3 3 20 
GBM 5 6 11 
TRP+/- 
A2   16 
117 A3 6 6 18 
GBM 19 20 21 
TRP-/- A2     9 67 
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A3 3 3 11 
GBM 5 5 16 
Total 41 43 226   
        
  Mean SD Min Max  
 
Age at induction (days) 107.9 22.2 31 183  
 
        
Abbreviations     
A2 Diffuse Astrocytoma     
A3 Anaplastic Astrocytoma     
GBM Glioblastoma     
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Table S2.5A-E. CNA in core GBM pathway genes in TR(P) HGG 
Rb Pathway  RTK Pathway  MAPK Pathway  PI3K Pathway  
Gene 
Mutated 
Samples (%)  Gene 
Mutated Samples 
(%)  Gene 
Mutated Samples 
(%)  Gene 
Mutated Samples 
(%)  
Gai
n 
Los
s 
Tota
l  
Gain Loss Total 
 
Gain Loss Total 
 
Gain Loss Total 
 
Ccnd2 67 67 67 
 
Met 67 0 67 
 
Braf 69 0 69 
 
Foxo
2 
5 0 5 
 
Stat1 21 0 21  Egfr 2 5 7  Kras 69 0 69  Pten 0 5 5  
E2f6 0 7 7 
 
Erbb
2 
2 5 7 
 
Raf1 67 0 67 
 
Akt2 0 2 2 
 
E2f7 0 7 7 
 
Pdgf
b 
7 0 7 
 
Map2k
4 
2 10 12 
 
Akt2s
2 
0 2 2 
 
Myc 7 0 7 
 
Pdgf
a 
5 0 5 
 
Dab2 10 0 10 
 
Akt5 2 0 2 
 
Stat3 2 5 7 
 
Fgf1 2 0 2 
 
Mapk9 2 7 10 
 
Pik3c
a 
2 0 2 
 
Stat5a 2 5 7 
 
Fgfr1 2 0 2 
 
Map2k
3 
2 5 7 
 
Pik3r
5 
2 0 2 
 
Stat5b 2 5 7 
 
Igf1r 0 2 2 
 
Map3k
3 
2 5 7 
 
Pdpk
2 
0 0 0 
 
Ccna1 5 0 5 
 
Pdgfr
b 
2 0 2 
 
Mapk1
2 
5 2 7 
 
Pik3r
2 
0 0 0 
 
E2f2 2 2 5 
 
Erbb
3 
0 0 0 
 
Mapk7 2 5 7 
 
Rheb 0 0 0 
 
E2f8 0 5 5  Igf1 0 0 0  Rab25 5 0 5  Tsc2 0 0 0  
Jak2 0 5 5  Kdr 0 0 0  Hras1 0 2 2  Tsc5 0 0 0  
Ccnd1 0 2 2 
 
Kit 0 0 0 
 
Map3k
2 
2 0 2 
      
Ccne1 0 2 2 
 
Pdgfr
a 
0 0 0 
 
Mapk1 2 0 2 
      
Cdk6 0 2 2 
 
Vegf
a 
0 0 0 
 
Mapk3 0 2 2 
      
Cdkn2
a 
0 2 2 
 
Vegf
b 
0 0 0 
 
Map2k
1 
0 0 0 
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E2f1 2 0 2 
      
Map2k
2 
0 0 0 
      
E2f3 0 2 2 
      
Map2k
5 
0 0 0 
      
E2f5 2 0 2 
      
Map3k
1 
0 0 0 
      
Jak1 0 2 2 
      
Map3k
4 
0 0 0 
      
Rbl1 2 0 2 
      
Map3k
5 
0 0 0 
      
Src 2 0 2 
      
Mapk1
4 
0 0 0 
      
Ccnb1 0 0 0       Mapk4 0 0 0       
Cdc25
a 
0 0 0 
      
Mapk6 0 0 0 
      
Cdk2 0 0 0       Mapk8 0 0 0       
Cdk4 0 0 0       Rassf1 0 0 0       
Cdkn1
a 
0 0 0 
                
E2f4 0 0 0                 
Rb1 0 0 0                 
Rbl2 0 0 0                 
Stat2 0 0 0                 
Table S2.5. CNA in core GBM pathway genes in TR(P) HGG. Copy number gains and losses for the indicated Rb, RTK, MAPK, 
PI3K, and Trp53 pathway genes in 41 HGA samples from 35 TR(P) mice are shown (Fig. 4).  
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Table S2.6. TR(P) HGG transcriptome samples 
Sample Name 
Mouse 
ID 
Genotyp
e 
Locatio
n 
HGG 
Subtype 
TCGA GBM Subtype 
Prediction 
Core 
Sample  
Survival 
(months)  
Censore
d 
Survival 
Diagnosi
s 
245304_BS 
24530
4 
TRP+/- BS S1 Classical Yes 4.27 No A3 
232366_BS 
23236
6 
TR BS S1 Mesenchymal Yes 3.52 No GBM 
235316_BS 
23531
6 
TR BS S1 Mesenchymal Yes 4.93 No GBM 
246742_CTX 
24674
2 
TR CTX S1 Mesenchymal Yes 4.83 No GBM 
236070_CTX 
23607
0 
TRP-/- CTX S1 Mesenchymal Yes 3.12 No A3 
245586_BS 
24558
6 
TRP-/- BS S1 Mesenchymal Yes 2.33 No A3 
233106_BS 
23310
6 
TRP+/- BS S1 Mesenchymal Yes 4.7 No GBM 
234451_OFB 
23445
1 
TRP+/- OFB S1 Mesenchymal Yes 4.24 No GBM 
236024_1_CT
X 
23602
4 
TRP+/- CTX S1 Mesenchymal Yes 3.94 No GBM 
244190_BS 
24419
0 
TRP+/- BS S1 Mesenchymal Yes 3.06 No A3 
244706_2_BS 
24470
6 
TRP+/- BS S1 Mesenchymal Yes 3.32 No GBM 
245016_BS 
24501
6 
TRP+/- BS S1 Mesenchymal Yes 3.55 No A3 
245660_1_BS 
24566
0 
TRP+/- BS S1 Mesenchymal Yes 3.81 No GBM 
245662_BS 
24566
2 
TRP+/- BS S1 Mesenchymal Yes 3.48 No GBM 
245936_BS 
24593
6 
TRP+/- BS S1 Mesenchymal Yes 3.52 No GBM 
246300_BS 
24630
0 
TRP+/- BS S1 Mesenchymal Yes 4.17 No GBM 
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246302_BS 
24630
2 
TRP+/- BS S1 Mesenchymal Yes 3.35 No GBM 
234458_DI 
23445
8 
TRP+/- DI S1 Neural 
No 
(Exclude
d) 
4.7 No GBM 
235344_2_DI 
23534
4 
TR DI S2 Classical Yes 4.47 No GBM 
236024_2_OF
B 
23602
4 
TRP+/- OFB S2 Classical Yes 3.94 No GBM 
235791_BS 
23579
1 
TR BS S2 Proneural Yes 4.27 No A3 
245665_OFB 
24566
5 
TRP-/- OFB S2 Proneural Yes 1.97 Yes A3 
233117_OFB 
23311
7 
TRP+/- OFB S2 Proneural Yes 3.68 No GBM 
241898_BS 
24189
8 
TRP+/- BS S2 Proneural Yes 4.6 No GBM 
244706_1_OF
B 
24470
6 
TRP+/- OFB S2 Proneural Yes 3.32 No GBM 
245660_2_OF
B 
24566
0 
TRP+/- CTX S2 Proneural Yes 3.81 No GBM 
242092_BS 
24209
2 
TR BS S3 Mesenchymal Yes 4.17 No A3 
234750_BS 
23475
0 
TR BS S3 Neural Yes 4.5 No GBM 
245861_DI 
24586
1 
TR DI S3 Neural Yes 3.94 No A3 
241102_DI 
24110
2 
TRP-/- DI S3 Neural Yes 3.25 No GBM 
242486_DI 
24248
6 
TRP-/- DI S3 Neural Yes 3.22 No GBM 
245237_DI 
24523
7 
TRP-/- DI S3 Neural Yes 2.1 No GBM 
246270_2_OF
B 
24627
0 
TRP-/- OFB S3 Neural Yes 1.91 No GBM 
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244189_DI 
24418
9 
TRP+/- DI S3 Neural Yes 3.91 No A3 
244605_CTX 
24460
5 
TRP+/- CTX S3 Neural Yes 4.14 No GBM 
244939_2_OF
B 
24493
9 
TRP+/- OFB S3 Neural Yes 3.94 No A3 
245116_1_CT
X 
24511
6 
TRP+/- CTX S3 Neural Yes 3.48 No GBM 
245116_2_DI 
24511
6 
TRP+/- DI S3 Neural Yes 3.48 No GBM 
235344_1_BS 
23534
4 
TR BS S3 Proneural Yes 4.47 No GBM 
246270_1_CT
X 
24627
0 
TRP-/- CTX S3 Proneural Yes 1.91 No GBM 
233352_OFB 
23335
2 
TRP+/- OFB S3 Proneural Yes 4.24 No GBM 
243852_OFB 
24385
2 
TRP+/- OFB S3 Proneural Yes 4.17 No GBM 
244939_1_CT
X 
24493
9 
TRP+/- CTX S3 Proneural Yes 3.94 No A3 
 
HGG subtypes in mice with 2 distinct tumors 
Mouse ID Genotype 
HGG 1   HGG 2 
TR(P) subtype Location TCGA subtype   TR(P) subtype 
Locatio
n 
TCGA subtype 
235344 TR S3 BS Proneural  S2 DI Classical 
236024 TRP+/- S1 CTX Mesenchymal  S2 OFB Classical 
244706 TRP+/- S1 BS Mesenchymal  S2 OFB Proneural 
244939 TRP+/- S3 CTX Proneural  S3 OFB Neural 
245116 TRP+/- S3 CTX Neural  S3 DI Neural 
245660 TRP+/- S1 BS Mesenchymal  S2 CTX Proneural 
246270 TRP+/- S3 CTX Proneural   S3 OFB Neural 
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HGG location by genotype    
Genotype 
Location 
Total    
CTX BS DI OFB    
TR 1 2 6  9    
TRP-/- 5 2 11 7 25    
TRP+/- 2 3 1 2 8    
Total 8 7 18 9 42    
Fisher's P=0.3    
      
   
HGG subtype by genotype     
Genotype 
Subtype 
Total 
 
   
S1 S2 S3     
TR 3 2 4 9     
TRP-/- 12 5 8 25     
TRP+/- 2 1 5 8     
Total 17 8 17 42     
Fisher's P=0.6     
      
   
HGG subtype by location     
Genotype 
Subtype 
Total 
 
   
S1 S2 S3     
CTX 3 1 4 8     
DI  1 6 7     
BS 13 2 3 18     
OFB 1 4 4 9     
Total 17 8 17 42     
Fisher's P=0.004     
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GEM HGG versus human GBM (TCGA) subtypes    
HGG Subtype 
TCGA Subtype 
Total    
Proneural Neural Classical Mesenchymal    
S1   1 16 17    
S2 6  2  8    
S3 5 11   1 17    
Total 11 11 3 17 42    
Fisher's P<0.0001    
      
   
Abbreviations      
A2 Diffuse Astrocytoma      
A3 Anaplastic Astrocytoma      
GBM Glioblastoma      
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Table S2.7.  HGG subtypes S1-S3 600-gene classifier 
Genes ordered as depicted in heatmaps in Figs. 2.5, S2.9E 
Gadd45a 
Cp 
Cald1 
Gpnmb 
Ctgf 
Mgp 
Crip2 
Itgb5 
Ephx1 
Mr1 
Hfe 
Fgfr1 
Itm2b 
Plxnb2 
Sypl 
Igdcc4 
Prex2 
Inf2 
Fxyd1 
Timp2 
Anxa7 
Fth1 
Stx3 
Foxo1 
Pnpla7 
Bcl6 
Phf15 
    
 
1
7
5 
Fam174a 
Mllt6 
Arhgap23 
Plekhm2 
Hagh 
Rabac1 
Ift172 
Nub1 
Spnb2 
Zbtb4 
Ezh1 
Inpp5k 
Mnt 
Rnf6 
Pacsin3 
Tacc1 
Fyco1 
Rab11fip5 
Hipk3 
Lats2 
Aff1 
Tnip1 
Acvr1b 
Ftsjd2 
Hgsnat 
Npr2 
Ccs 
Fnbp1 
Osmr 
    
 
1
7
6 
Hspb1 
Micall1 
Col11a1 
Lyz1 
Lyz2 
Abcg2 
Ppic 
Gnb4 
Tmem176a 
Tmem176b 
Dusp6 
Eps8 
Skap2 
Ppfibp1 
Lmnb1 
Suv39h2 
2700094K13Rik 
6720463M24Rik 
Cks1b 
Mdm1 
Eri1 
Hnrnpf 
Csda 
2810417H13Rik 
Rad51ap1 
Itgb1 
Lpar6 
Rhbdf1 
Haus4 
    
 
1
7
7 
Zwilch 
Fam111a 
Cav2 
Casp8 
Lrrfip1 
Plod2 
Cdr2l 
Scarb1 
Rhoc 
Rod1 
Elk3 
Hspg2 
Lims1 
Ostf1 
Ets1 
Litaf 
Stard13 
Vcan 
Fgfrl1 
Krcc1 
Orai1 
Lin9 
Tmem167 
Cbx3 
Sec61a1 
2610001J05Rik 
Adam10 
Lman1 
Golt1b 
    
 
1
7
8 
Tpm4 
2610020H08Rik 
Ppib 
Tram1 
Plekha8 
Lsm5 
Phf14 
Lsm3 
Snrpg 
Rpa3 
Naa38 
Nup205 
Errfi1 
Cast 
Rbms1 
Ank 
Man2a1 
Bicc1 
Ifngr1 
Mxra8 
Fkbp9 
Ltbp3 
Arhgap29 
Gpsm3 
Ifnar2 
Tgfbr2 
Arhgef6 
Fkbp7 
Ston1 
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9 
Pgcp 
Phldb2 
Flna 
Tmem43 
Nfkb1 
Ttc7 
Crtap 
Wasf2 
Ap3b1 
Eapp 
Tln1 
Esyt1 
Mgat1 
Ebp 
Gxylt1 
Surf4 
Nt5dc1 
Stx16 
Vcl 
Ptpn14 
Atl3 
Etv6 
Capns1 
Ppap2a 
P2rx4 
Tradd 
Scpep1 
Il10rb 
Anxa4 
    
 
1
8
0 
Tmem123 
Nck2 
Ano6 
Fbxo4 
Ncoa3 
Bpgm 
Glb1 
Crlf2 
Sumf1 
Lpp 
Rbms2 
Csgalnact2 
Lrp1 
2810474O19Rik 
Znrf2 
Ddi2 
Spty2d1 
Igf2r 
Fam114a1 
Fndc3b 
Mxra7 
Edem1 
Nucb1 
H2-K1 
B2m 
Ifi35 
Tgm2 
Ctsh 
Srgn 
    
 
1
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1 
Cybb 
Cyba 
Grn 
Tlr13 
Ehd4 
Syngr2 
Bag3 
Capg 
Dap 
Fzd1 
Etv5 
Arhgap31 
Map4k4 
Tnfrsf1a 
Cd302 
Mdfic 
Cpne8 
Igfbp7 
Ifi30 
Lamc1 
Nid1 
Fbxl7 
Fli1 
Spats2l 
Rhoj 
Col9a1 
Xpnpep1 
Atp1b1 
Got1 
    
 
1
8
2 
Cacna2d1 
Fbxl16 
Pgm2l1 
Chst1 
Stxbp5 
Tsc22d3 
Acsl3 
Phyhd1 
Ogfrl1 
Cd59a 
Ndrg1 
C2cd2l 
Trank1 
Kalrn 
Ppp3cb 
Ap2a2 
Ubqln2 
Epm2aip1 
Gsk3b 
Clip3 
1700019D03Rik 
Pbx1 
Atp6ap2 
Nceh1 
Atp6v1c1 
Atp6v1a 
Atp6v1d 
Ppp2r5b 
Ttc19 
    
 
1
8
3 
Kifap3 
Mapre2 
1500031L02Rik 
Ttc7b 
Atp6v1b2 
Rtn4 
Ywhah 
Nkiras1 
Rap1gds1 
Ppapdc2 
Spryd3 
2900097C17Rik 
Pja2 
Mapk8ip3 
Ap1b1 
Prkacb 
Slc25a22 
Synj1 
Sirt3 
Eif4a2 
Serinc1 
Ppip5k1 
Fam126b 
Gls 
Atg2b 
Bbs4 
Tmx4 
Ncdn 
Scamp1 
    
 
1
8
4 
Atp6v1g2 
Inpp4a 
Calm1 
Reep5 
Fam164a 
Ankrd13d 
Habp4 
Adcy9 
Map1lc3a 
Zrsr1 
Morn4 
Slu7 
Trim44 
Ccdc104 
Nicn1 
Oscp1 
Mink1 
Surf1 
Adrbk1 
Vti1b 
Atp6v0a1 
Vamp2 
Kidins220 
Atp6v0d1 
Kctd13 
Dgcr6 
Fis1 
Ggnbp2 
Vti1a 
    
 
1
8
5 
Tmem85 
Herc1 
Usp20 
Agtpbp1 
Napg 
Rnf14 
Ensa 
Wdr13 
Dnajb14 
Smpd1 
BC031181 
Wbp2 
2510003E04Rik 
Mgrn1 
Rogdi 
Pip4k2c 
Tmem66 
Bcas3 
Znhit2-ps 
Pex11b 
Golga2 
Use1 
1110003E01Rik 
Trappc6b 
Mat2b 
Tbc1d22a 
Mbnl2 
Zfyve27 
Cyth1 
    
 
1
8
6 
5430411K18Rik 
Cdc42bpa 
Megf8 
Coro2b 
Fam134b 
Clu 
Csrp1 
Prnp 
Ypel2 
Lpgat1 
Nrbp2 
Pitpnm1 
Stxbp1 
Fam110b 
Mllt11 
Gabbr1 
Snap47 
Trim2 
Pde4dip 
Araf 
Atl1 
Napb 
Trim37 
Kif21a 
Reps2 
Dnalc1 
Arf3 
Dlg4 
Nelf 
    
 
1
8
7 
Syt7 
Sgtb 
Syne1 
Olfm1 
Arrb1 
Ids 
Pfkp 
Wdr47 
Nedd4l 
Tspan7 
Zdhhc8 
Chn1 
Strbp 
Dlg3 
Parp6 
Cpe 
Cx3cl1 
Pdp1 
Marcksl1 
Rnf180 
Mex3b 
Phtf2 
Caprin1 
Gspt1 
Dhcr7 
Bzw2 
Tbc1d7 
Tpm1 
Polg 
    
 
1
8
8 
Isoc1 
Map3k1 
Rev3l 
Ppp1r14b 
Pus7l 
Actl6a 
Myef2 
Nasp 
Hnrnpab 
Srsf3 
Mtap 
Alg13 
Dctpp1 
1110034A24Rik 
2410127L17Rik 
Strap 
Srsf9 
Polr2d 
Ybx1 
Eif4g2 
Phf5a 
Zbtb10 
Gtf2h3 
Zbed4 
Kti12 
Fbl 
Snrpd3 
Hnrnpa1 
Nudt21 
    
 
1
8
9 
Cdk4 
Hmgn1 
Isg20l2 
Prpf40a 
Dhx15 
Ilf3 
Tdg 
Trib2 
Rpp30 
Sephs1 
Ppat 
Gtf2a2 
Ppih 
Ercc8 
Cpsf4 
Hspa14 
Cstf2 
Ythdf2 
1500001M20Rik 
Snrpa1 
Phf6 
Ap3m1 
Eif1ad 
Nudt5 
Slmo2 
G3bp1 
Cse1l 
Set 
Srd5a1 
    
 
1
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0 
Galnt10 
Nol7 
1700066M21Rik 
Hdac2 
Papss1 
Arl2bp 
Hnrnpk 
Prpf4 
Ankrd49 
Rnf138 
Rbmx 
Srsf1 
Gtf2f2 
1600012F09Rik 
Pdss1 
Abcb7 
Usp38 
Bri3bp 
Hnrnpul1 
Nap1l1 
Snrpd1 
Erh 
Lsm6 
Ilf2 
Mrpl50 
Clns1a 
Gpn1 
Fam118b 
Cct8 
    
 
1
9
1 
Abce1 
Ncbp1 
Hmgb3 
Midn 
Fam108c 
Clcn5 
Kif13a 
Mum1l1 
Ccnd2 
Mex3a 
Flrt3 
Gpr85 
Pak3 
Pkia 
Ppp2r2b 
Sox11 
Sh3gl3 
Tmeff1 
Bcl7a 
Fbxo21 
Dbn1 
Mmd 
Gcsh 
Apc 
Cwf19l1 
Bod1 
Naa30 
Nckap1 
Timm8b 
    
 
1
9
2 
Lcmt1 
Camsap1 
Ube2k 
Hdhd2 
Ikbkap 
Timm9 
Eif1b 
Ppp2ca 
Ube2n 
Ept1 
Ppp2cb 
Rab39b 
Usp22 
9330151L19Rik 
Ncoa1 
Exoc3 
Nhlrc1 
Atxn7l3b 
Slc39a3 
Irgq 
Klc1 
Pafah1b1 
Ppme1 
Dclk1 
Plxnc1 
Fasn 
Tle4 
B3gat1 
Mcart6 
    
 
1
9
3 
Phyhipl 
Cacna1h 
Ptbp2 
Phgdh 
Tfrc 
Enoph1 
Alg2 
Pfn2 
Calm3 
Ube2v2 
Sub1 
Yaf2 
1810041L15Rik 
Ptplad1 
Sall2 
S100a1 
Bdh1 
Ednrb 
Gphn 
Cadm2 
Macrod2 
Daam1 
Zdhhc14 
Fam49b 
Fam69b 
Celf2 
Lrp8 
Asphd2 
Fez1 
    
 
1
9
4 
Nipa1 
Hdac9 
Kif21b 
Dgat2 
Flrt1 
Ppm1l 
Asxl3 
Dlat 
Tsr2 
Clcn3 
Rab4a 
Ss18l1 
Trim32 
Gnl1 
Pdxp 
Fam171b 
Gpm6a 
Chst10 
Lrrtm2 
Smarca1 
BC068157 
Wasf1 
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Table S2.9A. Enriched GO terms from HGG SAM analyses (FDR cutoff 0.0001) - S1 
Subtype GO Term Description 
P-
value 
FDR q-
value 
S1 
(mesenchymal) GO:0002376 immune system process 
9.74E-
20 8.37E-16 
S1 
(mesenchymal) GO:0006955 immune response 
1.52E-
18 6.52E-15 
S1 
(mesenchymal) GO:0006952 defense response 
7.98E-
15 2.29E-11 
S1 
(mesenchymal) GO:0050896 response to stimulus 
1.51E-
13 3.24E-10 
S1 
(mesenchymal) GO:0002682 regulation of immune system process 
6.06E-
13 1.04E-09 
S1 
(mesenchymal) GO:0001817 regulation of cytokine production 
3.78E-
11 5.42E-08 
S1 
(mesenchymal) GO:0043207 response to external biotic stimulus 
1.26E-
10 1.55E-07 
S1 
(mesenchymal) GO:0006950 response to stress 
1.52E-
10 1.64E-07 
S1 
(mesenchymal) GO:0009607 response to biotic stimulus 
2.28E-
10 2.17E-07 
S1 
(mesenchymal) GO:0002684 positive regulation of immune system process 
2.29E-
10 1.97E-07 
S1 
(mesenchymal) GO:0050776 regulation of immune response 
3.90E-
10 3.05E-07 
S1 
(mesenchymal) GO:0051707 response to other organism 
4.99E-
10 3.58E-07 
S1 
(mesenchymal) GO:0045087 innate immune response 
8.17E-
10 5.40E-07 
S1 
(mesenchymal) GO:0042127 regulation of cell proliferation 
1.87E-
09 1.15E-06 
S1 
(mesenchymal) GO:0002252 immune effector process 
1.95E-
09 1.12E-06 
S1 
(mesenchymal) GO:0098542 defense response to other organism 
3.10E-
09 1.67E-06 
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S1 
(mesenchymal) GO:0001775 cell activation 
5.20E-
09 2.63E-06 
S1 
(mesenchymal) GO:0098602 single organism cell adhesion 
1.84E-
08 8.79E-06 
S1 
(mesenchymal) GO:0022610 biological adhesion 
3.17E-
08 1.44E-05 
S1 
(mesenchymal) GO:0007155 cell adhesion 
5.27E-
08 2.27E-05 
S1 
(mesenchymal) GO:0009605 response to external stimulus 
5.43E-
08 2.22E-05 
S1 
(mesenchymal) GO:0034109 homotypic cell-cell adhesion 
5.54E-
08 2.17E-05 
S1 
(mesenchymal) GO:0001819 positive regulation of cytokine production 
6.10E-
08 2.28E-05 
S1 
(mesenchymal) GO:0065007 biological regulation 
7.50E-
08 2.69E-05 
S1 
(mesenchymal) GO:0006954 inflammatory response 
1.30E-
07 4.47E-05 
S1 
(mesenchymal) GO:0043067 regulation of programmed cell death 
1.46E-
07 4.82E-05 
S1 
(mesenchymal) GO:0045321 leukocyte activation 
1.55E-
07 4.95E-05 
S1 
(mesenchymal) GO:0070486 leukocyte aggregation 
2.00E-
07 6.14E-05 
S1 
(mesenchymal) GO:0048584 positive regulation of response to stimulus 
2.30E-
07 6.82E-05 
S1 
(mesenchymal) GO:0048518 positive regulation of biological process 
2.64E-
07 7.57E-05 
S1 
(mesenchymal) GO:0010604 
positive regulation of macromolecule metabolic 
process 
2.86E-
07 7.93E-05 
S1 
(mesenchymal) GO:0051704 multi-organism process 
2.99E-
07 8.03E-05 
S1 
(mesenchymal) GO:0030155 regulation of cell adhesion 
3.47E-
07 9.03E-05 
S1 
(mesenchymal) GO:0042981 regulation of apoptotic process 
3.71E-
07 9.39E-05 
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S1 
(mesenchymal) GO:0010628 positive regulation of gene expression 
4.42E-
07 1.08E-04 
S1 
(mesenchymal) GO:0071593 lymphocyte aggregation 
4.47E-
07 1.07E-04 
S1 
(mesenchymal) GO:0050789 regulation of biological process 
4.85E-
07 1.13E-04 
S1 
(mesenchymal) GO:0048729 tissue morphogenesis 
6.76E-
07 1.53E-04 
S1 
(mesenchymal) GO:0031347 regulation of defense response 
7.60E-
07 1.68E-04 
S1 
(mesenchymal) GO:0009617 response to bacterium 
8.13E-
07 1.75E-04 
S1 
(mesenchymal) GO:0016337 single organismal cell-cell adhesion 
9.30E-
07 1.95E-04 
S1 
(mesenchymal) GO:0070489 T cell aggregation 
9.46E-
07 1.94E-04 
S1 
(mesenchymal) GO:0051239 regulation of multicellular organismal process 
9.47E-
07 1.89E-04 
S1 
(mesenchymal) GO:1902680 positive regulation of RNA biosynthetic process 
9.87E-
07 1.93E-04 
S1 
(mesenchymal) GO:0033993 response to lipid 
1.04E-
06 1.98E-04 
S1 
(mesenchymal) GO:0007165 signal transduction 
1.07E-
06 2.00E-04 
S1 
(mesenchymal) GO:0030198 extracellular matrix organization 
1.18E-
06 2.16E-04 
S1 
(mesenchymal) GO:0043062 extracellular structure organization 
1.18E-
06 2.11E-04 
S1 
(mesenchymal) GO:0009653 anatomical structure morphogenesis 
1.30E-
06 2.28E-04 
S1 
(mesenchymal) GO:0001525 angiogenesis 
1.32E-
06 2.27E-04 
S1 
(mesenchymal) GO:0007159 leukocyte cell-cell adhesion 
1.36E-
06 2.29E-04 
S1 
(mesenchymal) GO:0046649 lymphocyte activation 
1.41E-
06 2.33E-04 
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S1 
(mesenchymal) GO:0045893 positive regulation of transcription, DNA-templated 
1.45E-
06 2.36E-04 
S1 
(mesenchymal) GO:1903508 
positive regulation of nucleic acid-templated 
transcription 
1.45E-
06 2.31E-04 
S1 
(mesenchymal) GO:0019882 antigen processing and presentation 
1.46E-
06 2.29E-04 
S1 
(mesenchymal) GO:0010557 
positive regulation of macromolecule biosynthetic 
process 
1.55E-
06 2.38E-04 
S1 
(mesenchymal) GO:0097190 apoptotic signaling pathway 
1.58E-
06 2.39E-04 
S1 
(mesenchymal) GO:0048522 positive regulation of cellular process 
1.65E-
06 2.45E-04 
S1 
(mesenchymal) GO:0002250 adaptive immune response 
1.81E-
06 2.63E-04 
S1 
(mesenchymal) GO:0010033 response to organic substance 
2.02E-
06 2.90E-04 
S1 
(mesenchymal) GO:1903034 regulation of response to wounding 
2.04E-
06 2.88E-04 
S1 
(mesenchymal) GO:0042110 T cell activation 
2.06E-
06 2.86E-04 
S1 
(mesenchymal) GO:2000736 regulation of stem cell differentiation 
2.11E-
06 2.88E-04 
S1 
(mesenchymal) GO:0010941 regulation of cell death 
2.15E-
06 2.88E-04 
S1 
(mesenchymal) GO:0051254 positive regulation of RNA metabolic process 
2.46E-
06 3.25E-04 
S1 
(mesenchymal) GO:0030334 regulation of cell migration 
2.52E-
06 3.28E-04 
S1 
(mesenchymal) GO:0002237 response to molecule of bacterial origin 
3.95E-
06 5.07E-04 
S1 
(mesenchymal) GO:0008284 positive regulation of cell proliferation 
4.23E-
06 5.35E-04 
S1 
(mesenchymal) GO:0031349 positive regulation of defense response 
4.46E-
06 5.56E-04 
S1 
(mesenchymal) GO:2000738 positive regulation of stem cell differentiation 
4.51E-
06 5.54E-04 
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S1 
(mesenchymal) GO:0010717 regulation of epithelial to mesenchymal transition 
5.32E-
06 6.44E-04 
S1 
(mesenchymal) GO:0048002 antigen processing and presentation of peptide antigen 
5.68E-
06 6.78E-04 
S1 
(mesenchymal) GO:2000145 regulation of cell motility 
6.85E-
06 8.07E-04 
S1 
(mesenchymal) GO:0032680 regulation of tumor necrosis factor production 
7.42E-
06 8.62E-04 
S1 
(mesenchymal) GO:1903555 
regulation of tumor necrosis factor superfamily cytokine 
production 
7.42E-
06 8.51E-04 
S1 
(mesenchymal) GO:0080134 regulation of response to stress 
7.60E-
06 8.60E-04 
S1 
(mesenchymal) GO:0001818 negative regulation of cytokine production 
8.33E-
06 9.31E-04 
S1 
(mesenchymal) GO:0031325 positive regulation of cellular metabolic process 
9.97E-
06 1.10E-03 
S1 
(mesenchymal) GO:0042742 defense response to bacterium 
1.18E-
05 1.28E-03 
S1 
(mesenchymal) GO:0002474 
antigen processing and presentation of peptide antigen 
via MHC class I 
1.28E-
05 1.38E-03 
S1 
(mesenchymal) GO:0031589 cell-substrate adhesion 
1.41E-
05 1.49E-03 
S1 
(mesenchymal) GO:0040012 regulation of locomotion 
1.54E-
05 1.61E-03 
S1 
(mesenchymal) GO:0051241 negative regulation of multicellular organismal process 
1.62E-
05 1.68E-03 
S1 
(mesenchymal) GO:0051716 cellular response to stimulus 
1.81E-
05 1.85E-03 
S1 
(mesenchymal) GO:0007166 cell surface receptor signaling pathway 
1.88E-
05 1.90E-03 
S1 
(mesenchymal) GO:0019221 cytokine-mediated signaling pathway 
1.97E-
05 1.97E-03 
S1 
(mesenchymal) GO:0002683 negative regulation of immune system process 
1.97E-
05 1.95E-03 
S1 
(mesenchymal) GO:0050778 positive regulation of immune response 
2.05E-
05 2.00E-03 
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S1 
(mesenchymal) GO:0002286 T cell activation involved in immune response 
2.05E-
05 1.98E-03 
S1 
(mesenchymal) GO:0060351 
cartilage development involved in endochondral bone 
morphogenesis 
2.37E-
05 2.27E-03 
S1 
(mesenchymal) GO:0009893 positive regulation of metabolic process 
2.53E-
05 2.39E-03 
S1 
(mesenchymal) GO:0044767 single-organism developmental process 
2.58E-
05 2.41E-03 
S1 
(mesenchymal) GO:0002460 
adaptive immune response based on somatic 
recombination 
3.12E-
05 2.89E-03 
S1 
(mesenchymal) GO:0032496 response to lipopolysaccharide 
3.37E-
05 3.08E-03 
S1 
(mesenchymal) GO:1901342 regulation of vasculature development 
3.75E-
05 3.40E-03 
S1 
(mesenchymal) GO:0032103 positive regulation of response to external stimulus 
4.12E-
05 3.69E-03 
S1 
(mesenchymal) GO:0050727 regulation of inflammatory response 
4.12E-
05 3.65E-03 
S1 
(mesenchymal) GO:0097191 extrinsic apoptotic signaling pathway 
4.41E-
05 3.87E-03 
S1 
(mesenchymal) GO:0002449 lymphocyte mediated immunity 
4.46E-
05 3.87E-03 
S1 
(mesenchymal) GO:0031328 positive regulation of cellular biosynthetic process 
4.75E-
05 4.09E-03 
S1 
(mesenchymal) GO:0002697 regulation of immune effector process 
4.76E-
05 4.05E-03 
S1 
(mesenchymal) GO:0051270 regulation of cellular component movement 
5.03E-
05 4.24E-03 
S1 
(mesenchymal) GO:0048534 hematopoietic or lymphoid organ development 
5.50E-
05 4.59E-03 
S1 
(mesenchymal) GO:0009891 positive regulation of biosynthetic process 
5.84E-
05 4.83E-03 
S1 
(mesenchymal) GO:0042221 response to chemical 
5.95E-
05 4.87E-03 
S1 
(mesenchymal) GO:0003417 growth plate cartilage development 
6.02E-
05 4.88E-03 
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S1 
(mesenchymal) GO:0048384 retinoic acid receptor signaling pathway 
6.61E-
05 5.31E-03 
S1 
(mesenchymal) GO:0045765 regulation of angiogenesis 
7.36E-
05 5.86E-03 
S1 
(mesenchymal) GO:0045935 
positive regulation of nucleobase-containing compound 
metabolic process 
7.97E-
05 6.28E-03 
S1 
(mesenchymal) GO:0048771 tissue remodeling 
8.07E-
05 6.30E-03 
S1 
(mesenchymal) GO:0048513 animal organ development 
9.52E-
05 7.38E-03 
S1 
(mesenchymal) GO:1902533 positive regulation of intracellular signal transduction 
9.64E-
05 7.40E-03 
S1 
(mesenchymal) GO:0042035 regulation of cytokine biosynthetic process 
9.75E-
05 7.41E-03 
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Table S2.9B. Enriched GO terms from HGG SAM analyses (FDR cutoff 0.0001) - S2 
Subtype GO Term Description P-value FDR q-value 
S2 
(proneural) GO:0090304 nucleic acid metabolic process 2.72E-40 2.29E-36 
S2 
(proneural) GO:0006139 nucleobase-containing compound metabolic process 3.34E-38 1.41E-34 
S2 
(proneural) GO:0046483 heterocycle metabolic process 1.05E-36 2.94E-33 
S2 
(proneural) GO:0006725 cellular aromatic compound metabolic process 2.87E-36 6.05E-33 
S2 
(proneural) GO:0034641 cellular nitrogen compound metabolic process 3.52E-34 5.93E-31 
S2 
(proneural) GO:1901360 organic cyclic compound metabolic process 4.00E-34 5.62E-31 
S2 
(proneural) GO:0044260 cellular macromolecule metabolic process 9.07E-33 1.09E-29 
S2 
(proneural) GO:0006807 nitrogen compound metabolic process 1.13E-30 1.20E-27 
S2 
(proneural) GO:0006396 RNA processing 5.48E-29 5.13E-26 
S2 
(proneural) GO:0016070 RNA metabolic process 1.95E-28 1.65E-25 
S2 
(proneural) GO:0043170 macromolecule metabolic process 3.16E-26 2.42E-23 
S2 
(proneural) GO:0007049 cell cycle 6.26E-21 4.40E-18 
S2 
(proneural) GO:0008380 RNA splicing 1.07E-20 6.91E-18 
S2 
(proneural) GO:0044237 cellular metabolic process 9.15E-20 5.51E-17 
S2 
(proneural) GO:0044238 primary metabolic process 2.33E-19 1.31E-16 
S2 
(proneural) GO:0016071 mRNA metabolic process 9.81E-19 5.17E-16 
S2 
(proneural) GO:1903047 mitotic cell cycle process 1.93E-17 9.59E-15 
    
 
2
0
3 
S2 
(proneural) GO:0006259 DNA metabolic process 2.08E-17 9.75E-15 
S2 
(proneural) GO:0051301 cell division 2.22E-17 9.85E-15 
S2 
(proneural) GO:0006397 mRNA processing 2.72E-17 1.15E-14 
S2 
(proneural) GO:0022402 cell cycle process 6.33E-17 2.54E-14 
S2 
(proneural) GO:0071704 organic substance metabolic process 3.92E-16 1.50E-13 
S2 
(proneural) GO:0009059 macromolecule biosynthetic process 2.91E-15 1.07E-12 
S2 
(proneural) GO:0007067 mitotic nuclear division 4.13E-15 1.45E-12 
S2 
(proneural) GO:0000280 nuclear division 4.56E-15 1.54E-12 
S2 
(proneural) GO:0034645 cellular macromolecule biosynthetic process 1.37E-14 4.45E-12 
S2 
(proneural) GO:0048285 organelle fission 3.78E-14 1.18E-11 
S2 
(proneural) GO:0009058 biosynthetic process 3.82E-14 1.15E-11 
S2 
(proneural) GO:1901576 organic substance biosynthetic process 7.40E-14 2.15E-11 
S2 
(proneural) GO:0044249 cellular biosynthetic process 1.46E-13 4.11E-11 
S2 
(proneural) GO:0008152 metabolic process 8.22E-13 2.24E-10 
S2 
(proneural) GO:0034660 ncRNA metabolic process 1.09E-12 2.87E-10 
S2 
(proneural) GO:0006281 DNA repair 3.44E-12 8.79E-10 
S2 
(proneural) GO:0051171 regulation of nitrogen compound metabolic process 7.48E-12 1.86E-09 
S2 
(proneural) GO:0034470 ncRNA processing 7.62E-12 1.84E-09 
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S2 
(proneural) GO:0044271 cellular nitrogen compound biosynthetic process 2.71E-11 6.35E-09 
S2 
(proneural) GO:0006364 rRNA processing 4.67E-11 1.06E-08 
S2 
(proneural) GO:0016072 rRNA metabolic process 4.67E-11 1.04E-08 
S2 
(proneural) GO:0051276 chromosome organization 6.34E-11 1.37E-08 
S2 
(proneural) GO:0010556 regulation of macromolecule biosynthetic process 2.03E-10 4.29E-08 
S2 
(proneural) GO:2000112 
regulation of cellular macromolecule biosynthetic 
process 2.06E-10 4.24E-08 
S2 
(proneural) GO:0043933 macromolecular complex subunit organization 3.15E-10 6.32E-08 
S2 
(proneural) GO:0007346 regulation of mitotic cell cycle 4.14E-10 8.11E-08 
S2 
(proneural) GO:0019219 
regulation of nucleobase-containing compound 
metabolic process 5.72E-10 1.10E-07 
S2 
(proneural) GO:0000377 RNA splicing, via transesterification reactions  5.89E-10 1.10E-07 
S2 
(proneural) GO:0000375 RNA splicing, via transesterification reactions 5.89E-10 1.08E-07 
S2 
(proneural) GO:0000398 mRNA splicing, via spliceosome 5.89E-10 1.06E-07 
S2 
(proneural) GO:0010564 regulation of cell cycle process 7.84E-10 1.38E-07 
S2 
(proneural) GO:0015931 nucleobase-containing compound transport 1.42E-09 2.45E-07 
S2 
(proneural) GO:0034654 nucleobase-containing compound biosynthetic process 1.87E-09 3.15E-07 
S2 
(proneural) GO:1901987 regulation of cell cycle phase transition 2.25E-09 3.73E-07 
S2 
(proneural) GO:0034622 cellular macromolecular complex assembly 2.43E-09 3.95E-07 
S2 
(proneural) GO:0006260 DNA replication 2.54E-09 4.04E-07 
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S2 
(proneural) GO:0009889 regulation of biosynthetic process 2.78E-09 4.35E-07 
S2 
(proneural) GO:1901362 organic cyclic compound biosynthetic process 3.40E-09 5.22E-07 
S2 
(proneural) GO:0050658 RNA transport 3.92E-09 5.90E-07 
S2 
(proneural) GO:0050657 nucleic acid transport 3.92E-09 5.80E-07 
S2 
(proneural) GO:0051236 establishment of RNA localization 3.92E-09 5.70E-07 
S2 
(proneural) GO:0022618 ribonucleoprotein complex assembly 4.89E-09 6.99E-07 
S2 
(proneural) GO:0018130 heterocycle biosynthetic process 5.79E-09 8.14E-07 
S2 
(proneural) GO:0051252 regulation of RNA metabolic process 6.78E-09 9.37E-07 
S2 
(proneural) GO:0031326 regulation of cellular biosynthetic process 7.59E-09 1.03E-06 
S2 
(proneural) GO:0019438 aromatic compound biosynthetic process 1.32E-08 1.77E-06 
S2 
(proneural) GO:0071826 ribonucleoprotein complex subunit organization 1.92E-08 2.54E-06 
S2 
(proneural) GO:1901990 regulation of mitotic cell cycle phase transition 3.11E-08 4.03E-06 
S2 
(proneural) GO:0010468 regulation of gene expression 3.40E-08 4.35E-06 
S2 
(proneural) GO:0006974 cellular response to DNA damage stimulus 3.65E-08 4.59E-06 
S2 
(proneural) GO:0051028 mRNA transport 9.71E-08 1.20E-05 
S2 
(proneural) GO:0032774 RNA biosynthetic process 1.08E-07 1.31E-05 
S2 
(proneural) GO:0031323 regulation of cellular metabolic process 1.39E-07 1.68E-05 
S2 
(proneural) GO:0006351 transcription, DNA-templated 1.80E-07 2.14E-05 
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S2 
(proneural) GO:0097659 nucleic acid-templated transcription 1.80E-07 2.11E-05 
S2 
(proneural) GO:0051983 regulation of chromosome segregation 1.89E-07 2.19E-05 
S2 
(proneural) GO:0060255 regulation of macromolecule metabolic process 2.35E-07 2.68E-05 
S2 
(proneural) GO:0007059 chromosome segregation 4.09E-07 4.60E-05 
S2 
(proneural) GO:0051052 regulation of DNA metabolic process 4.44E-07 4.93E-05 
S2 
(proneural) GO:2001141 regulation of RNA biosynthetic process 7.64E-07 8.37E-05 
S2 
(proneural) GO:1903506 regulation of nucleic acid-templated transcription 7.64E-07 8.26E-05 
S2 
(proneural) GO:0006325 chromatin organization 8.51E-07 9.09E-05 
S2 
(proneural) GO:0006355 regulation of transcription, DNA-templated 9.36E-07 9.87E-05 
S2 
(proneural) GO:0065003 macromolecular complex assembly 1.09E-06 1.14E-04 
S2 
(proneural) GO:0080090 regulation of primary metabolic process 1.51E-06 1.55E-04 
S2 
(proneural) GO:0044085 cellular component biogenesis 2.16E-06 2.20E-04 
S2 
(proneural) GO:0006412 translation 2.21E-06 2.22E-04 
S2 
(proneural) GO:0051168 nuclear export 3.40E-06 3.37E-04 
S2 
(proneural) GO:0009987 cellular process 3.76E-06 3.69E-04 
S2 
(proneural) GO:0006310 DNA recombination 4.56E-06 4.42E-04 
S2 
(proneural) GO:0006401 RNA catabolic process 6.95E-06 6.67E-04 
S2 
(proneural) GO:0019222 regulation of metabolic process 7.92E-06 7.50E-04 
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S2 
(proneural) GO:0016568 chromatin modification 8.58E-06 8.04E-04 
S2 
(proneural) GO:0033119 negative regulation of RNA splicing 8.67E-06 8.04E-04 
S2 
(proneural) GO:0051726 regulation of cell cycle 1.09E-05 9.97E-04 
S2 
(proneural) GO:0090305 nucleic acid phosphodiester bond hydrolysis 1.25E-05 1.13E-03 
S2 
(proneural) GO:0022613 ribonucleoprotein complex biogenesis 1.42E-05 1.28E-03 
S2 
(proneural) GO:0000387 spliceosomal snRNP assembly 1.56E-05 1.38E-03 
S2 
(proneural) GO:0033365 protein localization to organelle 1.64E-05 1.44E-03 
S2 
(proneural) GO:0006275 regulation of DNA replication 1.84E-05 1.60E-03 
S2 
(proneural) GO:0007088 regulation of mitotic nuclear division 1.95E-05 1.68E-03 
S2 
(proneural) GO:0043043 peptide biosynthetic process 2.12E-05 1.80E-03 
S2 
(proneural) GO:0051310 metaphase plate congression 2.25E-05 1.90E-03 
S2 
(proneural) GO:0010948 negative regulation of cell cycle process 2.25E-05 1.88E-03 
S2 
(proneural) GO:0000075 cell cycle checkpoint 2.27E-05 1.88E-03 
S2 
(proneural) GO:0006402 mRNA catabolic process 2.27E-05 1.86E-03 
S2 
(proneural) GO:0006399 tRNA metabolic process 2.34E-05 1.90E-03 
S2 
(proneural) GO:0044267 cellular protein metabolic process 2.42E-05 1.95E-03 
S2 
(proneural) GO:1903312 negative regulation of mRNA metabolic process 3.31E-05 2.63E-03 
S2 
(proneural) GO:0048025 negative regulation of mRNA splicing, via spliceosome 3.40E-05 2.68E-03 
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S2 
(proneural) GO:0006405 RNA export from nucleus 4.08E-05 3.19E-03 
S2 
(proneural) GO:0032204 regulation of telomere maintenance 4.16E-05 3.22E-03 
S2 
(proneural) GO:0006913 nucleocytoplasmic transport 4.32E-05 3.31E-03 
S2 
(proneural) GO:0051169 nuclear transport 4.32E-05 3.28E-03 
S2 
(proneural) GO:0033044 regulation of chromosome organization 4.33E-05 3.26E-03 
S2 
(proneural) GO:0001756 somitogenesis 4.75E-05 3.54E-03 
S2 
(proneural) GO:0035282 segmentation 4.75E-05 3.51E-03 
S2 
(proneural) GO:0051783 regulation of nuclear division 5.04E-05 3.70E-03 
S2 
(proneural) GO:0033045 regulation of sister chromatid segregation 5.59E-05 4.07E-03 
S2 
(proneural) GO:0071840 cellular component organization or biogenesis 6.96E-05 5.02E-03 
S2 
(proneural) GO:0007051 spindle organization 8.22E-05 5.88E-03 
S2 
(proneural) GO:0006289 nucleotide-excision repair 9.20E-05 6.52E-03 
S2 
(proneural) GO:0032259 methylation 9.76E-05 6.86E-03 
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Table S2.9C. Enriched GO terms from HGG SAM analyses (FDR cutoff 0.0001) - S3 
Table S2.9C. Enriched GO terms from HGG SAM analyses (FDR cutoff 0.0001) - S3 
Subtype GO Term Description P-value FDR q-value 
S3 (neural) GO:0099536 synaptic signaling 
2.44E-
06 1.79E-02 
S3 (neural) GO:0099537 trans-synaptic signaling 
2.44E-
06 8.93E-03 
S3 (neural) GO:0007268 synaptic transmission 
2.44E-
06 5.95E-03 
S3 (neural) GO:0050804 modulation of synaptic transmission 
1.43E-
05 2.62E-02 
S3 (neural) GO:0050877 neurological system process 
1.90E-
05 2.78E-02 
S3 (neural) GO:0007270 neuron-neuron synaptic transmission 
3.63E-
05 4.42E-02 
S3 (neural) GO:0051049 regulation of transport 
5.23E-
05 5.46E-02 
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Table S2.10. CNA in spatially distinct TR(P) HGG show evidence of clonal evolution 
Mouse 
ID 
CNA 
HGG 1 Location   HGG 2 Location 
Chromosome Start End   Chromosome Start End 
235344 
  BS   DI 
Gain 
6 3407797 149520604  1 84771143 96148343 
    5 24498907 40604784 
    5 43178200 45514283 
    6 3386664 125527378 
    13 55502290 74249044 
    19 37295134 37505277 
Loss 
2 86040946 90813486   11 52603926 121796672 
8 49770240 69609457   14 68219133 68432377 
10 91355355 116504740   15 42866402 54539782 
13 17168563 29133133         
13 116505113 120606172         
14 79020241 115431576         
16 66635653 86219861         
17 35948984 42090956         
         
236024 
  CTX   OFB 
Gain 
4 111551341 112104179  4 111634766 112114746 
6 3734548 138332452  6 3373820 106180182 
Loss 
1 109642970 119351601   None     
2 85392180 89836288         
5 9630570 19355183         
8 99365014 106947658         
10 99835535 106828005         
13 116761502 120606172         
14 78985869 91624735         
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14 105500491 112936324         
15 13453095 24598294         
15 42245596 54539782         
16 59482110 83786212         
         
244706 
   OFB   BS 
Gain 
6 3763705 138332452  1 9863 169875650 
    6 3024849 131473159 
Loss 
1 159251360 170278139   2 137186961 149502225 
1 175677083 176180255   4 144867593 146628899 
2 137634657 149072625   8 14227242 17834414 
4 144867593 146659327   11 33530019 47916916 
11 71035484 71319408   11 62582530 72429309 
13 116761502 118916994   12 26428637 31422158 
        13 116754485 119063864 
        16 59406082 90816204 
         
244939 
  CTX   OFB 
Gain 17 30169694 30650214  6 3024849 105935318 
Loss 5 104804922 105242139   5 104488686 105176403 
         
245116 
  CTX   DI 
Loss 
4 111579573 112104179   2 136784609 149072625 
4 112114745 113386023   4 111579573 112091073 
12 16353603 30880108   4 112304580 113356036 
        12 16353603 31508274 
        13 116743684 119063864 
         
246270 
  CTX   OFB 
Loss 13 116754485 119072276   None     
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CNA in Rb, RTK/MAPK/PI3K, and Trp53 pathway genes 
Mouse 
ID 
  Genotype Common CNA Unique CNA 
235344   TR 
Ccnd2, Braf, Kras, 
Raf1 
E2f7, Stat3, Stat5a, Stat5b, Erbb2, Met, Map2k3, Map2k4, 
Map3k3, Mapk7, Trp53 
236024  TRP+/- 
Ccnd2, Met, Braf, 
Kras, Raf1 
E2f2 
244706   TRP+/- 
Ccnd2, Met, Braf, 
Kras, Raf1 
Stat1, Map2k4, Mdm4, Trp53 
244939  TRP+/- None Ccnd2, Met, Braf, Kras, Raf1 
245116   TRP+/- None E2f6 
246270   TRP-/- None None 
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Table S2.11. Transcriptome subtypes in GEM HGG validation set 
Sample 
TCGA GBM Subtype 
Prediction (Fig. 5D) 
HGG Subtype Cohort 
GSM566195 Mesenchymal S1 GSE22927 
GSM566350 Mesenchymal S1 GSE22927 
GSM566352 Mesenchymal S1 GSE22927 
GSM566354 Mesenchymal S1 GSE22927 
GSM566358 Mesenchymal S1 GSE22927 
GSM566359 Mesenchymal S1 GSE22927 
GSM566362 Mesenchymal S1 GSE22927 
GSM566405 Mesenchymal S1 GSE22927 
GSM566407 Mesenchymal S1 GSE22927 
GSM566410 Mesenchymal S1 GSE22927 
GSM566416 Mesenchymal S1 GSE22927 
GSM648523 Mesenchymal S1 GSE22927 
GSM566365 Classical S2 GSE22927 
GSM566415 Classical S2 GSE22927 
GSM566347 Mesenchymal S2 GSE22927 
GSM566364 Mesenchymal S2 GSE22927 
GSM566411 Mesenchymal S2 GSE22927 
GSM566351 Proneural S2 GSE22927 
GSM566361 Proneural S2 GSE22927 
GSM566363 Proneural S2 GSE22927 
GSM566366 Proneural S2 GSE22927 
GSM566367 Proneural S2 GSE22927 
GSM566406 Proneural S2 GSE22927 
GSM566412 Proneural S2 GSE22927 
GSM566414 Proneural S2 GSE22927 
GSM566417 Classical S3 GSE22927 
GSM566409 Mesenchymal S3 GSE22927 
GSM566346 Neural S3 GSE22927 
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GSM566348 Neural S3 GSE22927 
GSM566349 Neural S3 GSE22927 
GSM566353 Neural S3 GSE22927 
GSM566355 Neural S3 GSE22927 
GSM566360 Neural S3 GSE22927 
GSM566418 Neural S3 GSE22927 
GSM566356 Proneural S3 GSE22927 
GSM566357 Proneural S3 GSE22927 
GSM566408 Proneural S3 GSE22927 
GSM566413 Proneural S3 GSE22927 
GSM729233 Proneural S2 GSE29458 
GSM729234 Proneural S2 GSE29458 
GSM729235 Proneural S2 GSE29458 
GSM729237 Proneural S2 GSE29458 
GSM729238 Proneural S2 GSE29458 
GSM729239 Proneural S2 GSE29458 
GSM729240 Proneural S2 GSE29458 
GSM729241 Proneural S2 GSE29458 
GSM729242 Proneural S2 GSE29458 
GSM729243 Proneural S2 GSE29458 
GSM729244 Proneural S2 GSE29458 
GSM729245 Proneural S2 GSE29458 
GSM729246 Proneural S2 GSE29458 
GSM729247 Proneural S2 GSE29458 
GSM729251 Proneural S2 GSE29458 
GSM729253 Normal S3 GSE29458 
GSM729254 Normal S3 GSE29458 
GSM729255 Normal S3 GSE29458 
GSM729236 Proneural S3 GSE29458 
GSM729248 Proneural S3 GSE29458 
GSM729249 Proneural S3 GSE29458 
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GSM729250 Proneural S3 GSE29458 
GSM729252 Proneural S3 GSE29458 
GSM877357 Mesenchymal S1 GSE35917 
GSM877360 Mesenchymal S1 GSE35917 
GSM877361 Mesenchymal S1 GSE35917 
GSM877362 Mesenchymal S1 GSE35917 
GSM877363 Mesenchymal S1 GSE35917 
GSM877364 Mesenchymal S1 GSE35917 
GSM877369 Mesenchymal S1 GSE35917 
GSM877377 Mesenchymal S1 GSE35917 
GSM877378 Mesenchymal S1 GSE35917 
GSM877379 Mesenchymal S1 GSE35917 
GSM877380 Mesenchymal S1 GSE35917 
GSM877381 Mesenchymal S1 GSE35917 
GSM877382 Mesenchymal S1 GSE35917 
GSM877383 Mesenchymal S1 GSE35917 
GSM877385 Mesenchymal S1 GSE35917 
GSM877386 Mesenchymal S1 GSE35917 
GSM877359 Mesenchymal S3 GSE35917 
GSM877358 Neural S3 GSE35917 
GSM877370 Neural S3 GSE35917 
GSM877371 Neural S3 GSE35917 
GSM877372 Neural S3 GSE35917 
GSM877384 Neural S3 GSE35917 
GSM877365 Normal S3 GSE35917 
GSM877366 Normal S3 GSE35917 
GSM877367 Normal S3 GSE35917 
GSM877368 Normal S3 GSE35917 
GSM877373 Normal S3 GSE35917 
GSM877374 Normal S3 GSE35917 
GSM877375 Normal S3 GSE35917 
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GSM877376 Normal S3 GSE35917 
 
GEM HGG versus human GBM (TCGA) subtypes 
HGG Subtype 
TCGA Subtype 
Total 
PN N NL CL MES 
S1 0 0 0 0 28 28 
S2 23 0 0 2 3 28 
S3 9 12 11 1 2 35 
Total 32 12 11 3 33 91 
Fisher's P<0.0001 
       
Abbreviations   
PN Proneural   
N Normal   
NL Neural   
CL Classical   
MES Mesenchymal   
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Table S2.12. Consensus clustering of GEM, PDX, and human TCGA GBM (Fig. 6) 
Sample ID ClusterID Tumor Type TCGA subtype Cluster Silhouette width Clustered Subtype 
MV51_232366 1 GEM NA 1 0.027 MES 
MV51_233106 2 GEM NA 2 0.163 NL 
MV51_233117 3 GEM NA 3 0.211 PN 
MV51_233352 3 GEM NA 3 -0.179 PN 
MV51_234451 2 GEM NA 2 0.175 NL 
MV51_234458 2 GEM NA 2 -0.062 NL 
MV51_234750 3 GEM NA 3 -0.253 PN 
MV51_235316 2 GEM NA 2 0.048 NL 
MV51_235344 4 GEM NA 4 0.266 NT 
MV51_235791 3 GEM NA 3 0.159 PN 
MV51_236024 5 GEM NA 5 -0.028 CL 
MV51_236070 5 GEM NA 5 0.055 CL 
MV51_241102 2 GEM NA 2 -0.017 NL 
MV51_241898 3 GEM NA 3 0.191 PN 
MV51_242092 2 GEM NA 2 0.097 NL 
MV51_242486 4 GEM NA 4 0.275 NT 
MV55_244189 4 GEM NA 4 0.246 NT 
MV55_244605 3 GEM NA 3 -0.301 PN 
MV55_244706 3 GEM NA 3 0.114 PN 
MV55_244706 5 GEM NA 5 -0.008 CL 
MV55_244939 4 GEM NA 4 0.379 NT 
MV55_245016 1 GEM NA 1 -0.055 MES 
MV55_245116 2 GEM NA 2 -0.190 NL 
MV55_245116 2 GEM NA 2 -0.106 NL 
MV55_245586 1 GEM NA 1 0.019 MES 
MV55_245662 2 GEM NA 2 0.140 NL 
MV55_245665 3 GEM NA 3 0.041 PN 
MV55_245936 1 GEM NA 1 0.011 MES 
MV55_246270 3 GEM NA 3 -0.119 PN 
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MV62_235344 5 GEM NA 5 -0.027 CL 
MV62_236024 5 GEM NA 5 -0.007 CL 
MV62_243852 3 GEM NA 3 -0.225 PN 
MV62_244190 5 GEM NA 5 0.047 CL 
MV62_244939 4 GEM NA 4 0.383 NT 
MV62_245237 4 GEM NA 4 0.328 NT 
MV62_245304 2 GEM NA 2 0.064 NL 
MV62_245660 1 GEM NA 1 -0.019 MES 
MV62_245660 3 GEM NA 3 0.268 PN 
MV62_245861 4 GEM NA 4 0.369 NT 
MV62_246270 2 GEM NA 2 -0.153 NL 
MV62_246300 1 GEM NA 1 0.097 MES 
MV62_246302 5 GEM NA 5 0.119 CL 
MV62_246742 5 GEM NA 5 0.053 CL 
GBM10 3 PDX NA 3 -0.029 PN 
GBM102 2 PDX NA 2 0.031 NL 
GBM116 3 PDX NA 3 0.037 PN 
GBM117 2 PDX NA 2 0.125 NL 
GBM12 3 PDX NA 3 0.047 PN 
GBM16 5 PDX NA 5 -0.027 CL 
GBM22 2 PDX NA 2 0.052 NL 
GBM36 5 PDX NA 5 0.143 CL 
GBM38 2 PDX NA 2 0.041 NL 
GBM43 2 PDX NA 2 0.107 NL 
GBM46 3 PDX NA 3 -0.006 PN 
GBM5 1 PDX NA 1 0.031 MES 
GBM55 3 PDX NA 3 -0.040 PN 
GBM6 2 PDX NA 2 0.018 NL 
GBM61 5 PDX NA 5 0.009 CL 
GBM64 1 PDX NA 1 0.112 MES 
GBM76 3 PDX NA 3 -0.048 PN 
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GBM79 2 PDX NA 2 -0.105 NL 
GBM80 2 PDX NA 2 0.050 NL 
GBM84 3 PDX NA 3 -0.068 PN 
GBM85 1 PDX NA 1 -0.011 MES 
GBM91 3 PDX NA 3 -0.033 PN 
GBM59 3 PDX NA 3 0.070 PN 
GBM66 3 PDX NA 3 0.130 PN 
GBM14 2 PDX NA 2 0.117 NL 
GBM39 3 PDX NA 3 0.037 PN 
GBM44 3 PDX NA 3 -0.016 PN 
GS-2 5 PDX NA 5 -0.051 CL 
MDAGSC17 5 PDX NA 5 0.033 CL 
N30 5 PDX NA 5 0.109 CL 
NS2 5 PDX NA 5 0.084 CL 
HF2303 3 PDX NA 3 0.033 PN 
HF2354 5 PDX NA 5 0.151 CL 
HF2355 1 PDX NA 1 -0.035 MES 
HF2381 3 PDX NA 3 0.118 PN 
HF2414 3 PDX NA 3 0.055 PN 
SF7300 3 PDX NA 3 0.096 PN 
SF7796 2 PDX NA 2 0.165 NL 
X1016P16 3 PDX NA 3 0.094 PN 
TCGA_02_0038_01 5 TCGA GBM CL 5 0.001 CL 
TCGA_02_0057_01 2 TCGA GBM NL 2 0.240 NL 
TCGA_02_0055_01 1 TCGA GBM MES 1 0.337 MES 
TCGA_02_0058_01 4 TCGA GBM PN 4 0.290 NT 
TCGA_02_0047_01 3 TCGA GBM PN 3 0.106 PN 
TCGA_02_0024_01 3 TCGA GBM PN 3 0.135 PN 
TCGA_02_0003_01 3 TCGA GBM PN 3 -0.040 PN 
TCGA_02_0006_01 1 TCGA GBM MES 1 -0.210 MES 
TCGA_02_0007_01 2 TCGA GBM PN 2 -0.022 NL 
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TCGA_02_0046_01 3 TCGA GBM PN 3 0.148 PN 
TCGA_02_0021_01 5 TCGA GBM CL 5 0.338 CL 
TCGA_02_0009_01 5 TCGA GBM CL 5 0.319 CL 
TCGA_02_0014_01 3 TCGA GBM PN 3 0.173 PN 
TCGA_02_0034_01 1 TCGA GBM MES 1 0.175 MES 
TCGA_02_0060_01 3 TCGA GBM PN 3 -0.144 PN 
TCGA_02_0001_01 2 TCGA GBM CL 2 0.183 NL 
TCGA_02_0037_01 5 TCGA GBM CL 5 0.278 CL 
TCGA_02_0043_01 5 TCGA GBM CL 5 0.301 CL 
TCGA_02_0052_01 3 TCGA GBM NL 3 0.050 PN 
TCGA_02_0033_01 1 TCGA GBM MES 1 0.421 MES 
TCGA_02_0028_01 3 TCGA GBM PN 3 0.190 PN 
TCGA_02_0027_01 5 TCGA GBM CL 5 0.063 CL 
TCGA_02_0054_01 2 TCGA GBM MES 2 0.154 NL 
TCGA_02_0011_01 3 TCGA GBM PN 3 0.108 PN 
TCGA_02_0010_01 3 TCGA GBM PN 3 0.215 PN 
TCGA_02_0002_01 2 TCGA GBM NL 2 0.227 NL 
TCGA_02_0107_01 1 TCGA GBM MES 1 0.124 MES 
TCGA_02_0064_01 1 TCGA GBM MES 1 0.275 MES 
TCGA_02_0071_01 5 TCGA GBM CL 5 0.072 CL 
TCGA_02_0080_01 3 TCGA GBM PN 3 0.054 PN 
TCGA_02_0086_01 1 TCGA GBM MES 1 0.107 MES 
TCGA_02_0074_01 3 TCGA GBM PN 3 0.312 PN 
TCGA_02_0089_01 2 TCGA GBM NL 2 0.278 NL 
TCGA_02_0115_01 2 TCGA GBM NL 2 0.048 NL 
TCGA_02_0116_01 5 TCGA GBM MES 5 0.245 CL 
TCGA_02_0099_01 2 TCGA GBM MES 2 0.155 NL 
TCGA_02_0069_01 3 TCGA GBM PN 3 0.240 PN 
TCGA_02_0102_01 5 TCGA GBM CL 5 0.244 CL 
TCGA_02_0085_01 2 TCGA GBM MES 2 0.050 NL 
TCGA_02_0113_01 2 TCGA GBM NL 2 -0.022 NL 
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TCGA_02_0083_01 2 TCGA GBM NL 2 0.072 NL 
TCGA_02_0114_01 3 TCGA GBM PN 3 0.250 PN 
TCGA_02_0075_01 1 TCGA GBM MES 1 0.158 MES 
TCGA_06_0169_01 1 TCGA GBM MES 1 0.023 MES 
TCGA_06_0133_01 2 TCGA GBM NL 2 -0.155 NL 
TCGA_06_0147_01 1 TCGA GBM MES 1 0.311 MES 
TCGA_06_0125_01 5 TCGA GBM CL 5 0.292 CL 
TCGA_06_0130_01 1 TCGA GBM MES 1 0.376 MES 
TCGA_06_0129_01 3 TCGA GBM PN 3 0.193 PN 
TCGA_06_0141_01 1 TCGA GBM MES 1 -0.174 MES 
TCGA_06_0122_01 5 TCGA GBM MES 5 0.038 CL 
TCGA_06_0139_01 1 TCGA GBM MES 1 0.318 MES 
TCGA_06_0126_01 5 TCGA GBM CL 5 0.126 CL 
TCGA_06_0124_01 1 TCGA GBM MES 1 0.028 MES 
TCGA_06_0128_01 3 TCGA GBM PN 3 0.140 PN 
TCGA_06_0143_01 5 TCGA GBM MES 5 0.003 CL 
TCGA_06_0221_01 4 TCGA GBM NL 4 0.243 NT 
TCGA_06_0157_01 5 TCGA GBM CL 5 0.059 CL 
TCGA_06_0190_01 1 TCGA GBM MES 1 0.225 MES 
TCGA_06_0237_01 2 TCGA GBM NL 2 -0.102 NL 
TCGA_06_0189_01 1 TCGA GBM MES 1 0.282 MES 
TCGA_06_0185_01 2 TCGA GBM NL 2 0.046 NL 
TCGA_06_0197_01 1 TCGA GBM MES 1 0.330 MES 
TCGA_06_0184_01 2 TCGA GBM MES 2 0.198 NL 
TCGA_06_0195_01 4 TCGA GBM NL 4 0.368 NT 
TCGA_06_0219_01 2 TCGA GBM NL 2 -0.084 NL 
TCGA_06_0206_01 1 TCGA GBM MES 1 0.388 MES 
TCGA_06_0158_01 2 TCGA GBM CL 2 0.111 NL 
TCGA_06_0241_01 3 TCGA GBM PN 3 0.229 PN 
TCGA_06_0168_01 2 TCGA GBM MES 2 0.104 NL 
TCGA_06_0209_01 1 TCGA GBM NA 1 0.034 MES 
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TCGA_06_0201_01 1 TCGA GBM MES 1 0.080 MES 
TCGA_06_0214_01 2 TCGA GBM NL 2 0.137 NL 
TCGA_06_0213_01 1 TCGA GBM NL 1 -0.081 MES 
TCGA_06_0174_01 3 TCGA GBM PN 3 0.228 PN 
TCGA_06_0154_01 1 TCGA GBM MES 1 0.084 MES 
TCGA_06_0188_01 3 TCGA GBM NL 3 -0.106 PN 
TCGA_06_0166_01 3 TCGA GBM PN 3 0.124 PN 
TCGA_06_0171_01 2 TCGA GBM NL 2 -0.083 NL 
TCGA_06_0173_01 2 TCGA GBM NL 2 0.133 NL 
TCGA_06_0187_01 5 TCGA GBM CL 5 0.250 CL 
TCGA_06_0132_01 2 TCGA GBM NL 2 -0.113 NL 
TCGA_16_0848_01 3 TCGA GBM PN 3 0.162 PN 
TCGA_16_0849_01 3 TCGA GBM PN 3 -0.007 PN 
TCGA_12_0827_01 2 TCGA GBM MES 2 0.110 NL 
TCGA_06_0875_01 3 TCGA GBM PN 3 0.275 PN 
TCGA_14_0871_01 3 TCGA GBM MES 3 0.045 PN 
TCGA_12_0822_01 1 TCGA GBM NL 1 -0.062 MES 
TCGA_06_0876_01 5 TCGA GBM CL 5 0.077 CL 
TCGA_16_0846_01 3 TCGA GBM PN 3 -0.094 PN 
TCGA_16_0850_01 3 TCGA GBM PN 3 0.240 PN 
TCGA_06_0881_01 1 TCGA GBM MES 1 0.347 MES 
TCGA_14_0813_01 3 TCGA GBM PN 3 0.004 PN 
TCGA_12_0820_01 3 TCGA GBM CL 3 0.099 PN 
TCGA_14_0867_01 5 TCGA GBM MES 5 -0.081 CL 
TCGA_06_0879_01 5 TCGA GBM CL 5 0.212 CL 
TCGA_06_0877_01 5 TCGA GBM CL 5 0.272 CL 
TCGA_12_0821_01 3 TCGA GBM NL 3 0.010 PN 
TCGA_14_0789_01 1 TCGA GBM MES 1 0.112 MES 
TCGA_12_0828_01 5 TCGA GBM NL 5 -0.024 CL 
TCGA_06_0882_01 2 TCGA GBM NL 2 0.233 NL 
TCGA_14_0817_01 2 TCGA GBM NL 2 0.215 NL 
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TCGA_06_0878_01 5 TCGA GBM MES 5 0.199 CL 
TCGA_14_0787_01 5 TCGA GBM CL 5 0.182 CL 
TCGA_12_0826_01 2 TCGA GBM NL 2 0.077 NL 
TCGA_12_0670_01 2 TCGA GBM NL 2 -0.106 NL 
TCGA_16_0861_01 2 TCGA GBM CL 2 0.046 NL 
TCGA_12_0819_01 2 TCGA GBM CL 2 -0.110 NL 
TCGA_12_0829_01 2 TCGA GBM MES 2 0.204 NL 
TCGA_12_0818_01 3 TCGA GBM PN 3 0.044 PN 
TCGA_19_0960_01 3 TCGA GBM PN 3 0.130 PN 
TCGA_14_1454_01 3 TCGA GBM PN 3 0.191 PN 
TCGA_12_1093_01 2 TCGA GBM MES 2 0.091 NL 
TCGA_14_1034_01 1 TCGA GBM MES 1 -0.194 MES 
TCGA_14_1396_01 1 TCGA GBM MES 1 0.079 MES 
TCGA_12_1096_01 2 TCGA GBM MES 2 0.102 NL 
TCGA_12_1098_01 5 TCGA GBM CL 5 0.070 CL 
TCGA_14_1402_01 5 TCGA GBM CL 5 0.183 CL 
TCGA_12_1099_01 3 TCGA GBM PN 3 0.114 PN 
TCGA_14_1452_01 5 TCGA GBM MES 5 0.159 CL 
TCGA_14_1459_01 2 TCGA GBM NL 2 0.140 NL 
TCGA_15_1446_01 2 TCGA GBM CL 2 -0.045 NL 
TCGA_12_1097_01 2 TCGA GBM NL 2 0.063 NL 
TCGA_12_1089_01 4 TCGA GBM NL 4 0.217 NT 
TCGA_12_1095_01 2 TCGA GBM MES 2 0.135 NL 
TCGA_14_0736_01 2 TCGA GBM MES 2 0.035 NL 
TCGA_15_1449_01 3 TCGA GBM PN 3 -0.209 PN 
TCGA_19_0963_01 3 TCGA GBM NL 3 -0.282 PN 
TCGA_19_0955_01 2 TCGA GBM CL 2 0.069 NL 
TCGA_12_1091_01 5 TCGA GBM CL 5 0.240 CL 
TCGA_06_1086_01 5 TCGA GBM MES 5 0.023 CL 
TCGA_12_1090_01 5 TCGA GBM MES 5 0.135 CL 
TCGA_19_0962_01 2 TCGA GBM MES 2 0.193 NL 
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TCGA_12_1092_01 2 TCGA GBM MES 2 0.046 NL 
TCGA_14_0783_01 2 TCGA GBM MES 2 -0.084 NL 
TCGA_06_0155_01 5 TCGA GBM MES 5 0.126 CL 
TCGA_12_1088_01 3 TCGA GBM MES 3 0.039 PN 
TCGA_12_1094_01 5 TCGA GBM CL 5 0.136 CL 
TCGA_14_1401_01 3 TCGA GBM PN 3 -0.107 PN 
TCGA_14_1451_01 3 TCGA GBM PN 3 0.138 PN 
TCGA_14_0786_01 5 TCGA GBM CL 5 0.294 CL 
TCGA_06_1084_01 1 TCGA GBM MES 1 0.212 MES 
TCGA_06_1087_01 3 TCGA GBM PN 3 0.121 PN 
TCGA_16_1055_01 5 TCGA GBM CL 5 -0.026 CL 
TCGA_16_1060_01 5 TCGA GBM MES 5 0.126 CL 
TCGA_19_1392_01 3 TCGA GBM PN 3 0.140 PN 
TCGA_16_1045_01 2 TCGA GBM MES 2 0.160 NL 
TCGA_14_1453_01 5 TCGA GBM CL 5 0.062 CL 
TCGA_15_1447_01 4 TCGA GBM PN 4 0.216 NT 
TCGA_16_1063_01 2 TCGA GBM NL 2 -0.047 NL 
TCGA_16_1056_01 5 TCGA GBM CL 5 0.028 CL 
TCGA_26_1438_01 1 TCGA GBM MES 1 -0.098 MES 
TCGA_26_1443_01 5 TCGA GBM CL 5 0.310 CL 
TCGA_26_1440_01 2 TCGA GBM CL 2 -0.015 NL 
TCGA_19_0964_01 5 TCGA GBM CL 5 0.266 CL 
TCGA_16_1047_01 5 TCGA GBM CL 5 0.183 CL 
TCGA_16_1062_01 5 TCGA GBM CL 5 0.334 CL 
TCGA_02_0330_01 2 TCGA GBM MES 2 0.157 NL 
TCGA_02_0258_01 3 TCGA GBM PN 3 0.068 PN 
TCGA_02_0422_01 5 TCGA GBM CL 5 0.204 CL 
TCGA_02_0440_01 3 TCGA GBM PN 3 0.243 PN 
TCGA_08_0531_01 5 TCGA GBM CL 5 0.231 CL 
TCGA_02_0324_01 5 TCGA GBM NL 5 0.027 CL 
TCGA_06_0414_01 3 TCGA GBM PN 3 0.014 PN 
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TCGA_02_0451_01 2 TCGA GBM NL 2 0.187 NL 
TCGA_02_0339_01 3 TCGA GBM PN 3 0.064 PN 
TCGA_06_0175_01 2 TCGA GBM MES 2 0.152 NL 
TCGA_02_0317_01 5 TCGA GBM CL 5 0.343 CL 
TCGA_06_0413_01 3 TCGA GBM PN 3 0.183 PN 
TCGA_06_0177_01 3 TCGA GBM PN 3 0.188 PN 
TCGA_08_0525_01 5 TCGA GBM CL 5 0.275 CL 
TCGA_08_0522_01 1 TCGA GBM MES 1 0.360 MES 
TCGA_06_0412_01 1 TCGA GBM MES 1 -0.165 MES 
TCGA_08_0520_01 2 TCGA GBM NL 2 0.066 NL 
TCGA_06_0149_01 5 TCGA GBM MES 5 -0.040 CL 
TCGA_02_0289_01 5 TCGA GBM CL 5 0.276 CL 
TCGA_06_0194_01 1 TCGA GBM MES 1 0.123 MES 
TCGA_02_0285_01 5 TCGA GBM CL 5 0.215 CL 
TCGA_06_0179_01 2 TCGA GBM NL 2 -0.052 NL 
TCGA_06_0162_01 2 TCGA GBM NL 2 -0.046 NL 
TCGA_02_0290_01 5 TCGA GBM CL 5 0.258 CL 
TCGA_02_0321_01 3 TCGA GBM PN 3 0.120 PN 
TCGA_02_0439_01 3 TCGA GBM PN 3 0.000 PN 
TCGA_08_0517_01 3 TCGA GBM PN 3 0.109 PN 
TCGA_02_0106_01 1 TCGA GBM MES 1 0.125 MES 
TCGA_02_0269_01 5 TCGA GBM CL 5 0.311 CL 
TCGA_06_0410_01 3 TCGA GBM PN 3 0.041 PN 
TCGA_08_0524_01 3 TCGA GBM PN 3 0.190 PN 
TCGA_02_0325_01 3 TCGA GBM PN 3 0.188 PN 
TCGA_02_0087_01 3 TCGA GBM PN 3 0.102 PN 
TCGA_08_0514_01 5 TCGA GBM CL 5 0.194 CL 
TCGA_08_0521_01 1 TCGA GBM CL 1 -0.185 MES 
TCGA_06_0394_01 5 TCGA GBM CL 5 0.291 CL 
TCGA_02_0266_01 5 TCGA GBM CL 5 0.103 CL 
TCGA_02_0333_01 5 TCGA GBM CL 5 0.263 CL 
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TCGA_02_0332_01 5 TCGA GBM MES 5 -0.169 CL 
TCGA_06_0397_01 1 TCGA GBM MES 1 0.121 MES 
TCGA_02_0326_01 2 TCGA GBM MES 2 0.064 NL 
TCGA_08_0511_01 5 TCGA GBM CL 5 0.142 CL 
TCGA_08_0516_01 2 TCGA GBM CL 2 -0.092 NL 
TCGA_06_0409_01 1 TCGA GBM MES 1 0.188 MES 
TCGA_08_0518_01 5 TCGA GBM CL 5 0.327 CL 
TCGA_02_0271_01 5 TCGA GBM CL 5 0.058 CL 
TCGA_08_0510_01 5 TCGA GBM MES 5 0.076 CL 
TCGA_02_0111_01 1 TCGA GBM MES 1 0.114 MES 
TCGA_02_0446_01 3 TCGA GBM PN 3 0.043 PN 
TCGA_02_0281_01 3 TCGA GBM PN 3 0.250 PN 
TCGA_02_0456_01 1 TCGA GBM MES 1 0.306 MES 
TCGA_02_0337_01 2 TCGA GBM MES 2 0.037 NL 
TCGA_06_0164_01 1 TCGA GBM MES 1 0.137 MES 
TCGA_02_0338_01 3 TCGA GBM PN 3 0.147 PN 
TCGA_08_0512_01 1 TCGA GBM MES 1 0.317 MES 
TCGA_02_0432_01 3 TCGA GBM PN 3 -0.014 PN 
TCGA_08_0509_01 1 TCGA GBM MES 1 0.084 MES 
TCGA_08_0529_01 5 TCGA GBM CL 5 0.256 CL 
TCGA_06_0182_01 5 TCGA GBM NL 5 0.018 CL 
TCGA_06_0402_01 5 TCGA GBM CL 5 0.318 CL 
TCGA_02_0430_01 5 TCGA GBM CL 5 0.316 CL 
TCGA_02_0260_01 5 TCGA GBM CL 5 0.276 CL 
TCGA_06_0146_01 3 TCGA GBM PN 3 0.173 PN 
TCGA_08_0356_01 5 TCGA GBM CL 5 0.156 CL 
TCGA_08_0346_01 1 TCGA GBM MES 1 0.095 MES 
TCGA_02_0039_01 1 TCGA GBM MES 1 -0.018 MES 
TCGA_08_0389_01 3 TCGA GBM NL 3 -0.025 PN 
TCGA_08_0350_01 3 TCGA GBM PN 3 0.283 PN 
TCGA_08_0392_01 1 TCGA GBM MES 1 0.281 MES 
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TCGA_08_0355_01 5 TCGA GBM CL 5 0.069 CL 
TCGA_02_0068_01 5 TCGA GBM CL 5 0.141 CL 
TCGA_08_0390_01 1 TCGA GBM MES 1 -0.129 MES 
TCGA_08_0359_01 3 TCGA GBM PN 3 -0.053 PN 
TCGA_02_0059_01 1 TCGA GBM MES 1 0.353 MES 
TCGA_08_0380_01 2 TCGA GBM NL 2 0.119 NL 
TCGA_02_0016_01 2 TCGA GBM CL 2 -0.004 NL 
TCGA_08_0357_01 5 TCGA GBM CL 5 0.074 CL 
TCGA_08_0353_01 5 TCGA GBM PN 5 0.047 CL 
TCGA_02_0015_01 5 TCGA GBM CL 5 0.117 CL 
TCGA_08_0385_01 3 TCGA GBM PN 3 0.257 PN 
TCGA_08_0348_01 3 TCGA GBM PN 3 0.244 PN 
TCGA_08_0354_01 5 TCGA GBM CL 5 0.189 CL 
TCGA_08_0244_01 2 TCGA GBM CL 2 0.094 NL 
TCGA_08_0246_01 5 TCGA GBM CL 5 0.102 CL 
TCGA_08_0375_01 5 TCGA GBM CL 5 0.294 CL 
TCGA_02_0026_01 3 TCGA GBM PN 3 0.151 PN 
TCGA_08_0347_01 3 TCGA GBM PN 3 0.051 PN 
TCGA_02_0004_01 1 TCGA GBM MES 1 0.276 MES 
TCGA_02_0104_01 3 TCGA GBM PN 3 -0.110 PN 
TCGA_02_0070_01 5 TCGA GBM CL 5 0.167 CL 
TCGA_02_0051_01 1 TCGA GBM MES 1 0.341 MES 
TCGA_08_0245_01 3 TCGA GBM PN 3 0.222 PN 
TCGA_02_0048_01 3 TCGA GBM PN 3 -0.039 PN 
TCGA_08_0351_01 4 TCGA GBM PN 4 0.256 NT 
TCGA_08_0360_01 1 TCGA GBM MES 1 0.225 MES 
TCGA_08_0344_01 3 TCGA GBM PN 3 0.078 PN 
TCGA_02_0023_01 2 TCGA GBM CL 2 0.078 NL 
TCGA_02_0025_01 1 TCGA GBM MES 1 0.328 MES 
TCGA_08_0349_01 2 TCGA GBM NL 2 0.074 NL 
TCGA_06_0648_01 3 TCGA GBM PN 3 0.168 PN 
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TCGA_12_0615_01 2 TCGA GBM CL 2 0.065 NL 
TCGA_06_0646_01 3 TCGA GBM PN 3 0.034 PN 
TCGA_06_0127_01 2 TCGA GBM CL 2 0.025 NL 
TCGA_12_0618_01 3 TCGA GBM PN 3 0.128 PN 
TCGA_08_0386_01 2 TCGA GBM NL 2 -0.097 NL 
TCGA_12_0619_01 1 TCGA GBM MES 1 0.099 MES 
TCGA_12_0620_01 5 TCGA GBM MES 5 0.101 CL 
TCGA_06_0645_01 2 TCGA GBM MES 2 0.139 NL 
TCGA_12_0616_01 3 TCGA GBM PN 3 0.249 PN 
TCGA_06_0238_01 3 TCGA GBM PN 3 -0.020 PN 
TCGA_08_0358_01 5 TCGA GBM CL 5 0.313 CL 
TCGA_02_0079_01 2 TCGA GBM MES 2 0.081 NL 
TCGA_06_0152_01 5 TCGA GBM MES 5 0.135 CL 
TCGA_08_0352_01 2 TCGA GBM MES 2 0.040 NL 
TCGA_08_0345_01 3 TCGA GBM PN 3 0.074 PN 
TCGA_02_0084_01 3 TCGA GBM PN 3 0.062 PN 
TCGA_08_0373_01 2 TCGA GBM MES 2 0.097 NL 
TCGA_06_0644_01 1 TCGA GBM MES 1 0.371 MES 
TCGA_06_0750_01 5 TCGA GBM MES 5 -0.076 CL 
TCGA_12_0703_01 5 TCGA GBM CL 5 0.082 CL 
TCGA_06_0192_01 1 TCGA GBM MES 1 0.175 MES 
TCGA_06_0745_01 5 TCGA GBM PN 5 -0.061 CL 
TCGA_06_0744_01 5 TCGA GBM CL 5 0.055 CL 
TCGA_15_0742_01 5 TCGA GBM CL 5 0.267 CL 
TCGA_12_0654_01 1 TCGA GBM MES 1 0.090 MES 
TCGA_12_0780_01 5 TCGA GBM CL 5 0.169 CL 
TCGA_12_0656_01 5 TCGA GBM CL 5 0.186 CL 
TCGA_12_0778_01 1 TCGA GBM MES 1 -0.164 MES 
TCGA_06_0743_01 5 TCGA GBM CL 5 0.107 CL 
TCGA_12_0772_01 1 TCGA GBM MES 1 -0.068 MES 
TCGA_12_0691_01 5 TCGA GBM NA 5 -0.180 CL 
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TCGA_12_0688_01 5 TCGA GBM CL 5 0.320 CL 
TCGA_06_0749_01 4 TCGA GBM NL 4 0.256 NT 
TCGA_12_0773_01 1 TCGA GBM NL 1 -0.154 MES 
TCGA_12_0776_01 1 TCGA GBM MES 1 -0.018 MES 
TCGA_06_0686_01 3 TCGA GBM PN 3 0.093 PN 
TCGA_12_0769_01 5 TCGA GBM NA 5 0.179 CL 
TCGA_12_0657_01 5 TCGA GBM CL 5 0.222 CL 
TCGA_06_0649_01 2 TCGA GBM NL 2 0.201 NL 
TCGA_12_0775_01 1 TCGA GBM MES 1 0.041 MES 
TCGA_12_0707_01 2 TCGA GBM NL 2 0.070 NL 
TCGA_06_0747_01 5 TCGA GBM CL 5 0.160 CL 
TCGA_12_0662_01 1 TCGA GBM NA 1 0.037 MES 
TCGA_12_0692_01 5 TCGA GBM CL 5 0.106 CL 
TCGA_06_0678_11 4 TCGA GBM NT 4 0.569 NT 
TCGA_06_0681_11 4 TCGA GBM NT 4 0.584 NT 
TCGA_06_0676_11 4 TCGA GBM NT 4 0.576 NT 
TCGA_08_0626_11 4 TCGA GBM NT 4 0.581 NT 
TCGA_06_0673_11 4 TCGA GBM NT 4 0.592 NT 
TCGA_08_0625_11 4 TCGA GBM NT 4 0.565 NT 
TCGA_08_0627_11 4 TCGA GBM NT 4 0.584 NT 
TCGA_06_0675_11 4 TCGA GBM NT 4 0.597 NT 
TCGA_06_0680_11 4 TCGA GBM NT 4 0.602 NT 
TCGA_08_0623_11 4 TCGA GBM NT 4 0.564 NT 
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Table S2.13. Cluster assignment of GEM and PDX models to TCGA GBM subtypes (Fig. 6) 
Proneural 
  clustered    
   PN non-PN  Chi-sq 231.83 
assigned 
PN 69 6  p-value 2.3802E-52 
non-PN 8 224   p (hyper) 5.7087E-52 
       
       
Mesenchymal 
  clustered    
   MES non-MES  Chi-sq 125.74 
assigned 
MES 54 41  p-value 3.5125E-29 
non-MES 4 208   p (hyper) 4.5952E-29 
  
  
   
  
  
   
Classical 
  clustered    
   CL non-CL  Chi-sq 150.43 
assigned 
CL 67 15  p-value 1.3973E-34 
non-CL 21 204   p (hyper) 4.9707E-34 
  
  
   
  
  
   
Neural 
  clustered    
   NL non-NL  Chi-sq 59.106 
assigned 
NL 30 15  p-value 1.4944E-14 
non-NL 37 225   p (hyper) 1.1425E-12 
  
  
   
  
  
   
Non-tumor 
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  clustered    
   NT non-NT  Chi-sq 158.16 
assigned 
NT 10 0  p-value 2.8568E-36 
non-NT 7 290   p (hyper) 1.1005E-14 
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Table S2.14. GFAP-CreER mice with p53 deletion and combinations of T121, KrasG12D, and Pten deletion 
Mouse 
ID 
Genotype Sex 
Age at induction 
(days) 
Cause of 
death 
Survival 
(days) 
Diagnosis aCGH samples 
250645 p53+/- F 91 Sac 63 Normal   
250868 p53+/- M 91 Sac 63 Normal  
250647 R;p53+/- F 91 Sac 63 Normal   
250867 R;p53+/- M 91 Sac 63 Normal  
247825 RP+/-;p53+/- F 211 Sac 64 Normal   
248111 RP+/-;p53+/- M 188 Sac 64 Normal  
249666 RP+/-;p53+/- F 79 Sac 64 Normal   
241718 T;p53+/- M 130 
Brain 
tumor 
301 GBM Fig S2.10D 
250643 T;p53+/- F 91 Sac 63 A2 CTX (Fig S2.10C) 
248104 TP+/-;p53+/- F 188 Sac 64 A2 OFB (Fig S2.10C) 
249301 TP+/-;p53+/- F 103 Sac 64 A2 OFB (Fig S2.10C) 
251674 TP+/-;p53+/- F 113 Sac 184 A2  
251676 TP+/-;p53+/- F 113 Sac 184 A2   
250644 TR;p53+/- F 91 Sac 63 A2 CTX, OFB (Fig S2.10C) 
250651 TR;p53+/- F 91 Sac 63 A2 CTX (Fig S2.10C) 
251213 TR;p53+/- F 102 Sac 64 A2  
247731 TRP+/-;p53+/- M 166 
Brain 
tumor 
39 A2   
249669 TRP+/-;p53+/- M 79 Sac 64 A3 CTX, OFB (Fig S2.10C) 
249670 TRP+/-;p53+/- M 79 Sac 64 A3 CTX, OFB (Fig S2.10C) 
251226 TRP+/-;p53+/- M 102 Sac 64 A2  
    
 
2
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251685 TRP+/-;p53+/- M 113 
Brain 
tumor 
81 A3   
 
Summary 
 
Genotype Diagnosis 
Total 
aCGH 
samples 
Total 
mice 
 
p53+/- Normal  2 
 
R;p53+/- Normal  2 
 
RP+/-;p53+/- Normal   3 
 
T;p53+/- 
LGG (A2) 1 1 
 
HGG (GBM) 1 1 
 
TP+/-;p53+/- LGG (A2) 2 4 
 
TR;p53+/- LGG (A2) 3 3 
 
TRP+/-;p53+/- 
LGG (A2)  2 
 
HGG (A3) 4 3 
 
Total 11 21 
 
     
  Mean SD Min Max 
Age at induction (days) 114.4 39.4 79 211 
Post-induction Survival (days) 86.0 61.5 39 301 
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Chapter III: Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse 
models1 
 
INTRODUCTION 
Glioblastoma (GBM) is the most common and biologically aggressive primary brain tumor 
and has a dismal survival of 12-15 months. Current standard of care includes surgical resection 
followed by concurrent fractionated radiation and chemotherapy with temozolomide (3, 4). 
However, these treatments fail to prevent tumor recurrence. GBM continues to be diagnosed as 
a single disease entity based on histopathology, but these tumors display significant 
morphological, molecular, and biological heterogeneity. Indeed, comprehensive genomic profiling 
has identified multiple subtypes with distinct cellular composition, therapeutic responses, and 
clinical outcomes (5, 7, 8). Defining the underlying sources of the extensive heterogeneity in GBM 
would facilitate improved classification and development of mechanism-based strategies to 
manage these fatal diseases. 
Two models have been proposed to explain cancer heterogeneity (11). In the mutation 
model, distinct tumor subtypes develop via transformation of a single cell type by different 
oncogenic mutations. Support for this model in GBM has been obtained through large scale 
sequencing studies of surgically resected human tumors. These studies have shown common 
mutations in G1/S cell cycle checkpoint, receptor tyrosine kinase/mitogen activated protein 
kinase/phosphoinositide 3-kinase (RTK/MAPK/PI3K), and TP53 “core GBM signaling pathway” 
genes (12, 13). Genetically engineered mouse (GEM) models have become essential 
experimental tools for confirming the role of these mutations in driving tumorigenesis in the intact
                                                 
1 A version of this work was previously published as David M. Irvin, Robert S. McNeill, Ryan E. Bash, and C. Ryan 
Miller. Intrinsic astrocyte heterogeneity influences tumor growth in glioma mouse models. Brain Pathology. 
Accepted January, 13, 2016. 
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mammalian brain. Many, including loss-of-function mutations in Cdkn2a, Nf1, Pten, or Trp53 
tumor suppressor genes and activating mutations in Egfr, Kras, or Akt1 oncogenes, have been 
shown to produce gliomas when combined to transform cells of a single type: those expressing 
the glial fibrillary acidic protein (GFAP) (14-21). 
In contrast, the cellular origin model proposes that tumor subtypes arise via transformation 
of different cell types. Evidence supporting the cellular origin model in GBM was first obtained 
through comparative transcriptome profiling, which showed that human GBM subtypes harbor 
transcriptomes similar to purified mouse astrocytes, neurons, oligodendrocyte progenitor cells 
(OPC), and neural stem cells (NSC) (5). A variety of GEM models have shown that different 
mutations can transform each of these cells and induce gliomas. For example, mutations that 
inactivate RB family pocket proteins (18, 31, 32), Cdkn2a (20, 21, 25), Nf1 (33, 34), Pten (15, 18, 
32, 34), or Trp53 (15, 18, 25, 33-35) and activate Hras (19, 35), Kras (16, 21, 36) or Akt1 (36, 37) 
have been shown to transform terminally differentiated, GFAP+ astrocytes (hereafter GFAP 
astrocytes). The combination of Trp53 deletion and Hras activation has been shown to transform 
neurons expressing Synapsin 1 (Syn1) (35). Deletion of Cdkn2a (24), Nf1 (22, 38), or Trp53 (22, 
38), overexpression of Pdgfb (23), and activation of Kras (23, 24) or Akt1 (23, 24) has been shown 
to transform OPC expressing neural/glial antigen 2 (NG2, a proteoglycan encoded by Cspg4) or 
2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase encoded by Cnp). Finally, deletion of 
Cdkn2a (20, 21, 25), Nf1 (26), Pten (25, 26), or Trp53 (20, 26) and activation of Kras (21, 36) or 
Akt1 (21, 36) has been shown to transform NSC that express the intermediate filament protein 
nestin (encoded by Nes). These GEM models collectively demonstrate that gliomas can arise via 
transformation of multiple cell types through a variety of core GBM pathway mutations. They also 
suggest that the interaction between tumor initiating mutations and cellular origin may further 
contribute to GBM heterogeneity. 
The most fundamental ramification of the cellular origin model of cancer heterogeneity is 
that the biological state of the initially transformed cell may profoundly influence tumor 
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pathogenesis. Biologic factors intrinsic to the initially transformed cell include its ontogeny or 
developmental origin. Biological factors extrinsic to the cell include the cellular and biochemical 
milieu present in its local/regional microenvironment. These factors may be particularly important 
for glioma pathogenesis, especially for tumors originating from terminally differentiated or 
“mature” astrocytes (hereafter astrocytes), the most common, heterogeneous, and widely 
distributed glial cell in the mammalian brain. 
Astrocytes are a diverse population of glial cells with distinct ontogenies and 
developmental origins (41). They arise during embryonic to early post-natal development from 
precursor populations located in different regions of the brain (42, 43). Astrocytes are produced 
during embryogenesis from stem-like radial glia in ventricular (VZ) and subventricular zones 
(SVZ). Maximal astrocyte production occurs perinatally (44) from intermediate progenitors in the 
VZ/SVZ (45, 46), as well as from local GFAP astrocytes in other brain regions (43). VZ/SVZ (106) 
and local astrocyte production decreases to low levels in the young adult brain (43). Thus, adult 
astrocytes are terminally differentiated and essentially quiescent. 
During the perinatal period, regional astrocyte diversity is generated in part through 
production from specific subsets of intermediate forebrain progenitors. Dorsal (Emx1+), medial 
(Dbx-1+), and intermediate (Nkx2.1+) progenitors have been shown to produce astrocytes in the 
cortex, diencephalon, and hypothalamus, respectively (47). These distinct cellular ontogenies 
could potentially explain the region-specific transcriptome programs that have been documented 
in the adult mouse brain (49-51), as well as region-specific expression of astrocyte markers, such 
as glutamate aspartate transporter (GLAST encoded by Slc1a3) and Kir4.1 (encoded by Kcnj10) 
(42, 54, 55, 107). Differential expression of astrocyte markers has been utilized to develop GEM 
models that target transgene expression to astrocyte subpopulations (47, 48). Whereas 
astrocytes expressing ALDH1L1 and to a lesser extent GFAP are abundant in most brain regions 
(52), GLAST astrocyte expression levels are more regionally restricted (54, 55, 108, 109). 
However, GEM glioma models developed to date have exclusively used the GFAP promoter to 
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target oncogenic mutations to astrocytes (14). Thus, it remains unclear whether astrocyte 
subpopulations are uniformly susceptible to transformation. One recent report showed regional 
differences in growth of cultured NF1-null astrocytes harvested from various regions of the 
neonatal mouse brain (51). However, it remains unclear whether intrinsic astrocyte heterogeneity 
impacts glioma pathogenesis in the intact, adult mammalian brain. 
Conditional, inducible GEM models are ideally suited for experimentally addressing the 
mutation and cellular origin models of cancer heterogeneity. We have developed such models 
using mutations in the G1/S and RTK core GBM pathways in adult GFAP+ brain cells (14, 32). To 
disrupt the G1/S checkpoint, we inactivated all three members of the Rb family of pocket proteins 
using a single GFAP-driven transgene encoding the N-terminal 121 amino acids of SV40 large T 
antigen (T121, T) (31). A conditional knock-in encoding constitutively active Kras (KrasG12D, R) and 
a conditional Pten knockout (PtenDel, P) were used to separately activate the two major effector 
arms of RTK signaling, MAPK and PI3K (12, 75-77). 
We have shown that T121 alone was sufficient for tumor initiation in adult mice (32). Also, 
we have showed that the addition of KrasG12D and PtenDel facilitated malignant progression to high 
grade disease (32). However, it remained unclear whether subpopulations of adult astrocytes 
would respond similarly to the same initial oncogenic mutations. To further explore this issue, we 
targeted TRP mutations to subpopulations of fully differentiated astrocytes using GFAP-CreER 
and GLAST-CreER in the intact adult brain and used genetic lineage tracing to monitor tumor 
growth and immunofluorescence-based fate mapping to map the fate of transformed cells over 
time. Here, we demonstrate that TRP mutations transform GFAP astrocytes into rapidly growing 
tumors that are broadly distributed in multiple regions of the brain. In contrast to GFAP+ 
astrocytes, targeting these same TRP mutations to the GLAST+ subpopulation produce slower 
growing tumor cells in culture, as well as more indolent tumors with regional differences in growth, 
significant microenvironmental responses from local, proliferating glia, and delayed malignant 
progression in vivo in the intact mammalian brain. The results from these experiments highlight 
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the contribution of multiple intrinsic biological factors governing astrocyte heterogeneity to 
glioblastoma multiforme pathogenesis and open the door to future experiments exploring the 
influence of heterogeneity within an initiating cell type on resulting cancer development. 
  
  239  
MATERIALS AND METHODS 
Mice. Heterozygous TgGZT121 (T) (31), KrasG12D+/lsl (R) (76), PtenloxP (P) (77), GFAP-CreER (110), 
GLAST-CreER (111), and Rosa26-tdTomato (112) mice were maintained on a C57/Bl6 
background. PCR genotyping was performed as previously described. Cre expression was 
induced in 3 month old adult mice by 5 daily intraperitoneal injections of 4-hydroxytamoxifen 
(Sigma-Aldrich, St Louis, MO) at 100 mg/kg. Induced mice were sacrificed 1, 3, 8, or 16 weeks 
after induction. Prior to sacrifice, mice were given 5'-ethynyl-2'-deoxyuridine (EdU) at 5 mg/kg via 
intraperitoneal injection 4 hours before transcardial perfusion with 4% para-formaldehyde to label 
dividing cells. Brains were dissected and post-fixed in 4% para-formaldehyde overnight at 4°C. 
All data were obtained from 3 mice per cohort with 2 exceptions: competing causes of morbidity 
in TRP;GLAST-CreER;tdTomato mice, primarily large subcutaneous lesions, required euthanasia 
and limited the number analyzed at 8 (N=2) and 16 weeks (N=1).  
Separate cohorts of TRP;GFAP-CreER (N=50) and TRP;GLAST-CreER (N=7) mice were 
aged to neurological morbidity and sacrificed upon development of lethargy, weight loss, 
deterioration in body condition, poor grooming, bulging skull, seizures, ataxia, or paralysis.   
Survival was analyzed by Kaplan-Meier plots and compared using log-rank tests in GraphPad 
Prism (San Diego, CA) as previously described (75). 
Focal tumor formation was induced in three month old TRP;tdTomato mice via stereotactic 
injection of 2x107 plaque forming units (1 µL) of Ad-GFAPCre (University of Iowa Gene Transfer 
Vector Core) into the OFB (coordinates 4, 0.6, 2.5) or SVZ (coordinates 1, 1.3, 3.3 A,L,D). Brains 
were analyzed after four weeks using immunofluorescence. Animal studies were approved by 
and followed the euthanasia guidelines of the University of North Carolina Institutional Animal 
Care and Use Committee. 
 
Cell culture. Primary GFAP+ TRP astrocytes were cultured in DMEM supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin as previously described (75, 88). Cells were 
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sorted into GLAST+ and GLAST- subpopulations using a GLAST antibody (clone ACSA-1, Miltenyi 
Biotec, San Diego, CA, catalog 130-098-804, 1:100) and a Beckman Coulter MoFlo XDP in the 
UNC Flow Cytometry Facility. Cells were sorted in PBS supplemented with 1 mM EDTA, 25 mM 
HEPES pH 7.0, 1% BSA, and 1 µL/mL DNase and cultured as above. 
To examine growth of cultured astrocyte subpopulations, 5,000 cells per well were plated 
in quadruplicate in 96-well plates. Growth was assayed after 0-4 days using the CellTiter 96 
AQueous Proliferation Assay (Promega, Fitchburg, WI). Absorbance at 490 nm was determined 
on a Molecular Devices Emax plate reader (Chicago, IL) equipped with SoftMax Pro 5 software. 
Relative growth was calculated as absorbance relative to day 0. Data (mean ± SEM) were fit to a 
logarithmic equation to calculate doubling times that were compared using the extra-sum-of-
squares F test in GraphPad Prism. 
 
Immunohistochemistry (IHC) and immunocytochemistry (ICC). Fixed brains were embedded 
in 1% agarose (Promega) and 50 µm sagittal sections were cut using a Leica VT100S vibratome. 
Sections were permeabilized and blocked with 0.5% Triton X-100, 10% bovine serum albumin 
(BSA), 5% normal goat serum, and 0.01 M glycine in PBS for 1 hour. Sections were incubated in 
primary antibody overnight in 0.1% Triton X-100 in PBS. EdU was detected using a Click-It EdU 
imaging kit (Invitrogen, Grand Island, NY) per manufacturer’s instructions. Sections were washed 
and incubated for 4 hours with secondary antibody diluted in 0.1% Triton X100 in PBS. Slides 
were counterstained with DAPI and cover-slipped using PermaFluor (Thermo Scientific, Waltham, 
MA). The following primary antibodies were used: NeuN (EMD Millipore, Billerica, MA; MAB377; 
1:500), BLBP (EMD Millipore; AB2253; 1:500); GFAP (Dako, Carpinteria, CA; Z0334; 1:1000); 
PDGFRα (Cell Signaling, Danvers, MA; 3174; 1:500); Iba1 (Wako Chemicals, Richmond, VA; 
019-19741; 1:500); SV40 T antigen (EMD Millipore; DP02; 1:100); Nestin (Cell Signaling, 4760S; 
1:250); Ki-67 (EMD Millipore, Ab9260; 1:500). Secondary antibodies were cross-absorbed anti-
rabbit, mouse, or chicken IgG conjugated to CF488A, CF568 or CF647 (Biotium, Hayward, CA). 
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Cultured TRP cell subpopulations sorted based on GLAST expression were seeded on 
Nunc Lab-Tek II chamber slides (Thermo Scientific) coated with poly-D lysine (Sigma-Aldrich). 
EdU (10 µM) was added to each well 12 hours prior to fixation with 4% para-formaldehyde for 10 
min. Slides were then blocked with 1% bovine serum albumin fraction V and 5% goat serum in 
PBS (Sigma-Aldrich) and incubated (30 min at 4°C) with primary or secondary antibodies listed 
above and diluted in PBS with 0.05% Triton X100. EdU was detected a Click-It EdU imaging kit. 
Slides were counterstained with DAPI and coverslipped using PermaFluor. 
 
Image analyses. For genetic lineage tracing and quantification of cells in situ, 3-5 random IHC 
images of the cortex (CTX), diencephalon (DI), brain stem (BS), and olfactory bulb (OFB) (Fig 
S3.1) were taken from each of 2-3 sagittal sections per mouse. Four random ICC images were 
taken from each of four chamber wells. Images were obtained using LSM710 and LSM 780 
confocal microscopes (Zeiss, Oberkochen, Germany) equipped with 20X objectives and ZEN 
2012 software. The percentage of DAPI+ cells expressing tdTomato or incorporating EdU was 
quantified using ImageJ and images panels arranged in Adobe Photoshop CS5 (San Jose, CA). 
The mean percent of tdTomato+ or EdU+ cells ± s.e.m. from 24-36 images per brain region (IHC) 
and 16 images (ICC) per cell type was calculated. 
For quantification of tumor growth rates, 4-5 random images of each brain region were 
taken from 2-3 sagittal sections per mouse. The mean percent of tdTomato+ or EdU+ cells ± s.e.m. 
from 24-36 images was then calculated. Hyper-cellular areas with a two-fold increase in average 
cellular density were apparent 8-16 weeks after induction. ImageJ was used to quantify the mean 
percent ± s.e.m. of cortical cells expressing tdTomato or Ki-67 from 3-5 images of hyper-cellular 
and adjacent areas of diffuse tumor per mouse. ImageJ was also used to quantify proliferating 
(EdU+), recruited (tdTomato-) glial cells that expressed the astrocyte marker BLBP, the microglial 
marker Iba1, or the oligodendrocyte progenitor marker PDGFRα. The mean percent ± s.e.m. was 
then calculated from 4-8 images per brain region. 
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Histopathological evaluation. Brains were harvested, cut sagittally, immersion fixed in 10% 
neutral buffered formalin overnight, and stored in 70% ethanol prior to paraffin embedding. 
Formalin-fixed, paraffin embedded brains were cut on a rotary microtome in serial 4-5 μm 
sections, placed on glass slides, and stained with hematoxylin and eosin (H&E) on a Leica 
Microsystems Autostainer XL (Buffalo Grove, IL). H&E stained slides were scanned on an Aperio 
ScanScope XT (Vista, CA) using a 20X objective. The resulting svs files were imported into an 
Aperio eSlideManager web database. Histopathological analysis and grading was performed by 
CRM according to WHO 2007 criteria for human gliomas (113). 
Chromogenic IHC for SV40 T antigen, GFAP, BLBP, and Nestin was carried out on a 
Bond fully-automated stainer (Leica, Norwell, MA) as described (114). Slides were deparaffinized 
in Bond dewax and hydrated in Bond wash solutions. Antigen retrieval was performed for 30 min 
at 100°C in Bond epitope retrieval solutions at pH 6.0 (GFAP, BLBP, Nestin) or 9.0 (SV40). 
Sections were incubated with primary antibodies described above for 1 hour at 23°C (SV40, 
1:200; GFAP, 1:2000; BLBP, 1:500; Nestin, 1:250). Horseradish peroxidase and 3,3’-
diaminobenzidine (DAB) chromogen detection was performed using the Bond Polymer Refine 
Detection Kit with (SV40, Nestin) or without (GFAP, BLBP) a Dako EnVision+ goat anti-mouse 
secondary antibody. Photomicrographs were taken on an Olympus BX41 microscope and DP70 
digital camera (Center Valley, PA). 
 
Statistics. Data were analyzed using student’s t-tests, one-way and two-way ANOVA with 
Tukey’s correction for multiple comparisons, and non-linear and linear regression in GraphPad 
Prism 5. All comparisons were considered significant at α=0.05. 
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RESULTS 
Adult GLAST astrocytes are a limited, regionally restricted subpopulation of GFAP 
astrocytes. We examined the regional distribution of GFAP and GLAST astrocytes in adult 
GFAP- and GLAST-CreER;tdTomato mouse brains using genetic lineage tracing and found that 
4.5-6.1% and 0.3-4.4% of cells expressed tdTomato, respectively (Fig 3.1 A). GFAP cells were 
uniformly distributed in the CTX, DI, BS, and OFB. In contrast, GLAST cells were heterogeneously 
distributed and less abundant. Targeting efficiency differed between models, as brains stained for 
the astrocyte marker brain lipid binding protein (BLBP) showed co-expression in ~60% of GFAP 
and <40% of GLAST tdTomato+ cells (Fig 3.1 BE, Fig S3.2, and Fig S3.3). Targeting of NeuN+ 
neurons (Fig 3.1 CF, Fig S3.2, and Fig S3.3), Iba1+ microglia (Fig 3.1 CF), and PDGFRα+ OPC 
(Fig 31 CF) was extremely inefficient, as <0.3% of these cells expressed tdTomato in both models. 
Thus, recombination was >97% specific for BLBP+ astrocytes in both models (Fig 3.1 DG). 
GFAP is expressed in most astrocytes throughout the brain, except cortical gray matter 
(42). In contrast, GLAST has been shown to be expressed in a subset of GFAP+ astrocytes in 
vitro (115). We have confirmed that few gray matter astrocytes express GFAP, but the vast 
majority (≥96.3%) of GLAST astrocytes co-express GFAP in the areas analyzed (Fig S3.4). We 
therefore conclude that GLAST astrocytes comprise a less abundant and more regionally 
restricted subpopulation of GFAP astrocytes in these models. 
 
Cellular origin influences tumor growth. Multiple GBM mutations have been shown to 
transform astrocytes in GEM models (14). We previously described one such model using TRP 
mutations to transform adult GFAP astrocytes and showed that these mice develop lethal GBM 
after ~4.4 months (32). However, it remained unclear whether brain region influenced tumor 
growth. All astrocyte-targeted glioma GEM models described to date have employed the GFAP 
promoter (14, 18, 32, 35). Because this promoter targets a large and widely distributed population 
of astrocytes in adult mice, it remained unclear whether astrocyte subpopulations would also be 
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susceptible to transformation. We therefore monitored regional tumor burden using lineage 
tracing in TRP;GFAP- and TRP;GLAST-CreER;tdTomato mice to examine whether astrocyte 
subpopulations respond similarly to TRP mutations. In both models, tdTomato+ tumor cells 
expressed the T121 oncogene (>92%) and the vast majority (>97%) maintained BLBP expression. 
Tumor cells from both models also co-expressed the astrocyte markers GFAP and S100β (Fig 
S3.5). TRP mutations induced proliferation (EdU incorporation) and increased tumor burden in all 
brain regions after 3-16 weeks, but the magnitude of both differed markedly between GFAP 
versus GLAST astrocytes (Fig S3.6). Hyper-cellular rims of tdTomato+ tumor cells around neurons 
(perineuronal satellitosis, PNS), a widely recognized growth pattern in human gliomas (2), also 
developed in these mice. PNS composed of tdTomato+ tumor cells co-expressing GFAP and 
BLBP increased over time in both models. However, PNS development was slower and less 
pronounced in GLAST-derived tumors (Fig S3.7). We therefore conclude that cellular origin 
influences astrocyte-derived tumor growth. 
 
Brain region may influence growth of GLAST, but not GFAP astrocyte-derived tumors. To 
directly compare the growth rate of GFAP and GLAST astrocyte-derived tumors and to examine 
the effects of brain region, we quantified the density of tdTomato+ cells in different regions over 
time in mice with (≥ 3 weeks) and without (1 week) induced TRP mutations. Tumor growth from 
GFAP astrocytes was rapid and independent of brain region (Fig 3.2 A). In contrast, GLAST 
astrocyte tumor growth was slower and significantly influenced by brain region; growth was 
relatively rapid in OFB and slow in BS (Fig 3.2 B-D). Moreover, GLAST (Fig 3.2 F), but not GFAP 
astrocyte-derived (Fig 3.2 E) tumors showed significant regional differences in proliferation rates 
(Fig 3.2 GH). These results suggest that astrocyte subpopulations respond differently to identical 
tumor initiating mutations and that regional microenvironment may influence tumor growth. 
NSC in the SVZ express both GFAP (56%) and GLAST (6%) and have the ability to 
differentiate into neuroblasts that migrate through the rostral migratory stream to become OFB 
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interneurons (Fig S3.6). Thus, the migratory potential of transformed NSC progeny could 
theoretically complicate our regional astrocyte proliferation analyses. To explore whether 
transformed SVZ NSC contributed to tumor burden in the regions analyzed (Fig S3.1), we focally 
induced recombination with Ad-GFAPCre in either the SVZ or OFB of TRP;tdTomato mice. After 
four weeks, OFB injections produced focal tdTomato+;T121+ tumors in the OFB (Fig 3.3 A) that 
failed to migrate to other brain regions (Fig 3.3 B). Likewise, viral injections in the SVZ produced 
tumors in the periventricular parenchyma and striatum (Fig 3.3 C) that did not migrate to the 
analyzed brain regions (Fig 3.3 D). These results demonstrate that TRP mutations transform NSC 
to produce tumors, but that NSC-derived tumor cells fail to migrate to other brain regions in this 
model system. 
 
Cellular origin influences malignant progression. While regional microenvironment appeared 
to influence GLAST-derived tumor growth (Fig 3.2), it remained unclear whether intra-regional 
differences would also be evident. We therefore monitored intra-regional heterogeneity by 
imaging the entire cortex, the largest anatomical region of the brain. Tumor growth from both 
GFAP and GLAST (Fig S3.8) astrocytes was uniform over their initial growth phases (less than 3 
and 8 weeks, respectively). However, significant intra-regional heterogeneity appeared later in 
the course of tumor progression and multiple hyper-cellular tumor foci developed in both models 
(Fig S3.8 CG). 
We have previously found that high grade astrocytomas in the GFAP-driven TRP model 
acquire stochastic mutations during malignant progression, suggesting that clonal evolution may 
drive their heterogeneous proliferative response (32). To further explore this, we stained tumors 
from GFAP and GLAST mice at 8 and 16 weeks after induction for Ki-67 to mark proliferating cells 
(Fig 3.4 AB). These analyses identified hyper-cellular tumor foci with 5-10 fold higher proliferation 
compared to adjacent areas of diffuse tumor (Fig 3.4 CD). Due to this intra-cortical heterogeneity, 
we quantified diffuse tumor, hyper-cellular foci, and total tumor burden separately at later time 
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points. These analyses showed that initial growth of GFAP tumors was significantly higher than 
GLAST tumors and that hyper-cellular tumor foci emerged earlier (Fig 3.4 E). These results 
suggest that GFAP and GLAST astrocytes have inherently distinct proliferative responses to 
identical TRP mutations. However, tumors grew at similar rates after hyper-cellular foci 
developed, suggesting that the proliferative response to mutations acquired during malignant 
progression was similar in both models. 
GLAST mice survived significantly longer than GFAP mice when aged to morbidity, but 
their survival was limited by co-morbid development of subcutaneous masses requiring 
euthanasia (Fig 3.4 F). Histological analyses showed that GFAP mice died from large anaplastic 
astrocytomas (WHO grade III) or GBM (WHO grade IV) (32), while GLAST mice died with smaller 
diffuse astrocytomas (WHO grade II). Chromogenic IHC confirmed expression of T121 and the 
astrocytic markers GFAP and BLBP (Fig S3.5 and 3.6) and also showed that tumors gained 
expression of the NSC marker nestin (Fig S3.9). 
To examine whether TRP-mutated GLAST astrocytes have intrinsically distinct growth 
characteristics, we purified cultured, GFAP+ TRP astrocytes into subpopulations by GLAST flow 
sorting (Fig 3.4 I). Immunofluorescence analyses confirmed differential GLAST expression (Fig 
3.4 GH). GLAST+ TRP astrocytes harbored a lower S-phase fraction (Fig 3.4 J) and grew slower 
(Fig 3.4 K) than their GLAST- counterparts. These results suggest that the slower growth of 
GLAST-derived tumors in vivo is due to intrinsically distinct proliferative responses to identical 
TRP mutations. 
 
Recruited cells are abundant in GLAST astrocyte-derived tumors. Nearly all transformed 
GFAP (Fig S3.5 A) and GLAST astrocytes (Fig S3.5 E and Fig 3.5 A) co-expressed both tdTomato 
and T121 and a subpopulation proliferated (Fig S3.6 and Fig 3.2). While a subpopulation (~20%) 
of EdU+ cells lacked both tdTomato and T121 in the GFAP model (S3.10AEF), a substantial number 
of these cells were identified in the GLAST model (Fig 3.5 B), suggesting that these cells were 
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recruited. To further explore the identity of proliferating cells, we stained GLAST and GFAP 
tumors with BLBP, PDGFRα, and Iba1 to identify astrocytes, OPC, and microglia within the tumor 
microenvironment (Fig 3.5 C-I and Fig S3.10 B-F). Recruited glia constituted 64-80% of 
proliferating cells in 3-16 week GLAST tumors (Fig 3.5 H), but only 19-21% of proliferating cells 
in 3-8 week GFAP tumors (Fig S3.10 E). Recruited astrocytes increased over time, but microglia 
and OPC decreased in GLAST tumors (Fig 3.5 I). In contrast, proliferating, recruited astrocytes 
remained constant and there were minimal proliferating microglia and OPC in GFAP tumors (Fig 
S3.10 F). Proliferating glial cells differed markedly in GFAP- versus GLAST-derived tumors, both 
for tdTomato+ tumor cells and tdTomato- recruited astrocytes and OPC (Fig S3.11). These results 
suggest that transformation of GLAST astrocytes induces a heterogeneous cellular response and 
that the composition of proliferating, recruited glia in the tumor microenvironment dynamically 
changes over time. 
 
TRP mutations induce expression of the NSC marker nestin in tdTomato+ tumor cells. We 
have shown that TRP mutations induce a primitive, proneural GBM-like gene expression state in 
cultured murine astrocytes (75). We subsequently found that cultured TRP astrocytes acquire the 
functional properties of NSC in vitro and cancer stem cells in vivo (116). These results suggest 
that TRP mutations induce astrocyte de-differentiation into a more primitive cell type. To explore 
whether these mutations induce NSC marker expression in tumors induced in the intact 
mammalian brain in situ, we fate mapped tdTomato+ tumor cells in GFAP and GLAST mice. In 
the absence of oncogenic mutations, both GFAP (Fig 3.6 A) and GLAST (Fig 3.6 F) astrocytes 
lack the intermediate filament protein nestin, an established marker of NSC. In contrast, TRP 
mutations induced nestin expression in tumors derived from GFAP (Fig 3.6 B), and to a lesser 
extent, GLAST astrocytes (Fig 3.6 G) throughout the brain. These cells co-expressed tdTomato 
and BLBP (Fig 3.6 C-E). Moreover, these cells were more frequent and rapidly dividing in GFAP 
versus GLAST tumors (Fig 3.6 H-K) These results support the notion that TRP mutations induce 
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astrocyte de-differentiation into more primitive cell types in situ. Also, these results suggest that 
slower growth of tumors derived from GLAST+ astrocytes could be due to less efficient de-
differentiation. 
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DISCUSSION 
Targeting astrocyte subpopulations based on expression of the established markers 
GFAP and GLAST yielded biologically distinct growth patterns when these cells were transformed 
with identical oncogenic mutations. Transformed GFAP astrocytes produced anaplastic 
astrocytomas (WHO grade III) that lacked a significant proliferating, recruited glial component, 
grew uniformly in all brain regions, and rapidly underwent malignant progression. In contrast, 
transformed GLAST astrocytes formed slowly growing low-grade astrocytomas whose growth 
differed by brain region. The more indolent growth of TRP-transformed GLAST+ astrocytes was 
confirmed in vitro. GLAST derived tumors showed a significant proliferating, recruited glial 
component and underwent more gradual malignant progression. These results suggest that 
astrocyte subpopulations uniquely respond to the pro-proliferative signals of oncogenic TRP 
mutations. Further work is required to determine whether these distinct proliferative responses 
occur with other common glioma mutations. A model summarizing the effects of astrocyte 
heterogeneity on glioma pathogenesis and the microenvironmental differences between these 
models is shown in Fig 3.7. 
One possible explanation for the faster growth observed in GFAP astrocyte-derived 
tumors was the greater initial frequency of these cells in the adult brain. GFAP astrocytes 
constituted approximately 4-6% of cells in multiple brain regions (Fig 3.1 A). In contrast, GLAST 
astrocytes represented a smaller and more regionally restricted subpopulation (0.3-4%, Fig 3.1 
A). Of the latter, only those that co-expressed GFAP could be transformed, because T121 
transgene expression from the GFAP promoter is required for astrocyte transformation in these 
mice (32). However, the difference in initial target cell density is unlikely to be the primary factor 
contributing to differential tumor growth rates. For example, GLAST and GFAP targeted similar 
numbers of OFB cells (Fig 3.1 A). However, growth and proliferation rates of OFB tumors differed 
markedly in GFAP versus GLAST mice (Fig 3.2). Moreover, growth and proliferation of the 
GLAST+ subpopulation of TRP-transformed, GFAP+ astrocytes (Fig 3.4 I) was significantly slower 
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than their GLAST- counterparts in culture (Fig 3.4 JK). This suggests that intrinsic differences in 
the cell of origin likely influenced tumor growth. One such factor could be that their cell-
autonomous mitogenic signaling networks could impart differential susceptibility to particular 
mutations. This concept is supported by previous studies showing that regional astrocyte 
subpopulations differentially express tumor suppressor genes such as Nf1 and have distinct 
proliferative responses to its deletion (51). A second intrinsic factor could be the ability to de-
differentiate into a more primitive functional state. This concept is supported by the quantitative 
difference in nestin expression between the two models here (Fig 3.6). Future work will be 
required to further explore this possibility. 
We confirmed that SVZ NSC express both GFAP and GLAST (Fig S3.6). The migratory 
potential of their TRP-mutated progeny could theoretically complicate our regional analyses. 
However, genetic lineage tracing confirmed that the GFAP and GLAST drivers used here target 
BLBP+ astrocytes with >97% specificity in the brain regions analyzed (Fig 3.1), but target SVZ 
NSC less efficiently (56% and 6%, respectively). Moreover, we found that focal transformation of 
the more abundant GFAP+ population of NSC produced tumors only near the SVZ and striatum 
and that these tumor cells did not migrate outside these regions (Fig 3.3). In contrast, focal 
transformation of OFB astrocytes only produced OFB tumors. These results suggest that local 
astrocytes, not other transformed glia or NSC, are the source of tumor in the brain regions 
analyzed. 
GFAP astrocyte-derived tumors underwent rapid growth and malignant progression, while 
GLAST-derived tumors showed more indolent growth and delayed progression (Fig 3.4 E). These 
growth patterns mirror that of primary and secondary GBM in humans. Primary GBM have a 
clinically silent, pre-GBM growth phase and are thus thought to arise de novo. In contrast, 
secondary GBM arise from a documented low grade precursor and feature a more protracted 
clinical course (117). Distinct genetic and epigenetic differences (EGFR and PTEN mutations in 
the former; IDH1/2 and TP53 mutations and the CpG island methylation phenotype (G-CIMP) in 
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the latter) has strengthened the biological difference between these two clinical entities (6, 10, 
13, 117). Though their genetic differences are clearly established, it remains unclear how cellular 
origin might affect their growth patterns. We have argued that the GFAP model used here closely 
resembles primary GBM due to its rapid tumor growth and lack of IDH mutations (32). We have 
shown that these tumors stochastically acquire secondary mutations, such as homozygous Pten 
deletions, that likely potentiate their progression (32). In contrast, the GLAST model produces 
tumors with a protracted proliferative phase and delayed malignant progression, a growth pattern 
more similar to secondary GBM. We are currently exploring whether these tumors acquire 
alterations common in secondary GBM and whether these could be responsible for driving tumor 
expansion and malignant progression in this model system (Fig 3.4 and Fig 3.7). 
Tumor heterogeneity may be influenced by the local glial microenvironment, which is 
composed of astrocytes, oligodendrocytes, and microglia. Glial cell populations show 
transcriptome variability based on brain region, which may reflect their distinct ontogenies (57). It 
has long been known that the cellular composition of gliomas consists of a complex mixture of 
transformed cells, as well as recruited glia. In fact, recruited cells may constitute a majority within 
a given tumor (58). Recruited glia have also been shown to promote tumor invasion and 
neovascularization, disrupt the blood brain barrier, and create a symbiotic microenvironment that 
promotes tumor growth (37, 59, 61-63). Therefore, it logically follows that regional heterogeneity 
in the brain microenvironment may impact tumor pathogenesis. 
In contrast to the GFAP model, 64-80% of proliferating cells in the GLAST model were 
recruited glia (Fig 3.5, Fig S3.10, and Fig S3.11). Therefore, this model may provide a unique 
opportunity to examine the contributions of recruited glia to tumor growth in future studies. 
Extensive recruited glia proliferation suggests paracrine communication between these and 
tdTomato+ tumor cells within the tumor microenvironment, but the signaling mechanisms that 
mediate these effects remain to be defined. Recruited cells have been previously found in mouse 
models of platelet derived growth factor (PDGF)-driven tumors derived from PDGFRα+ OPC (58, 
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86). We have extended these findings by identifying recruited glia in tumors of astrocyte origin 
(Fig 3.5), suggesting that glial recruitment is a stereotypical response to cellular transformation in 
the brain. While the cellular identity and time course of recruited cells were not examined in the 
PDGF model, we found that astrocytes, OPC, and microglia are all present within the GLAST 
tumor microenvironment and their abundance varies over time. We are currently exploring 
whether these cells become transformed by stochastic oncogenic mutations and the mechanisms 
through which they contribute to astrocyte-derived tumor growth. 
Cells with stem-like properties have been identified in human GBM and may be 
responsible for treatment resistance and tumor recurrence (118). Identification of these cells 
currently relies on immunostaining with stem cell markers, such as CD133 and nestin. However, 
our data (Fig 3.6) and the work of other groups has shown that the differentiation state of tumor 
cells is dynamic. Thus, in contrast to the normal unidirectional lineage hierarchy in the normal 
brain, cancer cell lineage relationships are plastic. We have previously shown that transformation 
of cultured astrocytes by TRP mutations induces a primitive transcriptome state in vitro (75). We 
have also found that TRP astrocytes acquire the functional properties of NSC in vitro and cancer 
stem cells in vivo (116). Here, we show that TRP mutations induce the expression of the primitive 
maker nestin in situ (Fig 3.6). Together, these results suggest that TRP mutations induce 
astrocyte de-differentiation. Similar results have been found in astrocytes transformed by Cdkn2a, 
Egfr, Nf1, and Trp53 mutations, suggesting that astrocyte de-differentiation may be a stereotypical 
response to oncogenic mutations (17, 35). The opposite has been found in embryonic NSC with 
Nf1 and Trp53 deletion mutations, where transformed OPC drove tumor growth, suggesting that 
partial differentiation was required for NSC transformation (38). Thus, either de-differentiation or 
partial terminal differentiation may be required for oncogenic transformation in certain cellular and 
mutational contexts. As such, the mutated cell may differ from the transformed cell type that 
actually drives tumor growth. These dynamic changes in differentiation state of cancer cells 
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complicate efforts to identify tumor cells of origin by comparing their expression of cellular markers 
to purified brain cells, as we have described for human gliomas (5, 10).  
In contrast, the genetic lineage tracing and fate mapping techniques used here permit 
unambiguous identification of the tumor cell of origin and its impact on disease pathogenesis. 
Using these techniques, we found that GFAP and GLAST astrocytes can serve as a cell of origin 
for GBM, though the kinetics of growth and progression differed between these two 
subpopulations. Previously, we used lineage tracing to longitudinally monitor the growth kinetics 
of NG2+ OPC transformed by Nf1 and Trp53 deletions (22). In this mutational context, OPC 
proliferation peaks after initial transformation, then enters a sustained period of quiescence (22). 
In contrast, TRP mutations induced sustained proliferation and eventual clonal tumor outgrowth 
in both GFAP and GLAST astrocyte models. These divergent growth characteristics suggest that 
cellular origin has a significant impact on tumor growth and that astrocyte subpopulations may 
have inherently different responses to particular oncogenic mutations. Indeed, cellular origin has 
recently been shown to be a key contributor to tumor heterogeneity in Pik3ca-driven mammary 
tumors (119). To further probe the influence of cellular origin on glioma pathogenesis, we are 
currently investigating whether transformation of astrocytes and OPC with identical mutations 
induces similarly divergent patterns of tumor growth. 
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Figure 3.1. GLAST astrocytes are less abundant and more regionally restricted than GFAP 
astrocytes. Genetic lineage tracing in GFAP-CreER;tdTomato and GLAST-CreER;tdTomato 
mice sacrificed 1 week after induction shows significant brain region specific differences between 
drivers in CTX, DI, and BS (*, P<0.02), but not the OFB (P=0.7) (A). No brain region specific 
differences were evident in astrocyte targeting efficiency in GFAP-CreER;tdTomato mice (ANOVA 
P=0.8) (B), but cortical astrocyte targeting was more efficient (58.5 ± 1.6%) than NeuN+ neurons 
(0.2 ± 0.1%), IBA1+ microglia (0.05 ± 0.3%), and PDGFRα+ oligodendrocyte progenitor cells (0.02 
± 0.01%) (ANOVA P<0.0001) (C).  Moreover, targeting was specific to astrocytes, as 97.2% of 
the tdTomato+ cell population co-expressed BLBP (D). In contrast, brain region differences were 
evident in astrocyte targeting efficiency in GLAST-CreER;tdTomato mice (ANOVA P=0.02; *, 
Tukey’s P<0.05) (E) and cortical astrocyte targeting was more efficient (22.5 ± 3.3%) than NeuN+ 
neurons (0.09 ± 0.01%), IBA1+ microglia (0.03 ± 0.01%), and PDGFRα+ oligodendrocyte 
progenitor cells (0.02 ± 0.01%) (ANOVA P=0.0001) (F). Like GFAP, GLAST targeting was specific 
to astrocytes, as 97.2% of the tdTomato+ cell population co-expressed BLBP (G).  
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Figure 3.2: TRP-induced astrocytoma growth is slower and influenced by brain region in 
GLAST versus GFAP astrocytes. Quantification of tdTomato (A, B) and EdU (E, F) positive 
cells from GFAP-CreER;tdTomato (A, E) and GLAST-CreER;tdTomato (B, F) mice sacrificed 1 
week after induction show that tumors grow and proliferate more slowly upon induction of TRP 
mutations over 3-16 weeks in GLAST versus GFAP astrocytes. Tumors derived from GLAST 
(ANOVA P=0.01), but not GFAP (ANOVA P=0.6) astrocytes showed regional differences in 
tdTomato growth rates (C). Data from C are re-graphed in D to highlight the significantly increased 
tdTomato growth rate of GFAP versus GLAST derived tumors. Regional differences in 
proliferation rates (EdU incorporation) were significant in tumors derived from both GLAST 
(ANOVA P<0.0001) and GFAP astrocytes (ANOVA P=0.04) (G). Data from (G) are re-graphed in 
(H) to show the proliferation rate of GFAP derived tumors is significantly more than GLAST 
derived tumors. Significant regional differences in proliferation rates between drivers existed 
(P<0.03) (H).  Statistically significant pairwise comparisons (P<0.05) between brain regions are 
indicated by *.  
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Figure 3.3. TRP-transformed cells do not migrate to different brain regions. Stereotactic 
injection of Ad-GFAPCre into the olfactory bulb of TRP; tdTomato mice induced focal 
tdTomato;T121 co-expressing tumors specifically in the olfactory bulb (A), not in other brain regions 
(B). Similarly, focal induction in the SVZ induced tumors only in the SVZ (C), not elsewhere in the 
brain (D). Scale bar 10 µm. 
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Figure 3.4. TRP astrocytomas progress more slowly in GLAST versus GFAP astrocytes. 
Frequent hyper-cellular (HC, blue boxes) tumor foci (tdTomato, red) were evident in TRP;GFAP-
CreER;tdTomato mice sacrificed 8 weeks after induction (A). In contrast, occasional hyper-
cellular foci were only evident 16 weeks after induction in TRP;GLAST-CreER;tdTomato mice (B). 
HC areas were 5.2-fold more proliferative (student’s t P=0.0001) than adjacent areas of diffuse 
tumor (red boxes) and 57.7% of these cells (Ki67, green) were proliferating in GFAP mice (C). A 
similar increase in proliferation (11.2 fold, students’ t P<0.0001) and Ki67+ cell density (46.4%) 
was evident in GLAST mice (D). Despite induction by the same oncogenic TRP mutations, diffuse 
and total tumor growth was slower in GLAST than GFAP astrocytes (P<0.0001). Growth rates 
were similar after HC foci developed (P=0.2), but these appeared later in the course of GLAST 
tumor progression (E). GLAST mice survived significantly longer than GFAP mice (log-rank, 
p=0.02). The GLAST+ (G) and GLAST- (H) subpopulations of cultured GFAP+ TRP cells were 
purified by flow sorting (I) and differential GLAST expression was confirmed by 
immunocytochemical staining (GH). EdU-pulsed S-phase fraction of GLAST+ cells was 
significantly less than their GLAST- counterparts (J, *P=0.0002) and their growth rate was 
significantly slower (K, doubling time 1.2 versus 0.9 days, P<0.0001). Scale bars 100 µm (A-B), 
50 µm (G-H).  
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Figure 3.5. Recruited astrocytes, OPC, and microglia proliferate in GLAST+ astrocytomas. 
TRP mutations induced proliferation (incorporation of EdU) of transformed, tdTomato;T121+ 
astrocytes in TRP;GLAST-CreER;tdTomato mice (A). However, EdU+ cells that lacked both 
tdTomato and T121 were also evident (B). Immunostaining for BLBP (C), GFAP (D), S100β (E), 
PDGFRα (F), and IBA1 (G) showed that recruited (tdTomato;T121-) astrocytes (AC), as well as 
oligodendrocyte progenitor cells (OPC) and microglia (MG), proliferated in these tumors. Images 
in panels A-G were taken from the cortex of a mouse 16 weeks after transformation. Recruited 
astrocytes constituted the largest fraction of proliferating EdU+ cells (52-62%) 3 to 16 weeks after 
transformation, while tdTomato+ tumor cells (20-36%), recruited OPC (3-18%), and recruited MG 
(0-6%) were less abundant (H). Moreover, the cellular composition of recruited, proliferating glial 
cells was dynamic:  recruited astrocytes increased while other glial populations decreased over 
time (I). Scale bars 10 µm. 
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Figure 3.6: TRP mutations induce expression of NSC markers in transformed tdTomato+ 
tumor cells. In contrast to GLAST-CreER;tdTomato (A) and GFAP-CreER;tdTomato (F) mice 
sacrificed 1 week after induction, TRP mutations induced expression of the intermediate filament 
protein nestin in tdTomato+ cells in both TRP;GLAST-CreER;tdTomato (B) and TRP;GFAP-
CreER;tdTomato (G) mice sacrificed at 3 weeks. Nestin-expressing cells were tdTomato;BLBP+ 
astrocytes in both models (C, H). However, 82.2% ± 1.3% of proliferating (EdU+) cells in 
TRP;GFAP-CreER;tdTomato mice (I) co-expressed tdTomato and nestin , but these were 
infrequent (9.4% ± 3.6%, DE) in TRP;GLAST-CreER;tdTomato mice (J, P<0.0001). tdTomato+ 
cells expressed nestin less frequently in GLAST than GFAP tumors over time (K). Scale bars 50 
µm (A-B, F-G), 10 µm (C-E, H-I). 
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Figure 3.7. Cellular origin influences glioma pathogenesis. Targeting the same oncogenic 
TRP mutations to GLAST and GFAP astrocytes (AC) produced tumors with divergent growth 
characteristics. GFAP tumors grew rapidly and quickly progressed to high-grade tumors. In 
contrast, GLAST tumors grew more indolently, progressed later, and contained proliferating, 
recruited glial cells, suggesting that their local microenvironment contributes to their growth. 
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Fig S3.1: Analyzed brain regions. Brain regions which showed the most tumor included the 
CTX (red), DI (dark blue), BS (yellow), and OFB (purple) were analyzed. Areas which produced 
less tumor, including the corpus callosum (CC, light blue) and striatum (STR, yellow), were 
excluded. 
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Figure S3.2. GFAP-CreER targets astrocytes and not neurons in multiple brain regions. 
Genetic lineage tracing in GFAP-CreER;tdTomato mice sacrificed 1 week after induction (Fig. 
3.1) shows recombination-mediated expression of tdTomato in cortical (CTX), diencephalic (DI), 
brainstem (BS), and olfactory bulb (OFB) astrocytes as defined by their stellate morphology and 
co-expression of brain lipid binding protein (BLBP, A). Minimal tdTomato+ neurons (0.2 ± 0.1% of 
DAPI+ cells), defined by their cellular morphology and co-expression of NeuN, were evident (B). 
Scale bar 10 µm. 
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Figure S3.3. GLAST-CreER targets astrocytes and not neurons in multiple brain regions. 
Genetic lineage tracing in GLAST-CreER;tdTomato mice sacrificed 1 week after induction (Fig. 
3.1) shows recombination-mediated expression of tdTomato in CTX, DI, BS, and OFB astrocytes 
as defined by their stellate morphology and co-expression of brain lipid binding protein (BLBP, 
A). Minimal tdTomato+ neurons (0.2 ± 0.1% of DAPI+ cells), defined by their cellular morphology 
and co-expression of NeuN, were evident (B). Scale bar 10 µm. 
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Figure S3.4. GLAST-CreER targets GFAP+ astrocytes in multiple brain regions. Genetic 
lineage tracing in GLAST-CreER;tdTomato mice sacrificed 1 week after induction shows 
recombination-mediated expression of tdTomato in >96% of white matter (WM), DI, BS, and OFB 
astrocytes as defined by their stellate morphology and co-expression of glial fibrillary acid protein 
(GFAP). Few tdTomato+ astrocytes in the grey matter (GM) co-expressed GFAP. The percentage 
of tdTomato;GFAP+ cells in each region is indicated. Scale bar 10 µm. 
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Figure S3.5. GFAP and GLAST-driven TRP astrocytoma cells retain expression of 
astrocytic markers. Three weeks after induction of TRP;GFAP-CreER;tdTomato mice, cortical 
GFAP+ astrocytes transformed by TRP mutations co-express tdTomato and T121 (98.3 ± 1.3%, A) 
and retain expression of the astrocytic markers BLBP (99.3 ± 0.3%) (B), GFAP (C), and S100β 
(D). Likewise, transformed cortical GLAST+ astrocytes in TRP;GLAST-CreER;tdTomato mice co-
express tdTomato and T121 (91.8 ± 2.9%, E) and retain their expression of BLBP (96.8 ± 2.9%) 
(F), GFAP (G), and S100β (H). Scale bar 10 µm. 
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Figure S3.6. TRP mutations induce proliferation of GFAP and GLAST astrocytes in multiple 
brain regions. GFAP cells (56 ± 1.7%) in the subventricular zone (SVZ) express tdTomato, 
endogenously proliferate, and incorporate EdU in GFAP-CreER;tdTomato mice sacrificed 1 week 
after induction. In contrast, GFAP astrocytes in the CTX, DI, BS, OFB express tdTomato, but do 
not proliferate, and fail to incorporate EdU in the absence of oncogenic mutations. However, TRP 
mutations induce progressive increases in GFAP astrocyte proliferation throughout the brains of 
TRP;GFAP-CreER;tdTomato mice sacrificed 3 and 8 weeks after induction (A). GLAST cells (5.8 
± 0.6%) in the SVZ express tdTomato, endogenously proliferate, and incorporate EdU in GLAST-
CreER;tdTomato mice sacrificed 1 week after induction.  In contrast, GLAST astrocytes in the 
CTX, DI, BS, and OFB express tdTomato, but do not proliferate, and fail to incorporate EdU in 
the absence of oncogenic mutations. However, TRP mutations induce progressive increases in 
GLAST astrocyte proliferation (incorporation of EdU) throughout the brains of TRP;GLAST-
CreER;tdTomato mice sacrificed 3, 8, and 16 weeks after induction (B). Driver, TRP status, and 
sacrifice time point after induction are indicated. Scale bar 10 µm. 
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Figure S3.7. Astrocytic perineuronal satellites increase over time in GFAP and GLAST-
driven TRP astrocytomas. Perineuronal satellites composed of tdTomato+ (red) astrocytoma 
cells surrounding NeuN+ (green) cortical neurons increased over time after induction of TRP 
mutations in GFAP-CreER;tdTomato mice (A). In contrast, perineuronal satellite development in 
GLAST-CreER;tdTomato mice was delayed and less frequent (B, C). TRP status and sacrifice 
time point after induction are indicated. Tumors induced in both TRP;GFAP-CreER;tdTomato (D, 
E) and TRP;GLAST-CreER;tdTomato (F, G) mice display perineuronal satellites that co-stain with 
the astrocyte markers GFAP (D, F) and BLBP (E, G). Scale bars 10 µm. 
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Fig. S3.8. Cortical GFAP and GLAST-driven TRP astrocytoma burden increases over time. 
Compared to GFAP-CreER;tdTomato mice sacrificed 1 week after induction (A), a time-
dependent increase in astrocytoma burden (tdTomato, red) was evident throughout the cortex of 
TRP;GFAP-CreER;tdTomato mice sacrificed after 3 (B) and 8 (C) weeks. Compared to GLAST-
CreER;tdTomato mice sacrificed 1 week after induction (D), a time-dependent increase in cortical 
tumor burden was evident in TRP;GLAST-CreER;tdTomato sacrificed after 3 (E), 8 (F), and 16 
(G) weeks. Tumors became more heterogeneously distributed after 8 weeks (C) in GFAP and 16 
weeks (G) in GLAST mice due to emergence of hyper-cellular foci (Fig. 3.4). Nuclei were 
counterstained with DAPI (blue). Orientation: C, caudal; D, dorsal; R, rostral; V, ventral. Scale 
bars 1 mm. 
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Figure S3.9. GFAP and GLAST-driven TRP astrocytoma cells retain expression of 
astrocytic markers and express the stem cell marker nestin. Anaplastic astrocytoma, WHO 
grade III, and diffuse astrocytoma, WHO grade II, tumors arose in the olfactory bulbs (OFB) (A-
E) three months after induction of TRP mutations in TRP;GFAP-CreER;tdTomato and 
TRP;GLAST-CreER;tdTomato mice, respectively (A). Black arrowheads indicate mitoses in the 
former. Diffuse astrocytoma burden was lower in the cortex (CTX) of both models (F-J) at the 
same time point (F). In contrast to wild-type mouse OFB and CTX, tumor cells expressed T121 
(B,G) retained expression of the astrocyte markers GFAP (C,H) and BLBP (D,I), and gained 
expression of stem cell markers such as nestin (E,J), particularly in GFAP mice. Scale bars 20 
µm. 
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Figure S3.10. Astrocytes, but not other glia, proliferate in GFAP+ astrocytomas. TRP 
mutations induced proliferation (incorporation of EdU) of transformed, tdTomato;T121+ astrocytes 
in TRP;GFAP-CreER;tdTomato mice (A, arrowheads). However, EdU+ cells that lacked both 
tdTomato and T121 were also evident (A, arrows). Immunostaining for BLBP (B), PDGFRα (C), 
and IBA1 (D) showed that recruited (tdTomato;T121-) astrocytes (AC), as well as oligodendrocyte 
progenitor cells (OPC) and microglia (MG), proliferated in these tumors. Images in panels A-D 
were taken from the cortex of a mouse 8 weeks after transformation. Transformed astrocytes 
constituted the largest fraction of proliferating EdU+ cells (79-81%) 3 to 8 weeks after 
transformation, while untransformed astrocytes (18-20%), recruited OPC (0-0.7%), and recruited 
MG (0.6-0.8%) were less abundant (E). Moreover, the cellular composition of recruited, 
proliferating glial cells was dynamic, as recruited astrocytes increased while other glial 
populations decreased over time (F). Scale bars 10 µm. 
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Fig S3.11. The microenvironment of GLAST- and GFAP-derived tumors harbor distinct 
proliferating, recruited glial cell populations. TRP mutations induced significantly more 
proliferation (EdU+) in GFAP than GLAST-derived tumor cells (P≤0.007; A). In contrast, GLAST-
derived tumors harbored more proliferating, recruited astrocytes (P≤0.002; B), OPC (P≤0.02; C), 
and microglia (P≤0.3; D). 
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Chapter IV: Sox2 expression in adult astrocytes is involved in cell cycle reentry 
 
Introduction 
 
Astrocytes are the most abundant cell glial cell in the brain and are critical mediators of 
brain repair following injury. Other astrocyte functions include maintenance of synaptic plasticity, 
extracellular ion balance, and the blood brain barrier (42). Astrocytes exhibit molecular and 
functional heterogeneity in different brain regions, where they are exposed to varied 
microenvironmental cues, express differing amounts of tumor suppressor genes (51, 120) and 
respond differently to traumatic brain injury (121). Moreover, astrocytes may be a potential cell of 
origin in gliomas, the most common primary malignant brain tumors (122). Despite being 
biologically and clinically heterogeneous, glioblastoma (GBM), the most common and biologically 
aggressive glioma, is diagnosed and treated as a single disease. Defining the brain cells where 
tumorigenesis is initiated would facilitate molecular classification of glioma subtypes and lead to 
mechanism-based strategies to manage these fatal diseases. 
Tumor cells with neural stem cell (NSC)-like capacity for unlimited self-renewal and multi-
lineage differentiation, termed glioma stem cells (GSC), have been identified in human GBM 
(123). GSC are thought to express proteins found in adult NSC such as Sox2. In the normal adult 
brain, Sox2 expression was thought to be restricted to NSC due to its role in neurogenesis. This 
led to the concept that Sox2 was a characteristic marker of NSC (124-131). However, Sox2 has 
been detected in rat astrocytes (132) and in Bergmann glia cells of the cerebellum in the adult 
mouse brain (133) using immunohistochemistry. Moreover, mRNA expression profiling of purified 
astrocytes from the mouse cerebral cortex has suggested that Sox2 may be expressed in 
astrocytes during early development (134-136). However, expression of Sox2 was only explored 
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in specific brain regions or during the perinatal period when Sox2 expression is significantly more 
widespread than in the adult brain (137). Therefore, we used a combination of 
immunohistochemistry and reporter mice to show that the majority of differentiated astrocytes in 
the adult brain express Sox2. The presence of transcription factors such as Sox2 in astrocytes in 
the adult brain, suggests that astrocytes may be primed for dedifferentiation and cell cycle reentry 
in response to brain pathology, thus making them a strong candidate cell of origin in gliomas. 
Stem cell transcription factors including Sox2 have previously been shown to induce 
dedifferentiation of a variety of terminally differentiated cell types. For example, a four transcription 
factor cocktail including Sox2, Oct4, c-Myc, and Klf-4 has been shown to induce dedifferentiation 
of fibroblasts into induced pluripotent stem cells (iPS) (71). Sox2 is likely the most important of 
these transcription factor. Removal of Sox2 from the cocktail resulted in reduced efficiency of iPS 
induction. In contrast, removal of c-Myc did not completely ablate iPS induction, suggesting that 
that Sox2 is more critical than c-Myc (72). Additional evidence of the central role of Sox2 reversion 
to a stem-like phenotype is that generation of iPS from fibroblasts is achievable with the use of 
Oct4/Sox2/Nanog/Lin28. These results suggest that c-Myc and Klf4 are alternative supporting 
factors, while Sox2 and Oct4 hold a central importance in the generation of iPS (73). Moreover, 
Sox2 is specifically involved in the induction of NSC from fibroblasts (74). This evidence indicates 
that Sox2 is critical in the induction of stemness, especially in the brain. 
Terminally differentiated astrocytes do not replicate in the normal adult brain. However, 
under pathological conditions, astrocytes adopt a more primitive functional state and 
symmetrically divide in response to extrinsic stimuli such as trauma, a process termed reactive 
astrocytosis (138). Conditional, inducible GEMM are ideally suited for experimentally addressing 
the role Sox2 plays in the proliferative response of astrocytes in vivo. To test whether Sox2 is 
involved in the proliferative response to extrinsic stimuli, we conditionally ablated Sox2 specifically 
in astrocytes and subsequently wounded the murine brain. We found that Sox2 ablation interferes 
with cell proliferation around the healing wound. Astrocyte reentry into the cell cycle may also 
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occur in a cell autonomous fashion in response to intrinsic stimuli such as mutagenesis. We have 
functionally inactivated the G1/S cell cycle checkpoint with truncated SV40 large T antigen 
(abbreviated, T) and activate RTK (KrasG12D and PTENDEL abbreviated [R] and [P], respectively) 
mutations to define the genetic requirements of glioma pathogenesis in murine astrocytes (75) 
and conditional inducible genetically engineered mouse models (GEMM) (32). To test whether 
Sox2 is involved in the proliferative response of astrocytes to intrinsic stimuli, we used 
immortalized T(RP) murine astrocytes and TRP GEMM where Sox2 is expressed or ablated. We 
found that stable knockdown of Sox2 does influence the proliferation of T(RP) astrocytes in vitro 
in a genotype dependent manner, however genetic ablation of Sox2 does not influence tumor 
initiation in vivo. In combination, these results suggest that Sox2 expression in adult astrocytes 
influences their ability to reenter the cell cycle in response to certain pathological stimuli.  
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Results 
Sox2 is expressed in adult astrocytes throughout the brain 
Overview images of adult Sox2-GFP mice revealed GFP+ signal in the SVZ, however 
GFP+ cells were clearly present outside of the SVZ (Fig. S4.1). Homogenously distributed GFP+ 
cells constituted between 6-14% of cells in the cortex (CTX), olfactory bulb (OFB), diencephalon 
(DI), brainstem (BS), and cerebellum (CB) (Fig. 4.1). We used Sox2 antibodies to verify that that 
GFP+ cells express Sox2 and found Sox2+/GFP+ cells in the SVZ, CTX, OFB (Fig. S4.2a-c), and 
rest of the brain (data not shown), confirming that Sox2+ cells exist outside of neurogenic regions 
in the adult brain. 
Next, we sought to identify GFP+ cells in non-neurogenic regions. Because GFAP is 
detectably expressed in a subset of adult astrocytes, we stained for the more widely expressed 
astrocyte marker brain lipid binding protein (BLBP) (52, 65). We found GFP+/BLBP+ NSC in the 
SVZ (Fig. 4.2), confirming previous work (139). We also found GFP+/BLBP+ astrocytes in the 
OFB, CTX, DI, BS, and CB (Fig. 4.2). These GFP+ cells outside of the SVZ expressed the 
additional astrocytic markers GFAP (Fig. S4.3) and Aldhl1 (data not shown). We failed to observe 
GFP+/NeuN+ neurons in the CTX and elsewhere throughout the adult brain (Fig. S4.4). 
Quantification showed that the majority of GFP+ cells (between 87±1% and 59±4% per region) 
were BLBP+ (Fig. S4.5a). To determine if additional glial cells expressed Sox2, we stained with 
PDGFRα, a marker of oligodendrocyte progenitor cells (OPC), and IBA-1, a marker of microglia. 
Quantification of GFP+ cells in the adult CTX showed that the majority (83±2%) were BLBP+ 
astrocytes. In confirmation with previous reports noting the presence of PDGFRα+/Sox2+ cortical 
OPC (140), 15±1% of GFP+ cells were PDGFRα+ OPC, while 0.5±0.3% of GFP+ cells were IBA-
1+ microglia (Fig. S4.5b), Thus, Sox2+ cells throughout the brain are nearly entirely BLBP+ 
astrocytes. 
To further confirm Sox2 expression in the adult brain, we induced recombination in Sox2-
CreER;tdTomato mice and found tdTomato+ cells throughout the rest of the mouse brain (Fig. 
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S4.6) with a frequency between 2-4% (Fig. S4.7). With immunostaining, we confirmed that these 
tdTomato+ cells were BLBP+ astrocytes (Fig. S4.8). We calculated that 18.4± 1.0% of BLBP+ 
astrocytes in the cortical grey matter expressed tdTomato.  
Role of Sox2 in astrocytes in response to extrinsic stimuli 
Sox2+ astrocytes outside of neurogenic niches fail to proliferate in the normal brain absent 
pathological stimuli (Fig. S4.9). However, under pathological conditions, astrocytes adopt a more 
primitive functional state and symmetrically divide in response to extrinsic stimuli such as trauma, 
a process termed reactive astrocytosis. To test whether Sox2+ astrocytes were involved in wound 
healing, we injured the brain of adult Sox2-GFP mice via needle stick, following a previously 
developed method to induce reactive gliosis (141, 142). We found GFP+ astrocytes at the site of 
wounding which expressed primitive markers and actively divided, suggesting that Sox2+ 
astrocytes are involved in wound healing (Fig. S4.10). OPC and microglia proximal to the wound 
also divided in response to wounding (Fig. S4.11). Quantification of overview images of the wound 
site revealed an increase in GFP+ astrocytes around the wound three days after wounding (Fig. 
4.3b). Ten days after wounding, a higher percentage of GFP+ cells remained, consistent with 
reports showing sustained reactive gliosis up to a month after the stab wound (141, 142). 
Proliferating GFP+ astrocytes were most prevalent 100 microns around the stab wound three days 
after wounding (Fig. 4.3c) (21% ± 0.9% versus 13% ± 0.8% without wounding) and decreased 
with distance from the needle track. The percentage of proliferating cells peaked 3 days after 
injury, however this proliferation was transient and virtually absent 7 and 10 days after wounding.  
To specifically test the role Sox2 plays in astrocyte cell cycle reentry upon extrinsic stimuli, 
we wounded the brain of hGFAP-CreER;Sox2f;Sox2-GFP mice after conditional ablation of Sox2 
specifically in astrocytes. Immunofluorescence analysis revealed that Sox2 expression was 
specifically ablated in astrocytes (Fig. S4.12a), however Sox2 levels in microglia and OPC 
remained unchanged (Fig. S4.12b-c). Antibody staining against Sox2 confirmed cell type specific 
deletion (Fig. S4.12d). Quantification of dividing cells around the wound showed that Sox2 
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ablation in astrocytes led to higher levels of cellular division around the wound site and increased 
the time window over which proliferation occurs. In combination, this data suggests that Sox2 
expression in astrocytes is critical for their reentry into the cell cycle after external stimuli. 
Role of Sox2 in astrocytes in response to intrinsic stimuli 
In addition to extrinsic stimuli, astrocyte proliferation may also occur in a cell autonomous 
fashion in response to intrinsic stimuli such as mutagenesis. To test the role that Sox2 plays in 
response to combinations of oncogenic mutations, we stably knocked down Sox2 using a shRNA 
in a panel of immortalized astrocytes and assessed resulting growth via MTS assay. We found 
that Sox2 ablation impedes the growth of both T and TR astrocytes (Fig. 4.5a-b). Transfection of 
a mutated version of Sox2 resistant to the shRNA rescued growth in T and TR cells indicating 
that decrease in Sox2 is responsible for growth ablation (Fig. 4.5c-d). In contrast, Sox2 
knockdown in TP-/- and TRP-/- cell lines did not ablate growth (Fig. 4.5e-f) suggesting an interaction 
between PTEN and Sox2. To explore how Sox2 loss might alter tumor growth in vivo, we injected 
TRP astrocytes with Sox2 knocked down into the brains of syngeneic host mice. We found no 
differences in survival or histology of the resulting tumors with Sox2 knocked down versus intact 
(Fig. S4.13). 
Next we asked whether Sox2 loss influences tumor initiation. To answer this, we induced 
tumors in GFAP-CreER;TRP;Sox2f/f mice and found after two months that diffuse disease was 
present throughout the entire brain which was consistent with levels seen in GFAP-CreER;TRP 
mice (Fig. 4.6). In a parallel approach, we injected the brains of TRP;Sox2f/f mice with GFAP-Cre 
adenovirus to focally induce tumor. One month after induction, TRP;Sox2f/f mice had tumors 
consistent with those virally induced in TRP mice, expressing markers of stemness such as nestin 
and actively dividing (Fig. S4.14). In combination, this data suggesting that Sox2 deletion does 
not influence ability to initiate tumors in the adult mouse brain 
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Discussion 
In summary, our data demonstrated the presence of differentiated, Sox2+ astrocytes 
throughout the brains of adult mice. To test if Sox2 expression was necessary for astrocyte cell 
division in response to extrinsic pathological stimuli, we conditionally knocked out Sox2 in the 
brains of hGFAP-CreER;Sox2f;Sox2-GFP mice and showed that the response to wound healing 
was altered. To test if Sox2 expression in astrocytes was necessary for cell division in response 
to intrinsic stimuli, we knocked down Sox2 in immortalized astrocytes and genetically ablated 
Sox2 in two separate glioma GEMM. We found that Sox2 knockdown with shRNA ablated cell 
growth in immortalized astrocytes with PTEN intact, however PTEN deficient cell lines were 
unaffected by Sox2 deletion. We also found that Sox2 deletion in tamoxifen induced GFAP-
CreER;TRP;Sox2f/f and virally induced TRP;Sox2f/f mice did not inhibit tumor formation in vivo. 
These results suggest that Sox2 is important in the response of astrocytes to certain but not all 
pathological stimuli. 
We noticed that Sox2 deletion led to increased proliferation across all timepoints and that 
astrocytes, microglia, and OPC were involved in this response. However, how proliferating glial 
populations around the wound change in response to Sox2 deletion remains unknown. We 
hypothesize that the majority of proliferative cells in the absence of Sox2 are macrophages. Sox2 
deletion has been shown to interfere with entry into the cell cycle (143) and differentiation (144) 
in other cell types, potentially leading to a decrease of proliferating astrocytes around the wound. 
If the wound takes longer to heal, more macrophages could be necessary to remove intracellular 
debris and aide in healing. OPC could proliferate at the later stages of wound healing due to 
remyelinated around the wound. Further staining experiments quantifying proliferative cell types 
around the wound in astrocytes are necessary to access how populations of proliferative glia 
change in response to Sox2 deletion. 
We showed that Sox2 knockdown in our panel of immortalized astrocytes decreased 
proliferation in cell types which had intact PTEN, however cell types with PTEN deletions did not 
  281  
show growth ablation. The molecular mechanism for these growth patterns remain unknown, 
however other groups have shown that AKT directly activates Sox2 via phosphorylation in breast 
cancer (145). This relationship has not been shown in astrocytes, however could explain 
differential growth patterns as PTEN is a negative regulator of AKT signaling. Future experiments 
re-expressing PTEN in our astrocyte panel as well as experiments genetically or 
pharmacologically ablating AKT signaling would help elucidate if a similar mechanism is utilized. 
We found that Sox2 ablation in tamoxifen induced GFAP-CreER;TRP;Sox2f/f and virally 
induced TRP;Sox2f/f mice did not inhibit tumor formation in vivo. These lack of tumor growth 
differences in vivo is in some ways unsurprising given that deletion of Sox2 in medulloblastoma 
has led to compensatory upregulation of other transcription factors involved in maintaining 
stemness (146). Similar mechanisms could be at play in our tumor model, as we have shown 
Oct4 deletion in addition to Sox2 deletion is able to ablate growth in TRP cells. Additionally, 
increasing the number of mice would be useful to explore whether survival differences exist 
between cohorts of mice with tumors with and without Sox2. Also using alternative TRP genotypes 
without PTEN would be useful to confirm the in vitro findings that PTEN deletion is required to 
ablate Sox2 growth hold up in vivo. Sequencing tumors with Sox2 ablation would also provide 
interesting insight into the molecular growth mechanisms. 
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Methods 
Mice: Heterozygous TgGZT121 (T) (31), KrasG12D+/lsl (R) (76), PtenloxP (P) (77), GFAP-CreER (110), 
Sox2-CreER (147), Sox2f (144), Sox2-GFP (69) and Rosa26-tdTomato (112) mice were 
maintained on a C57/Bl6 background. PCR genotyping was performed as previously described. 
Cre expression was induced in 3 month old adult mice by 5 daily intraperitoneal injections of 4-
hydroxytamoxifen (Sigma-Aldrich, St Louis, MO) at 100 mg/kg. Induced mice were sacrificed 1, 
8, or 16 weeks after induction for tumorigenesis and reporter quantification. Induced mice were 
sacrificed at 1, 3, 7, or 10 days post wounding. Prior to sacrifice, mice were given 5'-ethynyl-2'-
deoxyuridine (EdU) at 5 mg/kg via intraperitoneal injection 4 hours before transcardial perfusion 
with 4% para-formaldehyde to label dividing cells. Brains were dissected and post-fixed in 4% 
para-formaldehyde overnight at 4°C. Animals were monitored for neurological symptoms and 
sacrificed upon development of lethargy, weight loss, deterioration in body condition, poor 
grooming, bulging skull, seizures, ataxia, paralysis or other abnormalities. 
Focal tumor formation was induced in three month old TRP;Sox2f/f mice anesthetized with 
Avertin (250 mg/kg) and placed in a stereotactic frame (Kopf, Tujunga, CA). Stereotactic injection 
into CTX (coordinates 1, 1.3, 3.3 A,L,D) of 2x107 plaque forming units of Ad-GFAPCre (University 
of Iowa Gene Transfer Vector Core) were performed. Brains were analyzed after four weeks using 
immunofluorescence described below. Animal studies were approved by and followed the 
euthanasia guidelines of the University of North Carolina Institutional Animal Care and Use 
Committee. 
 
Immunofluorescence Staining: Fixed tissues was cut into 50 µm sagittal sections using a Leica 
VT100S vibratome, permeabilized and blocked with 0.5% Triton X-100, 10% BSA, 5 % normal 
goat serum and 0.01M glycine in PBS for 1 hour, followed by incubation with primary antibody 
overnight in 0.1% Triton X-100 in PBS. For EdU detection, manufacturer’s instructions were 
followed using a Click-It EdU imaging kit (Invitrogen, Grand Island, NY) directly prior to incubation 
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with primary antibody. After washing, sections were incubated for 4 hours with secondary antibody 
diluted in 0.1% Triton X100 in PBS, followed by washing and mounting on glass slides. Images 
were acquired with a LSM710 or LSM780 confocal microscope with ZEN 2012 software (Zeiss, 
Oberkochen, Germany). The following primary antibodies were used: GFP (Aves Labs, San 
Diego, CA, cat# GFP-1010 - 1:2000); Sox2, NeuN, BLBP, NG2 (EMD Millipore, Billerica, MA, cat# 
AB5603 – 1:500, MAB377 – 1:500, AB2253 – 1:500 AB5320 – 1:250); GFAP (Dako, Carpinteria, 
CA, cat# Z0334 – 1:1000); Sox2 (R&D Systems, Minneapolis, MN, cat# MAB2018 – 1:500); 
PDGFRα (Cell Signaling Technology, Danvers, MA, cat # 3174 – 1:500); Iba1 (Wako Chemicals, 
Richmond, VA, cat # 019-19741. Secondary antibodies were cross-absorbed IgG conjugated to 
CF488A, CF568 or CF647 (Biotium, Hayward, CA). 
 
Cell Quantification: For reporter quantification, five random images of the CTX, DI, BS, OFB, 
and CB and for wound quantification five images of the wounded area were taken using a Zeiss 
LSM 710 or 780 microscope with a 20X objective from two to three sagittal sections, located 
approximately 1.35 mm lateral to midline. ImageJ was used to count GFP+, TdTomato+, EdU+, 
and DAPI+ nuclei. The mean percent of GFP or tdTomato positive cells ± s.e.m. from 9-36 images 
for reporter quantification and 6-15 images for wound quantification was then calculated for each 
brain region from N=2-3 replicate mice per genotype. 
 
Cell Growth. Primary GFAP+ T(RP) astrocytes were cultured in DMEM supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin as previously described (75, 88). To examine 
growth of cultured astrocyte subpopulations, 5,000 cells per well were plated in quadruplicate in 
96-well plates. Growth was assayed after 0-6 days in culture using the CellTiter 96 AQueous 
Proliferation Assay (Promega, Fitchburg, WI). Absorbance at 490 nm was determined on a 
Molecular Devices Emax plate reader (Chicago, IL) equipped with SoftMax Pro 5 software. 
Relative growth was calculated as absorbance relative to day 0. Data (mean ± SEM) were fit to a 
  284  
logarithmic equation to calculate doubling times that were compared using the extra-sum-of-
squares F test in GraphPad Prism. 
 
Stab Wound Assay: Three month old Sox2-GFP mice were anaesthetized and stabbed in the 
frontal and rostral CTX once with a 30-gauge sterile needle. Mice were sacrificed 1, 3, 7, and 10 
days after wounding. Before sacrifice, mice were injected twice with EdU four hours prior to 
transcardial perfusion. Two sagittal sections for each timepoint were stained, imaged, and 
quantified. For quantification, four bins with a width of 100 µm were drawn on each side of the 
central needle tract stretching from the pia to the corpus callosum (Fig 4.3) and GFP+/EdU+ cells 
were quantified in each bin. Data are presented as mean ± s.e.m. 
 
Orthotopic Allograft: Three month old C57Bl/6 mice were anesthetized and placed into a 
stereotactic frame as described above. After a 0.5-cm scalp incision, 105 cells in 5 mL of 5% 
methylcellulose were injected into the right basal ganglia using coordinates 1, -2, and -4 mm (A, 
L, D) from the Bregma suture as previously described (148). 
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Figure 4.1. Sox2-GFP is expressed throughout the adult brain. GFP+ cells were quantified 
in cortex (CTX), diencephalon (DI), brainstem (BS), olfactory bulb (OFB), and cerebellum (CB). 
The mean percentage ± SEM of GFP+ cells in 8-15 images from N=3 mice is shown (a). 
Representative images from each brain region shows GFP+ (green) cells; nuclei are 
counterstained with DAPI (blue, b) (scale bar 100 µm). 
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Figure 4.2. Sox2-GFP cells are BLBP+ astrocytes. Brain sections of adult Sox2-GFP mice were 
immunostained with BLBP antibodies. GFP+ cells colocalized with BLBP+ astrocytes in the SVZ, 
OFB, CTX, DI, BS, and CB (scale bars, 10 µm). 
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Figure 4.3. Sox2+ astrocytes are involved in wound healing. Anaesthetized, adult Sox2-GFP 
mice were stabbed in the CTX and sacrificed 1, 3, 7, or 10 days after injury. A sagittal overview 
of a cortical stab wound, with the needle tract marked with a white line, is shown three days 
after stabbing stained with DAPI (blue), GFP (green), and EdU (red) (a). The percentage of 
Sox2-GFP+ (b) and EdU+ (c) cells is shown as a function of days after stab wound. The highest 
percentages of Sox2-GFP+ and EdU+ cells were seen 3 days post injury, however elevated 
percentages of only GFP+ cells were still seen 10 days post injury. The blue line labeled center 
indicates the 100 µm wide column on either side of the needle tract. The red, green, and black 
lines mark consecutive 100 µm wide columns moving outwards from the center columns around 
the stab wound. Data are presented as mean ± s.e.m. for n=1-3 animals (scale bars, 200 µm). 
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Figure 4.4. Sox2 knockout in astrocytes disrupts normal wound healing. Anaesthetized, 
adult Sox2GFP or Sox2GFP;GFAP-CreER;Sox2f mice were stabbed in the CTX once and 
sacrificed 1, 3, 7, or 10 days after injury. The raw number of proliferative, EdU+ cells around the 
wound site was counted in each sagittal section. While dividing cells around the wound were only 
present three days after wounding in Sox2GFP mice (blue line), proliferative cells in 
Sox2GFP;GFAP-CreER;Sox2f mice with Sox2 deleted (red line) were present at 1, 3, 7 and 10 
days after wounding, suggesting that Sox2 expression in astrocytes is important in wound healing. 
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Figure 4.5. Pten status influences growth response after Sox2 deletion in immortalized 
mouse astrocytes. Stable knock down of Sox2 with shRNA T and TR astrocytes revealed 
impeded growth upon decreased Sox2 expression (a,b). Expression of Sox2 resistant to the short 
hairpin rescued growth (c,d). In contrast, the growth of TP and TRP astrocytes was unaffected 
by the knockdown of Sox2, suggesting an interaction between Sox2 and PTEN signaling (e,f).  
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Figure 4.6. Sox2 deletion fails to prevent low grade tumor formation across the brain in 
GFAP-CreER;TRP+/- mice after two months. Two months after tamoxifen, GFAP-
CreER;TRP;Sox2f/f  mice showed diffuse glioma at levels consistent with GFAP-
CreER;TRP;Sox2f/f  mice, suggesting that Sox2 deletion does not interfere with initial tumor 
formation. (scale bars, (a) 100µm, (b) 10 µm) 
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Figure S4.1. Sox2-GFP is expressed throughout the adult brain. Sagittal brain overviews of 
adult Sox2-GFP knock-in mice show GFP+ cells in the neurogenic sub ventricular zone (SVZ) as 
well as throughout the adult brain (a, b) (scale bar (a) 1 mm and (b) 100 µm). 
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Figure S4.2. Antibody staining confirms presence of Sox2 in Sox2-GFP knock-in mice. 
Brain sections of adult Sox2-GFP mice were immunostained with Sox2 antibodies revealing 
GFP+/Sox2+ cells throughout the brain. Representative images are shown from the SVZ (a), CTX 
(b), and OFB (c) (scale bars, 10 µm). 
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Figure S4.3. Sox2-GFP cells are GFAP+ astrocytes. Brain sections of adult Sox2-GFP mice 
immunostained with GFAP antibodies showed GFP expression in GFAP+ NSC in the SVZ as well 
as GFAP+ astrocytes in the OFB, CTX, and CB (scale bars, 10 µm). 
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Figure S4.4. Sox2-GFP+ cells are not neurons. Sox2-GFP cells fail to express neuronal markers 
such as NeuN+ neurons in the CTX, DI, BS, OFB, and CB (scale bars, 10 µm). 
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Figure S4.5. Sox2-GFP is expressed in astrocytes and OPC. BLBP+ astrocytes were 
quantified in the BS, CTX, DI, and OFB and expressed as a percentage of DAPI+ cells (a). Data 
are presented as mean ± s.e.m. Mean is shown for n=3 mice, scoring each mouse for at least 
150 GFP+ cells from four images per brain region (b). In the CTX, BLBP+ astrocytes, PDGFRα+ 
OPC, and IBA1+ microglia were quantified and expressed as a percentage of GFP+ cells. Data 
are presented as mean ± s.e.m. Mean is shown for n=2 mice, scoring for each animal at least 
1000 GFP+ cells from 5 images per brain region. 
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Figure S4.6. Sox2-CreER;tdTomato transgenic mice confirm Sox2 expression throughout 
the adult brain. tdTomato expression is present throughout the brain 8 days after induction of 
adult Sox2-CreER;tdTomato mice (a) (scale bar,). A magnified view of the CTX (b) shows single 
tdTomato+ cells, (scale bars 1 mm (a) and 100 µm (b)). 
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Figure S4.7. Sox2tdt cells are found throughout the adult brain. tdTomato+ cells were 
quantified (a) in the CTX, DI, BS, OFB, and CB. The number of tdTomato+ cells is expressed as 
percentage of DAPI+ cells in each region. The percentages of tdTomato+ cells per brain region 
are presented as mean ± s.e.m. for n=2-3 animals. Two to three brain slices with four images per 
slice for each brain region were quantified. Over 200 tdTomato+ cells were counted for each brain 
region. Representative images from each brain region shows tdTomato+ (red) cells distributed 
throughout the cell cytoplasm showing morphology consistent with protoplasmic astrocytes in the 
cortical grey matter; nuclei are counterstained with DAPI (b) (scale bar 100 µm). 
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Figure S4.8. Sox2-CreER induces recombination in BLBP+ and GFAP+ astrocytes 
throughout the brain. Sox2-CreER;tdTomato mice induced in adulthood displayed strong 
tdTomato signal in BLBP+ and GFAP+ astrocytes throughout cortical grey matter (GM) (a), cortical 
white matter (WM) (b), OFB (c), DI (d), BS (e), and CB (f), further confirming our findings in Sox2-
GFP mice (Fig. 3) (scale bar, 10 µm). 
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Figure S4.9. Sox2+ cells fail to proliferate in the absence of pathologic stimuli. In the absent 
of pathological stimuli such as trauma or oncogenic mutations, astrocytes in the adult brain do 
not actively incorporate the nucleotide analogue EdU into their DNA (a) or express proteins 
associated with cell division (b). Similarly, these astrocytes fail to express markers of stemness 
such as nestin (a) (scale bars, 10 µm). 
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Figure S4.10. GFP+ astrocytes at site of brain injury proliferate and express markers of 
reactive gliosis. Three days after wounding, cortical GFP+ astrocytes close to the wound 
expressed molecular markers of reactive gliosis, including GFAP (a) and Nestin (b), and actively 
proliferated, as indicated by EdU incorporation (b). Markers of reactive gliosis and proliferation 
were absent in unwounded grey matter (Fig. 5 and 6) (scale bars, 10 µm). 
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Figure S4.11. Dividing cells proximal to the wound are astrocytes, OPC, and microglia. Cell 
division only occurs in the neurogenic niches in the normal adult brain. However, when the brain 
is wounded, cells proximal to the wound reenter the cell cycle to aide with healing. The identity of 
these dividing cells are BLBP+ astrocytes (a), PDGFRα+ OPC (b), and IBA1+ microglia (c) (scale 
bars, 10 µm). 
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Figure S4.12. Astrocytes lose expression of Sox2 in Sox2KO model. Three days after 
induction, Sox2-GFP;GFAP-CreER;Sox2f mice were wounded via needlestick and sacrificed one 
day later. Immunofluorescent staining reveals that Sox2 expression is selectively absent from 
BLBP+ astrocytes (a), however expression of Sox2 in microglia (b) and OPC (c) remains 
unchanged. We confirmed deletion of Sox2 with an additional antibody (d) (scale bars, 10 µm). 
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Figure S4.13. Sox2-deficiency in TRP-/- allografts does not influence survival or histology. 
Orthotopic injection of 105 TRP-/- and TRP-/- astrocytes with stable Sox2 knockdown in N=10 mice 
yielded uniform levels of tumor via BLI analysis (a). Allografts of TRP-/- and TRP-/-;Sox2-/- 
astrocytes produce uniformly lethal disease (b) with histologically indistinguishable tumors (c). 
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Figure S4.14. Sox2 deletion fails to prevent tumor formation in virally induced TRP+/- 
tumors. TRP;Sox2f/f mice were injected with GFAP-Cre adenovirus. One month after injection, 
diffuse glioma was evident at the injection site (a,b). Immunofluorescent analysis revealed that 
these tumors lacked Sox2 while actively dividing and expressing T121, the primitive marker nestin, 
and GFAP at levels consistent with previously performed viral inductions in TRP mice, suggesting 
that Sox2 deletion does not impede glioma formation (scale bars, (a) 1mm, (b) 50µm, (c-d) 10 
µm). 
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Figure S4.15. Knockout of Oct4 and Sox2 decreases proliferation in TRP-/- cells. Stable 
knockdown with shRNA against both Oct4 and Sox2 in TRP-/- astrocytes decreases growth in 
vitro, suggesting that functional compensation exists among primitive transcription factors. 
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Chapter V: Discussion 
 
The previous chapters should provide insight into future studies on mouse modeling of 
glioma and the response of astrocytes to pathology. In summary, we defined the mutational 
requirements for glioma initiation and progression in GFAP astrocytes, the effects of these 
mutations on the resulting glioma genome and transcriptome, the results of targeting identical 
mutations to two different astrocyte populations, and the impact of Sox2 deletion in astrocytes on 
cell cycle reentry during tumor initiation and wound healing. 
In Chapter II, we used a novel GEMM to target mutations to the RB and RTK signaling 
pathways to generate glioma in GFAP astrocytes in adult mice. In this context, we showed that 
functional inactivation of all three Rb family proteins was essential for low-grade glioma initiation, 
while mutations activating MAPK signaling were unequal in their ability to potentiate malignant 
progression. The growth rate of the resulting tumors differed regionally. Driver mutation- and 
region-specific transcriptome profiles were present in resulting low grade glioma, implicating both 
initiating mutations and cellular origin as variables which influence glioma genomic heterogeneity. 
Using MRI, we determined that low grade glioma stochastically underwent malignant progression 
and that this progression could be partially driven by CNA. Resulting high-grade tumors showed 
transcriptome variability and consisted of three subtypes that mimicked human GBM 
transcriptome subtypes. These subtypes were confirmed in a validation set of high-grade mouse 
gliomas driven by different oncogenic mutations in different cells of origin. Moreover, high-grade 
tumor subtypes mirrored the expression profiles of purified brain cells and correlated with brain 
region. These results suggest initiating mutations influence resulting low-grade glioma 
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transcription profiles and that regional astrocyte identity and progression-acquired mutations 
contribute strongly to glioma heterogeneity. 
In Chapter III, we used our conditional, inducible TRP GEM glioma model to transform 
GFAP and GLAST astrocytes and performed genetic lineage tracing to monitor the cellular 
composition of the tumor and surrounding microenvironment over time. Transformation of GFAP 
astrocyte lead to uniformly rapid tumor growth independent of brain region, however 
transformation of GLAST astrocytes produced more slowly growing tumors with significant 
regional bias. Moreover, transformed GLAST astrocytes had reduced proliferative response and 
malignant progression was delayed in these tumors. Different populations of recruited glial cells 
changed over time and were a significant component of tumors derived from GLAST astrocytes, 
but not GFAP astrocyte-derived tumors. These results suggest that, in addition to initiating 
mutations as described in Chapter II, regional microenvironment and heterogeneity within 
astrocyte populations significantly contribute to glioma pathogenesis. 
In Chapter IV, we used Sox2-GFP mice to establish that terminally differentiated 
astrocytes in the adult brain express Sox2, a transcription factor shown to be essential for 
maintenance of pluripotency in adult NSC and dedifferentiation of fibroblasts into iPS. In adult 
astrocytes, Sox2 could be critical for maintenance of plasticity, providing strong evidence that 
terminally differentiated, adult astrocytes could serve as a glioma cell of origin. We used hGFAP-
CreER;Sox2f;Sox2-GFP mice to show that Sox2 deletion in astrocytes alters time course of 
wound healing. Also, Sox2 knockdown in a panel of tumorigenic astrocytes immortalized with 
TRP mutations influenced cell growth in a genotype dependent fashion, while tumor initiation in 
our glioma GEMM remained unchanged upon Sox2 deletion. These results suggest that Sox2 is 
important for astrocyte proliferation, however further experiments need to be done to determine 
how tumor initiating mutations interact with Sox2 loss to alter growth. 
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Influence of initiating mutations on glioma heterogeneity 
As mentioned in Chapter II, TCGA has provided evidence that human transcriptome 
subtypes are enriched in certain mutations. For example, IDH1 mutations were enriched in the 
proneural subtype, EGFR mutations in the classical subtype, PDGFR mutations in the neural 
subtype, and NF1 mutations in the mesenchymal subtype (5). This suggests that mouse models 
with these particular mutations could produce specific transcriptomes in human disease. 
However, mouse models with Nf1 deletions, a mutation characteristic of the mesenchymal 
subtype in humans, have resulted in tumors with proneural signatures (38). Other groups have 
shown that deletion of Rb1 does not influence resulting tumor transcriptome subtype in a mouse 
model with Trp53 and Pten deletions (18). 
Using our glioma GEMM, we showed that TRP mutations targeted to GFAP cells in the 
adult brain are able to generate three transcriptome subtypes of human GBM. Low-grade 
transcriptomes clustered by KrasG12D mutational status, however Pten status was unimportant for 
clustering. Low grade glioma generated using the Kras allele harbored a gene expression 
signature enriched in the IDH wild-type, pre-GBM subtype of aggressive, lower grade human 
gliomas that have poor prognoses and are enriched in mutations commonly seen in GBM (10, 79-
81). The transcriptome subtype of high grade TR(P) glioma in our discovery set failed to correlate 
with initiating mutation, suggesting that Pten deletion does not influence resulting high-grade 
tumor transcriptome. In combination, this evidence from multiple mouse models points to the fact 
that the initiating mutational profile alone is most likely only one variable which influences the 
resulting tumor transcriptome diversity. Other factors such as regional differences in cell types 
could play critical roles in the resulting tumor. This data shows that the GEMM initiating mutational 
profile alone is insufficient to determine the resulting transcriptome subtypes. Therefore, 
experimental validation is necessary to label a GEMM as generating a specific transcriptomal 
subtype, something which remains to be done for a large number of glioma GEMM and limits our 
understanding of the disease (14). 
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Future work with GEMM is essential to further understand the influence of initiating 
mutations on resulting glioma heterogeneity. As an extension of the work in Chapter II, we have 
engineered different combinations of oncogenic mutations commonly seen in human tumors. 
These include combinations of deletions in genes such as Trp53, Cdkn2a, Nf1, and Pten. Lineage 
tracing in these models with the fluorescent reporter gene tdTomato will facilitate tracking the 
evolution of the tumor over time. Flow sorting will allow the tumor to be separated from the 
surrounding stroma which will allow exploring molecular consequences of differing initiating 
mutations on the tumor as well as its interaction with the tumor microenvironment. These models 
with different combinations of initiating mutations will lead to a deeper understating of the impact 
of different, early oncogenic events on the resulting tumors over time.  
Influence of cell of origin on glioma heterogeneity 
As mentioned in Chapter I, TCGA has shown that the transcriptomes of murine neural cell 
types including astrocytes, neurons, OPC, and purified astrocytes mimic the transcriptome 
subtypes seen in human GBM (5), implicating these cell types as potential cells of origin for the 
disease. We found gene expression evidence in our TRP glioma GEMM suggesting that certain 
neural cell types could serve as a cell of origin for GBM. 
We used unsupervised analysis to identify GFAP-driven S2 proneural-like high grade 
glioma. These tumors occurred predominantly in the olfactory bulb, expressed markers of OPC 
such as PDGFRα, and were enriched in a signature similar to purified OPC despite being 
generated from GFAP+ NSC and astrocytes. Other groups have used lineage tracing to show that 
deletion of Trp53 and Nf1 in embryonic NSC leads to OPC-driven growth of proneural GBM (38). 
The GFAP promoter present in our adult inducible GEM is not active in the oligodendroglial 
lineage, as GFAP-driven expression of a conditional tdTomato reporter gene does not co-localize 
with OPC markers in these cells (110). This promoter targets approximately 60% of astrocytes 
throughout the brain as well as a majority of NSC within the SVZ. Thus, olfactory bulb tumors 
could theoretically arise from either directly transformed astrocytes within the olfactory bulb or 
  311  
progeny from NSC that migrate from the SVZ through the rostral migratory stream and populate 
the olfactory bulb. We showed that focal injection of an astrocyte-specific, Ad-GFAPCre into the 
olfactory bulb of TRP;tdTomato mice induces tumors only in the olfactory bulb; viral injection into 
the SVZ induces tumors only in the SVZ and adjacent diencephalon (82). Taken together, these 
data suggest that the S2, proneural-like transcriptome profile present in olfactory bulb TRP tumors 
is due to induction of an OPC-like transcriptional program specifically in dedifferentiated local 
astrocytes rather than transformed NSC migrating to the olfactory bulb. 
Proneural GBM have also been produced in GEM by virally infecting NSC to overexpress 
PDGF, indirectly targeting PDGFRα+ OPC (149). Moreover, viral and Cre-lox based GEM have 
shown that proneural GBM arises from mutations directly targeting OPC.58,65 In combination, 
these models suggests that high-grade tumors may arise either through targeting mutations to 
OPC or other cell types which dedifferentiate through a common proneural transcriptome state 
when induced in the embryonic (38, 149) or adult brain (22, 86). 
A transcriptome shift from the proneural to the mesenchymal subtype has been 
demonstrated in response to Nf1 loss or radiation therapy (7, 84, 104). Here, we found that S1, 
mesenchymal-like, high-grade tumors often arose in the brainstem and expressed signatures 
similar to cultured astrocytes. Like our TR(P) models, mesenchymal-like tumors primarily 
developed in the brainstem of adult GEM in which Trp53 and Pten deletions were targeted to 
GFAP+ astrocytes (18). Mesenchymal-like glioma have also been induced in cortical astrocytes 
using lentiviral-based targeting of various mutations, including Trp53 plus Hras or Nf1 mutations 
(35, 105). Taken together, these data suggest that regional astrocyte heterogeneity may be an 
important determinant in the development of high-grade mesenchymal glioma. 
Finally, we described S3, neural-like high-grade tumors that occurred throughout the brain. 
These tumors had the most heterogeneous transcriptomes that were enriched in neuron signature 
genes. Immunostaining showed that these tumors maintained expression of astrocytic markers, 
but individual S3 high-grade tumors highly expressed OPC, astrocyte, and oligodendrocyte 
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signatures, suggesting that these tumors acquired divergent differentiation programs upon 
transformation. Interestingly, similar transcriptome heterogeneity was evident in neural-like 
gliomas induced by Trp53 plus Hras mutations in hippocampal NSC (35). 
GEMM will be essential to the success of future studies understanding how the cell of 
origin influences resulting glioma biology. We are targeting our TRP mutations as well as 
combinations of Trp53, Nf1, and Cdkn2a deletions to alternative cell types including Nestin+ NSC 
and Ng2+ OPC, in addition to GFAP+ and GLAST+ cells. Using lineage tracing, we are completing 
time courses outlining the impact of initiating cell type and mutations on tumor growth dynamics 
over time. We will be able to utilize lineage tracing in combination with flow sorting as mentioned 
above to explore the interaction of the tumor with the surrounding microenvironment. Sequencing 
tumors derived from different combinations of oncogenic mutations in different cell types would 
uncover valuable information about the influence of individual variables such as initiating 
mutations or cell type on resulting tumor transcriptome heterogeneity. 
We have previously shown that orthotopic allografts using cells isolated from TRP GEMM 
produced only the proneural subtype of GBM (75). We anticipate that cells isolated from GEMM 
driven by different combinations of mutations in various initiating cells could yield other GBM 
subtypes upon allograft. This would be useful given that inducible TRP mice are unsuitable as 
preclinical models due to variable tumor latency and expense. 
Influence of intracellular heterogeneity on resulting tumor heterogeneity 
In Chapter II, we targeted TRP mutations to GFAP+ cells throughout the brain and were 
able to generate three distinct transcriptome subtypes found in human disease. These three 
subtypes discovered in our TRP GEMM mice were also present in an independent cohort of high-
grade GEM tumors driven by diverse initiating mutations and cellular origins. Moreover, we 
showed that the transcriptomes of low-grade glioma retained location specific signatures and that 
high-grade tumors regional acquired CNA. Finally, high-grade tumors showed region specific 
CNA and transcriptome subtype of these tumors correlated with regional origin. In combination, 
  313  
this data from our TRP GEMM suggests that transcriptome heterogeneity may arise in part from 
regional differences in astrocyte biology. 
Astrocytes throughout the brain vary molecularly (41), however appreciating how these 
variations influence tumor growth has been limited to in vitro studies exploring differential levels 
of Nf1 expression (51). In Chapter III, we showed that that targeting identical oncogenic mutations 
to astrocyte subpopulations yielded distinct growth patterns, suggesting that astrocyte 
subpopulations uniquely respond to the pro-proliferative signals of oncogenic TRP mutations. We 
have argued that targeting TRP mutations to GFAP+ astrocytes results in tumors which closely 
resemble primary GBM due to rapid tumor growth and lack of IDH mutations (32). When TRP 
mutations are targeted to GLAST astrocytes, the resulting tumors have a protracted proliferative 
phase and delayed malignant progression, growth patterns similar to secondary GBM. We will 
explore if the molecular drivers of GLAST derived tumors are alterations commonly seen in 
secondary GBM such as mutations in IDH1. 
To further explore how heterogeneity within cell types influences tumor subtype, GEMM 
using additional CreER systems to target other populations of astrocyte such as ALDH1L1+ and 
GLT1+ cells in the adult brain. In a parallel approach, stereotactic injections of a lentivirus 
delivering GFAP-Cre could regionally induce focal tumors in GFAP+ astrocytes to more 
reproducibly explore the influence of region on resulting tumors. Other cell types including OPC 
and NSC can be regionally targeted with virally delivered Nestin-Cre and Ng2-Cre. In addition to 
astrocytes, other neural cell types including oligodendrocytes and NSC are extremely 
heterogeneous within the adult brain (150, 151). CreER based systems typically utilized to study 
developmental neurobiology could be used to target oncogenic mutations to populations of these 
cells to explore the impact of this heterogeneity on resulting glioma pathology. In summary, 
tumors derived from these models could reveal cell, mutation, and region-specific vulnerabilities 
in resulting glioma transcriptomes to help better inform patient care. 
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Influence of Sox2 on astrocyte reentry into the cell cycle 
As mentioned in Chapter IV, we utilized three separate methods to test how Sox2 
expression in astrocytes influences the proliferative response of astrocytes to pathology. We first 
wounded the brains of mice with Sox2 conditionally deleted in astrocytes and found an increase 
in proliferative cells and a disruption in wound healing, suggesting that Sox2 is involved in the 
proliferative response to extrinsic pathological stimuli. Molecular characterization of the Sox2-null 
astrocytes as well as other glial cell types in response to wounding could elucidate molecular 
processes which could be coopted during oncogenesis. Future mouse models could conditionally 
delete other transcription factors in astrocytes or other glial cell populations to probe additional 
mechanisms of cell cycle reentry during response to wounding. 
We showed that Sox2 knockdown in a panel of tumorigenic astrocytes immortalized with 
TRP mutations decreased proliferation in cell types with intact Pten, however cell types with Pten 
deletion did not show growth ablation. The molecular mechanism for these growth patterns remain 
unknown, however other groups have shown that AKT directly activates Sox2 via phosphorylation 
in breast cancer (145). This relationship has not been shown in astrocytes, however could explain 
differential growth patterns as PTEN is a negative regulator of AKT signaling. Future experiments 
re-expressing PTEN in our astrocyte panel as well as experiments genetically or 
pharmacologically ablating AKT signaling would help elucidate the molecular interaction between 
PTEN and Sox2. 
Using our TRP glioma GEMM, we found that Sox2 ablation in tamoxifen induced GFAP-
CreER;TRP;Sox2f/f and virally induced TRP;Sox2f/f mice did not inhibit tumor growth and initiation 
in vivo. However, molecular differences between tumors with and without Sox2 could be 
elucidated with sequencing technology. Our in vitro data indicates that tumor growth following 
Sox2 deletion in GFAP-CreER;T;Sox2f/f or GFAP-CreER;TR;Sox2f/f mice could be influenced, 
suggesting a possible direction for future experiments. 
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Conclusion 
In the work above, we have used complementary approaches with GEMM and tumorigenic 
astrocytes to outline how astrocyte respond to intrinsic and extrinsic pathologic stimuli. Only when 
cellular origin, regional cell type heterogeneity, and initiating mutations among other variables are 
systematically adjusted in a single GEMM, and tumors are uniformly analyzed, will we be able to 
determine how each variable influences resulting glioma heterogeneity. This knowledge will 
facilitate molecular classification of glioma subtypes, the development of preclinical models of 
disease, and mechanism-based therapies. 
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